{"idB": "886163_12_item1_p62_s0", "idA": "886163_11_item1_p0_s0", "sentA": "Caution: This discussion and analysis may contain predictions, estimates and other forward-looking statements that involve a number of risks and uncertainties, including those discussed in Item 1A. Risk Factors.", "sentB": "Product development and approval within this regulatory framework takes a number of years and involves the expenditure of substantial resources.", "type": 1, "words": ["<tag1>", "Caution:", "This", "discussion", "and", "analysis", "may", "contain", "predictions,", "estimates", "and", "other", "forward-looking", "statements", "that", "involve", "a", "number", "of", "risks", "and", "uncertainties,", "including", "those", "discussed", "in", "Item", "1A.", "Risk", "Factors.", "<tag2>", "Product", "development", "and", "approval", "within", "this", "regulatory", "framework", "takes", "a", "number", "of", "years", "and", "involves", "the", "expenditure", "of", "substantial", "resources.", "<tag3>"], "wordsA": ["Caution:", "This", "discussion", "and", "analysis", "may", "contain", "predictions,", "estimates", "and", "other", "forward-looking", "statements", "that", "involve", "a", "number", "of", "risks", "and", "uncertainties,", "including", "those", "discussed", "in", "Item", "1A.", "Risk", "Factors."], "wordsB": ["Product", "development", "and", "approval", "within", "this", "regulatory", "framework", "takes", "a", "number", "of", "years", "and", "involves", "the", "expenditure", "of", "substantial", "resources."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_12_item1_p11_s2", "idA": "886163_11_item1_p13_s1", "sentA": "GSK has listed a patent in the FDA s Orange Book for PROMACTA with an expiration date in 2024.", "sentB": "Additionally, it was reported in November 2011 that the Risk Evaluation and Mitgation Strategies (REMS) program that PROMACTA had been operating under in the US was being significantly reduced in scope by the FDA due to data that had been submitted by GSK demonstrating the long term safety of PROMACTA.", "type": 1, "words": ["<tag1>", "GSK", "has", "listed", "a", "patent", "in", "the", "FDA", "s", "Orange", "Book", "for", "PROMACTA", "with", "an", "expiration", "date", "in", "2024.", "<tag2>", "Additionally,", "it", "was", "reported", "in", "November", "2011", "that", "the", "Risk", "Evaluation", "and", "Mitgation", "Strategies", "(REMS)", "program", "that", "PROMACTA", "had", "been", "operating", "under", "in", "the", "US", "was", "being", "significantly", "reduced", "in", "scope", "by", "the", "FDA", "due", "to", "data", "that", "had", "been", "submitted", "by", "GSK", "demonstrating", "the", "long", "term", "safety", "of", "PROMACTA.", "<tag3>"], "wordsA": ["GSK", "has", "listed", "a", "patent", "in", "the", "FDA", "s", "Orange", "Book", "for", "PROMACTA", "with", "an", "expiration", "date", "in", "2024."], "wordsB": ["Additionally,", "it", "was", "reported", "in", "November", "2011", "that", "the", "Risk", "Evaluation", "and", "Mitgation", "Strategies", "(REMS)", "program", "that", "PROMACTA", "had", "been", "operating", "under", "in", "the", "US", "was", "being", "significantly", "reduced", "in", "scope", "by", "the", "FDA", "due", "to", "data", "that", "had", "been", "submitted", "by", "GSK", "demonstrating", "the", "long", "term", "safety", "of", "PROMACTA."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_12_item1_p28_s0", "idA": "886163_11_item1_p14_s3", "sentA": "Royalties are paid at a rate of 5% on sales up to $200 million and a higher rate above $200 million.", "sentB": "Certain patient groups with severely compromised renal function exhibit extreme proteinuria resulting in progression to dialysis and a high mortality rate.", "type": 1, "words": ["<tag1>", "Royalties", "are", "paid", "at", "a", "rate", "of", "5%", "on", "sales", "up", "to", "$200", "million", "and", "a", "higher", "rate", "above", "$200", "million.", "<tag2>", "Certain", "patient", "groups", "with", "severely", "compromised", "renal", "function", "exhibit", "extreme", "proteinuria", "resulting", "in", "progression", "to", "dialysis", "and", "a", "high", "mortality", "rate.", "<tag3>"], "wordsA": ["Royalties", "are", "paid", "at", "a", "rate", "of", "5%", "on", "sales", "up", "to", "$200", "million", "and", "a", "higher", "rate", "above", "$200", "million."], "wordsB": ["Certain", "patient", "groups", "with", "severely", "compromised", "renal", "function", "exhibit", "extreme", "proteinuria", "resulting", "in", "progression", "to", "dialysis", "and", "a", "high", "mortality", "rate."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_12_item1_p27_s3", "idA": "886163_11_item1_p16_s0", "sentA": "In October 2010, we announced that our partner Pfizer, Inc. launched VIVIANT (bazedoxifene) in Japan for the treatment of postmenopausal osteoporosis.", "sentB": "In February 2012, we announced that we had licensed the full world-wide rights to DARA (a Dual Acting Receptor Antagonist of Angiotension and Endothelin receptors).", "type": 1, "words": ["<tag1>", "In", "October", "2010,", "we", "announced", "that", "our", "partner", "Pfizer,", "Inc.", "launched", "VIVIANT", "(bazedoxifene)", "in", "Japan", "for", "the", "treatment", "of", "postmenopausal", "osteoporosis.", "<tag2>", "In", "February", "2012,", "we", "announced", "that", "we", "had", "licensed", "the", "full", "world-wide", "rights", "to", "DARA", "(a", "Dual", "Acting", "Receptor", "Antagonist", "of", "Angiotension", "and", "Endothelin", "receptors).", "<tag3>"], "wordsA": ["In", "October", "2010,", "we", "announced", "that", "our", "partner", "Pfizer,", "Inc.", "launched", "VIVIANT", "(bazedoxifene)", "in", "Japan", "for", "the", "treatment", "of", "postmenopausal", "osteoporosis."], "wordsB": ["In", "February", "2012,", "we", "announced", "that", "we", "had", "licensed", "the", "full", "world-wide", "rights", "to", "DARA", "(a", "Dual", "Acting", "Receptor", "Antagonist", "of", "Angiotension", "and", "Endothelin", "receptors)."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_12_item1_p43_s1", "idA": "886163_11_item1_p16_s2", "sentA": "Pfizer received manufacturing and marketing approval for the product in Japan in July 2010.", "sentB": "Under the Supply Agreement, we exclusively licensed intellectual property rights related to CAPTISOL to commercialize the licensed product worldwide and non-exclusively licensed such intellectual property rights and data related to CAPTISOL to engage in activities related to regulatory approval for the licensed product worldwide.", "type": 1, "words": ["<tag1>", "Pfizer", "received", "manufacturing", "and", "marketing", "approval", "for", "the", "product", "in", "Japan", "in", "July", "2010.", "<tag2>", "Under", "the", "Supply", "Agreement,", "we", "exclusively", "licensed", "intellectual", "property", "rights", "related", "to", "CAPTISOL", "to", "commercialize", "the", "licensed", "product", "worldwide", "and", "non-exclusively", "licensed", "such", "intellectual", "property", "rights", "and", "data", "related", "to", "CAPTISOL", "to", "engage", "in", "activities", "related", "to", "regulatory", "approval", "for", "the", "licensed", "product", "worldwide.", "<tag3>"], "wordsA": ["Pfizer", "received", "manufacturing", "and", "marketing", "approval", "for", "the", "product", "in", "Japan", "in", "July", "2010."], "wordsB": ["Under", "the", "Supply", "Agreement,", "we", "exclusively", "licensed", "intellectual", "property", "rights", "related", "to", "CAPTISOL", "to", "commercialize", "the", "licensed", "product", "worldwide", "and", "non-exclusively", "licensed", "such", "intellectual", "property", "rights", "and", "data", "related", "to", "CAPTISOL", "to", "engage", "in", "activities", "related", "to", "regulatory", "approval", "for", "the", "licensed", "product", "worldwide."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_12_item1_p55_s4", "idA": "886163_11_item1_p20_s3", "sentA": "In December 2001, the companies amended their agreement to allow Pfizer to use SBE-CD in animal health products, which allowed for the development and commercialization of Cerenia Injectable Solution.", "sentB": "In December 2011, the contract was amended to allow certain bulk quantities of CAPTISOL to be distributed directly from Hovione.", "type": 1, "words": ["<tag1>", "In", "December", "2001,", "the", "companies", "amended", "their", "agreement", "to", "allow", "Pfizer", "to", "use", "SBE-CD", "in", "animal", "health", "products,", "which", "allowed", "for", "the", "development", "and", "commercialization", "of", "Cerenia", "Injectable", "Solution.", "<tag2>", "In", "December", "2011,", "the", "contract", "was", "amended", "to", "allow", "certain", "bulk", "quantities", "of", "CAPTISOL", "to", "be", "distributed", "directly", "from", "Hovione.", "<tag3>"], "wordsA": ["In", "December", "2001,", "the", "companies", "amended", "their", "agreement", "to", "allow", "Pfizer", "to", "use", "SBE-CD", "in", "animal", "health", "products,", "which", "allowed", "for", "the", "development", "and", "commercialization", "of", "Cerenia", "Injectable", "Solution."], "wordsB": ["In", "December", "2011,", "the", "contract", "was", "amended", "to", "allow", "certain", "bulk", "quantities", "of", "CAPTISOL", "to", "be", "distributed", "directly", "from", "Hovione."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_12_item1_p43_s3", "idA": "886163_11_item1_p21_s0", "sentA": "CyDex receives royalties on product sales ending on a country by country basis as the valid claims relating to the licensed patents relevant to each product expire.", "sentB": "In consideration for the associated data package and intellectual property rights, Merck agreed to make milestone payments associated with specified regulatory events related to the licensed product.", "type": 1, "words": ["<tag1>", "CyDex", "receives", "royalties", "on", "product", "sales", "ending", "on", "a", "country", "by", "country", "basis", "as", "the", "valid", "claims", "relating", "to", "the", "licensed", "patents", "relevant", "to", "each", "product", "expire.", "<tag2>", "In", "consideration", "for", "the", "associated", "data", "package", "and", "intellectual", "property", "rights,", "Merck", "agreed", "to", "make", "milestone", "payments", "associated", "with", "specified", "regulatory", "events", "related", "to", "the", "licensed", "product.", "<tag3>"], "wordsA": ["CyDex", "receives", "royalties", "on", "product", "sales", "ending", "on", "a", "country", "by", "country", "basis", "as", "the", "valid", "claims", "relating", "to", "the", "licensed", "patents", "relevant", "to", "each", "product", "expire."], "wordsB": ["In", "consideration", "for", "the", "associated", "data", "package", "and", "intellectual", "property", "rights,", "Merck", "agreed", "to", "make", "milestone", "payments", "associated", "with", "specified", "regulatory", "events", "related", "to", "the", "licensed", "product."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_12_item1_p64_s5", "idA": "886163_11_item1_p21_s1", "sentA": "The last of such patents expires in 2013.", "sentB": "The last to expire United States patents relating to PROMACTA is not expected to expire until December 2024.", "type": 1, "words": ["<tag1>", "The", "last", "of", "such", "patents", "expires", "in", "2013.", "<tag2>", "The", "last", "to", "expire", "United", "States", "patents", "relating", "to", "PROMACTA", "is", "not", "expected", "to", "expire", "until", "December", "2024.", "<tag3>"], "wordsA": ["The", "last", "of", "such", "patents", "expires", "in", "2013."], "wordsB": ["The", "last", "to", "expire", "United", "States", "patents", "relating", "to", "PROMACTA", "is", "not", "expected", "to", "expire", "until", "December", "2024."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_12_item1_p64_s6", "idA": "886163_11_item1_p21_s1", "sentA": "The last of such patents expires in 2013.", "sentB": "The last to expire United States patents related to CAPTISOL is not expected to expire until 2029.", "type": 1, "words": ["<tag1>", "The", "last", "of", "such", "patents", "expires", "in", "2013.", "<tag2>", "The", "last", "to", "expire", "United", "States", "patents", "related", "to", "CAPTISOL", "is", "not", "expected", "to", "expire", "until", "2029.", "<tag3>"], "wordsA": ["The", "last", "of", "such", "patents", "expires", "in", "2013."], "wordsB": ["The", "last", "to", "expire", "United", "States", "patents", "related", "to", "CAPTISOL", "is", "not", "expected", "to", "expire", "until", "2029."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_12_item1_p56_s0", "idA": "886163_11_item1_p23_s1", "sentA": "Under the terms the agreement, Prism is responsible, under an exclusive worldwide license from CyDex, for all development and commercialization of Nexterone at its sole expense.", "sentB": "Management s Discussion and Analysis of Financial Condition and Results of Operations.", "type": 1, "words": ["<tag1>", "Under", "the", "terms", "the", "agreement,", "Prism", "is", "responsible,", "under", "an", "exclusive", "worldwide", "license", "from", "CyDex,", "for", "all", "development", "and", "commercialization", "of", "Nexterone", "at", "its", "sole", "expense.", "<tag2>", "Management", "s", "Discussion", "and", "Analysis", "of", "Financial", "Condition", "and", "Results", "of", "Operations.", "<tag3>"], "wordsA": ["Under", "the", "terms", "the", "agreement,", "Prism", "is", "responsible,", "under", "an", "exclusive", "worldwide", "license", "from", "CyDex,", "for", "all", "development", "and", "commercialization", "of", "Nexterone", "at", "its", "sole", "expense."], "wordsB": ["Management", "s", "Discussion", "and", "Analysis", "of", "Financial", "Condition", "and", "Results", "of", "Operations."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_12_item1_p63_s6", "idA": "886163_11_item1_p23_s1", "sentA": "Under the terms the agreement, Prism is responsible, under an exclusive worldwide license from CyDex, for all development and commercialization of Nexterone at its sole expense.", "sentB": "Significant resources are now required on an ongoing basis to ensure such compliance.", "type": 1, "words": ["<tag1>", "Under", "the", "terms", "the", "agreement,", "Prism", "is", "responsible,", "under", "an", "exclusive", "worldwide", "license", "from", "CyDex,", "for", "all", "development", "and", "commercialization", "of", "Nexterone", "at", "its", "sole", "expense.", "<tag2>", "Significant", "resources", "are", "now", "required", "on", "an", "ongoing", "basis", "to", "ensure", "such", "compliance.", "<tag3>"], "wordsA": ["Under", "the", "terms", "the", "agreement,", "Prism", "is", "responsible,", "under", "an", "exclusive", "worldwide", "license", "from", "CyDex,", "for", "all", "development", "and", "commercialization", "of", "Nexterone", "at", "its", "sole", "expense."], "wordsB": ["Significant", "resources", "are", "now", "required", "on", "an", "ongoing", "basis", "to", "ensure", "such", "compliance."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_12_item1_p65_s1", "idA": "886163_11_item1_p23_s1", "sentA": "Under the terms the agreement, Prism is responsible, under an exclusive worldwide license from CyDex, for all development and commercialization of Nexterone at its sole expense.", "sentB": "Of these employees, 6 hold Ph.D. or M.D. degrees.", "type": 1, "words": ["<tag1>", "Under", "the", "terms", "the", "agreement,", "Prism", "is", "responsible,", "under", "an", "exclusive", "worldwide", "license", "from", "CyDex,", "for", "all", "development", "and", "commercialization", "of", "Nexterone", "at", "its", "sole", "expense.", "<tag2>", "Of", "these", "employees,", "6", "hold", "Ph.D.", "or", "M.D.", "degrees.", "<tag3>"], "wordsA": ["Under", "the", "terms", "the", "agreement,", "Prism", "is", "responsible,", "under", "an", "exclusive", "worldwide", "license", "from", "CyDex,", "for", "all", "development", "and", "commercialization", "of", "Nexterone", "at", "its", "sole", "expense."], "wordsB": ["Of", "these", "employees,", "6", "hold", "Ph.D.", "or", "M.D.", "degrees."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_12_item1_p62_s1", "idA": "886163_11_item1_p23_s4", "sentA": "On November 19, 2010, Prism received marketing approval from the FDA for Nexterone and has announced plans to launch Nexterone in the United States in 2011.", "sentB": "The steps required before a pharmaceutical agent may be marketed in the United States include (1) preclinical laboratory tests, (2) the submission to the FDA of an IND, which must become effective before human clinical trials may commence, (3) adequate and well-controlled human clinical trials to establish the safety and efficacy of the drug, (4) the submission of an NDA to the FDA and (5) the FDA approval of the NDA prior to any commercial sale or shipment of the drug.", "type": 1, "words": ["<tag1>", "On", "November", "19,", "2010,", "Prism", "received", "marketing", "approval", "from", "the", "FDA", "for", "Nexterone", "and", "has", "announced", "plans", "to", "launch", "Nexterone", "in", "the", "United", "States", "in", "2011.", "<tag2>", "The", "steps", "required", "before", "a", "pharmaceutical", "agent", "may", "be", "marketed", "in", "the", "United", "States", "include", "(1)", "preclinical", "laboratory", "tests,", "(2)", "the", "submission", "to", "the", "FDA", "of", "an", "IND,", "which", "must", "become", "effective", "before", "human", "clinical", "trials", "may", "commence,", "(3)", "adequate", "and", "well-controlled", "human", "clinical", "trials", "to", "establish", "the", "safety", "and", "efficacy", "of", "the", "drug,", "(4)", "the", "submission", "of", "an", "NDA", "to", "the", "FDA", "and", "(5)", "the", "FDA", "approval", "of", "the", "NDA", "prior", "to", "any", "commercial", "sale", "or", "shipment", "of", "the", "drug.", "<tag3>"], "wordsA": ["On", "November", "19,", "2010,", "Prism", "received", "marketing", "approval", "from", "the", "FDA", "for", "Nexterone", "and", "has", "announced", "plans", "to", "launch", "Nexterone", "in", "the", "United", "States", "in", "2011."], "wordsB": ["The", "steps", "required", "before", "a", "pharmaceutical", "agent", "may", "be", "marketed", "in", "the", "United", "States", "include", "(1)", "preclinical", "laboratory", "tests,", "(2)", "the", "submission", "to", "the", "FDA", "of", "an", "IND,", "which", "must", "become", "effective", "before", "human", "clinical", "trials", "may", "commence,", "(3)", "adequate", "and", "well-controlled", "human", "clinical", "trials", "to", "establish", "the", "safety", "and", "efficacy", "of", "the", "drug,", "(4)", "the", "submission", "of", "an", "NDA", "to", "the", "FDA", "and", "(5)", "the", "FDA", "approval", "of", "the", "NDA", "prior", "to", "any", "commercial", "sale", "or", "shipment", "of", "the", "drug."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_12_item1_p24_s2", "idA": "886163_11_item1_p23_s5", "sentA": "PROMACTA is approved for ITP and we receive royalties from GSK on world-wide sales.", "sentB": "Pfizer has completed PIII studies of Aprela and we expect an NDA filing in 2012.", "type": 1, "words": ["<tag1>", "PROMACTA", "is", "approved", "for", "ITP", "and", "we", "receive", "royalties", "from", "GSK", "on", "world-wide", "sales.", "<tag2>", "Pfizer", "has", "completed", "PIII", "studies", "of", "Aprela", "and", "we", "expect", "an", "NDA", "filing", "in", "2012.", "<tag3>"], "wordsA": ["PROMACTA", "is", "approved", "for", "ITP", "and", "we", "receive", "royalties", "from", "GSK", "on", "world-wide", "sales."], "wordsB": ["Pfizer", "has", "completed", "PIII", "studies", "of", "Aprela", "and", "we", "expect", "an", "NDA", "filing", "in", "2012."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_12_item1_p62_s2", "idA": "886163_11_item1_p25_s1", "sentA": "Onyx has recently reported positive Phase II data for this program and has initiated the filing of a rolling NDA with the FDA based upon this data.", "sentB": "In addition to obtaining FDA approval for each product, each domestic drug-manufacturing establishment must be registered with the FDA and, in California, with the Food and Drug Branch of California.", "type": 1, "words": ["<tag1>", "Onyx", "has", "recently", "reported", "positive", "Phase", "II", "data", "for", "this", "program", "and", "has", "initiated", "the", "filing", "of", "a", "rolling", "NDA", "with", "the", "FDA", "based", "upon", "this", "data.", "<tag2>", "In", "addition", "to", "obtaining", "FDA", "approval", "for", "each", "product,", "each", "domestic", "drug-manufacturing", "establishment", "must", "be", "registered", "with", "the", "FDA", "and,", "in", "California,", "with", "the", "Food", "and", "Drug", "Branch", "of", "California.", "<tag3>"], "wordsA": ["Onyx", "has", "recently", "reported", "positive", "Phase", "II", "data", "for", "this", "program", "and", "has", "initiated", "the", "filing", "of", "a", "rolling", "NDA", "with", "the", "FDA", "based", "upon", "this", "data."], "wordsB": ["In", "addition", "to", "obtaining", "FDA", "approval", "for", "each", "product,", "each", "domestic", "drug-manufacturing", "establishment", "must", "be", "registered", "with", "the", "FDA", "and,", "in", "California,", "with", "the", "Food", "and", "Drug", "Branch", "of", "California."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_12_item1_p62_s3", "idA": "886163_11_item1_p25_s2", "sentA": "Onyx expects to complete filing of the NDA by mid-2011 and will receive expedited review by the FDA because of the program s FDA-granted Fast Track status.", "sentB": "Domestic manufacturing establishments are subject to pre-approval inspections by the FDA prior to marketing approval, then to biennial inspections, and must comply with current Good Manufacturing Practices (cGMP).", "type": 1, "words": ["<tag1>", "Onyx", "expects", "to", "complete", "filing", "of", "the", "NDA", "by", "mid-2011", "and", "will", "receive", "expedited", "review", "by", "the", "FDA", "because", "of", "the", "program", "s", "FDA-granted", "Fast", "Track", "status.", "<tag2>", "Domestic", "manufacturing", "establishments", "are", "subject", "to", "pre-approval", "inspections", "by", "the", "FDA", "prior", "to", "marketing", "approval,", "then", "to", "biennial", "inspections,", "and", "must", "comply", "with", "current", "Good", "Manufacturing", "Practices", "(cGMP).", "<tag3>"], "wordsA": ["Onyx", "expects", "to", "complete", "filing", "of", "the", "NDA", "by", "mid-2011", "and", "will", "receive", "expedited", "review", "by", "the", "FDA", "because", "of", "the", "program", "s", "FDA-granted", "Fast", "Track", "status."], "wordsB": ["Domestic", "manufacturing", "establishments", "are", "subject", "to", "pre-approval", "inspections", "by", "the", "FDA", "prior", "to", "marketing", "approval,", "then", "to", "biennial", "inspections,", "and", "must", "comply", "with", "current", "Good", "Manufacturing", "Practices", "(cGMP)."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_12_item1_p34_s2", "idA": "886163_11_item1_p28_s0", "sentA": "Dinaciclib is a CDK inhibitor that resulted from our collaboration with Merck (formerly Schering-Plough).", "sentB": "IRAK4 is a key signaling component downstream of both toll-like receptors and interleukin-1 receptors suggesting that it may have therapeutic value for a range of autoimmune and inflammatory conditions.", "type": 1, "words": ["<tag1>", "Dinaciclib", "is", "a", "CDK", "inhibitor", "that", "resulted", "from", "our", "collaboration", "with", "Merck", "(formerly", "Schering-Plough).", "<tag2>", "IRAK4", "is", "a", "key", "signaling", "component", "downstream", "of", "both", "toll-like", "receptors", "and", "interleukin-1", "receptors", "suggesting", "that", "it", "may", "have", "therapeutic", "value", "for", "a", "range", "of", "autoimmune", "and", "inflammatory", "conditions.", "<tag3>"], "wordsA": ["Dinaciclib", "is", "a", "CDK", "inhibitor", "that", "resulted", "from", "our", "collaboration", "with", "Merck", "(formerly", "Schering-Plough)."], "wordsB": ["IRAK4", "is", "a", "key", "signaling", "component", "downstream", "of", "both", "toll-like", "receptors", "and", "interleukin-1", "receptors", "suggesting", "that", "it", "may", "have", "therapeutic", "value", "for", "a", "range", "of", "autoimmune", "and", "inflammatory", "conditions."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_12_item1_p27_s4", "idA": "886163_11_item1_p37_s1", "sentA": "Preclinical studies conducted with LGD-4033 suggest that the compound may have favorable activity in the treatment of cachexia, frailty, osteoporosis, hypogonadism as well as other disorders.", "sentB": "Retrophin intends to develop DARA for orphan indications of severe kidney diseases including Focal Segmental Glomerulosclerosis (FSGS) as well as conduct proof-of-concept studies in resistant hypertension and diabetic nephropathy.", "type": 1, "words": ["<tag1>", "Preclinical", "studies", "conducted", "with", "LGD-4033", "suggest", "that", "the", "compound", "may", "have", "favorable", "activity", "in", "the", "treatment", "of", "cachexia,", "frailty,", "osteoporosis,", "hypogonadism", "as", "well", "as", "other", "disorders.", "<tag2>", "Retrophin", "intends", "to", "develop", "DARA", "for", "orphan", "indications", "of", "severe", "kidney", "diseases", "including", "Focal", "Segmental", "Glomerulosclerosis", "(FSGS)", "as", "well", "as", "conduct", "proof-of-concept", "studies", "in", "resistant", "hypertension", "and", "diabetic", "nephropathy.", "<tag3>"], "wordsA": ["Preclinical", "studies", "conducted", "with", "LGD-4033", "suggest", "that", "the", "compound", "may", "have", "favorable", "activity", "in", "the", "treatment", "of", "cachexia,", "frailty,", "osteoporosis,", "hypogonadism", "as", "well", "as", "other", "disorders."], "wordsB": ["Retrophin", "intends", "to", "develop", "DARA", "for", "orphan", "indications", "of", "severe", "kidney", "diseases", "including", "Focal", "Segmental", "Glomerulosclerosis", "(FSGS)", "as", "well", "as", "conduct", "proof-of-concept", "studies", "in", "resistant", "hypertension", "and", "diabetic", "nephropathy."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_12_item1_p25_s3", "idA": "886163_11_item1_p39_s1", "sentA": "Phase I clinical trials began in June 2009.", "sentB": "We announced in June 2011 that we had licensed the full world-wide rights to our CAPTISOL -enabled clopidogrel program to The Medicines Company.", "type": 1, "words": ["<tag1>", "Phase", "I", "clinical", "trials", "began", "in", "June", "2009.", "<tag2>", "We", "announced", "in", "June", "2011", "that", "we", "had", "licensed", "the", "full", "world-wide", "rights", "to", "our", "CAPTISOL", "-enabled", "clopidogrel", "program", "to", "The", "Medicines", "Company.", "<tag3>"], "wordsA": ["Phase", "I", "clinical", "trials", "began", "in", "June", "2009."], "wordsB": ["We", "announced", "in", "June", "2011", "that", "we", "had", "licensed", "the", "full", "world-wide", "rights", "to", "our", "CAPTISOL", "-enabled", "clopidogrel", "program", "to", "The", "Medicines", "Company."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_12_item1_p56_s2", "idA": "886163_11_item1_p39_s1", "sentA": "Phase I clinical trials began in June 2009.", "sentB": "There were no research and development expenses from discontinued operations in 2011, 2010, and 2009.", "type": 1, "words": ["<tag1>", "Phase", "I", "clinical", "trials", "began", "in", "June", "2009.", "<tag2>", "There", "were", "no", "research", "and", "development", "expenses", "from", "discontinued", "operations", "in", "2011,", "2010,", "and", "2009.", "<tag3>"], "wordsA": ["Phase", "I", "clinical", "trials", "began", "in", "June", "2009."], "wordsB": ["There", "were", "no", "research", "and", "development", "expenses", "from", "discontinued", "operations", "in", "2011,", "2010,", "and", "2009."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_12_item1_p63_s4", "idA": "886163_11_item1_p39_s1", "sentA": "Phase I clinical trials began in June 2009.", "sentB": "A number of states now regulate, for example, pharmaceutical marketing practices and the reporting of marketing activities, controlled substances, clinical trials and general commercial practices.", "type": 1, "words": ["<tag1>", "Phase", "I", "clinical", "trials", "began", "in", "June", "2009.", "<tag2>", "A", "number", "of", "states", "now", "regulate,", "for", "example,", "pharmaceutical", "marketing", "practices", "and", "the", "reporting", "of", "marketing", "activities,", "controlled", "substances,", "clinical", "trials", "and", "general", "commercial", "practices.", "<tag3>"], "wordsA": ["Phase", "I", "clinical", "trials", "began", "in", "June", "2009."], "wordsB": ["A", "number", "of", "states", "now", "regulate,", "for", "example,", "pharmaceutical", "marketing", "practices", "and", "the", "reporting", "of", "marketing", "activities,", "controlled", "substances,", "clinical", "trials", "and", "general", "commercial", "practices."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_12_item1_p40_s0", "idA": "886163_11_item1_p3_s0", "sentA": "References to Ligand Pharmaceuticals Incorporated , Ligand , the Company , we or our include our wholly owned subsidiaries Ligand JVR, Allergan Ligand Retinoid Therapeutics, Seragen, Inc., or Seragen; Pharmacopeia, LLC; Neurogen Corporation, CyDex Pharmaceuticals, Inc., Metabasis Therapeutics, and Nexus Equity VI LLC, or Nexus.", "sentB": "Others Recent Acquisitions and Other Transactions CyDex Pharmaceuticals, Inc.", "type": 1, "words": ["<tag1>", "References", "to", "Ligand", "Pharmaceuticals", "Incorporated", ",", "Ligand", ",", "the", "Company", ",", "we", "or", "our", "include", "our", "wholly", "owned", "subsidiaries", "Ligand", "JVR,", "Allergan", "Ligand", "Retinoid", "Therapeutics,", "Seragen,", "Inc.,", "or", "Seragen;", "Pharmacopeia,", "LLC;", "Neurogen", "Corporation,", "CyDex", "Pharmaceuticals,", "Inc.,", "Metabasis", "Therapeutics,", "and", "Nexus", "Equity", "VI", "LLC,", "or", "Nexus.", "<tag2>", "Others", "Recent", "Acquisitions", "and", "Other", "Transactions", "CyDex", "Pharmaceuticals,", "Inc.", "<tag3>"], "wordsA": ["References", "to", "Ligand", "Pharmaceuticals", "Incorporated", ",", "Ligand", ",", "the", "Company", ",", "we", "or", "our", "include", "our", "wholly", "owned", "subsidiaries", "Ligand", "JVR,", "Allergan", "Ligand", "Retinoid", "Therapeutics,", "Seragen,", "Inc.,", "or", "Seragen;", "Pharmacopeia,", "LLC;", "Neurogen", "Corporation,", "CyDex", "Pharmaceuticals,", "Inc.,", "Metabasis", "Therapeutics,", "and", "Nexus", "Equity", "VI", "LLC,", "or", "Nexus."], "wordsB": ["Others", "Recent", "Acquisitions", "and", "Other", "Transactions", "CyDex", "Pharmaceuticals,", "Inc."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_12_item1_p26_s1", "idA": "886163_11_item1_p46_s2", "sentA": "Captisol-enabled IV topiramate is designed to meet the needs of physicians that require the benefits of Topamax therapy, but in the acute care setting.", "sentB": "The CAPTISOL-enabled clopidogrel formulation is designed to provide an intravenous option in situations where the administration of oral platelet inhibitors is not feasible or desirable.", "type": 1, "words": ["<tag1>", "Captisol-enabled", "IV", "topiramate", "is", "designed", "to", "meet", "the", "needs", "of", "physicians", "that", "require", "the", "benefits", "of", "Topamax", "therapy,", "but", "in", "the", "acute", "care", "setting.", "<tag2>", "The", "CAPTISOL-enabled", "clopidogrel", "formulation", "is", "designed", "to", "provide", "an", "intravenous", "option", "in", "situations", "where", "the", "administration", "of", "oral", "platelet", "inhibitors", "is", "not", "feasible", "or", "desirable.", "<tag3>"], "wordsA": ["Captisol-enabled", "IV", "topiramate", "is", "designed", "to", "meet", "the", "needs", "of", "physicians", "that", "require", "the", "benefits", "of", "Topamax", "therapy,", "but", "in", "the", "acute", "care", "setting."], "wordsB": ["The", "CAPTISOL-enabled", "clopidogrel", "formulation", "is", "designed", "to", "provide", "an", "intravenous", "option", "in", "situations", "where", "the", "administration", "of", "oral", "platelet", "inhibitors", "is", "not", "feasible", "or", "desirable."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_12_item1_p42_s1", "idA": "886163_11_item1_p51_s2", "sentA": "We paid $31.2 million in cash, of which $20.0 million was financed, with an additional $4.3 million to be paid on the one-year anniversary of the transaction.", "sentB": "Under this License Agreement, we received a $1.8 million upfront payment, of which $0.9 million was remitted to the CyDex CVR holders.", "type": 1, "words": ["<tag1>", "We", "paid", "$31.2", "million", "in", "cash,", "of", "which", "$20.0", "million", "was", "financed,", "with", "an", "additional", "$4.3", "million", "to", "be", "paid", "on", "the", "one-year", "anniversary", "of", "the", "transaction.", "<tag2>", "Under", "this", "License", "Agreement,", "we", "received", "a", "$1.8", "million", "upfront", "payment,", "of", "which", "$0.9", "million", "was", "remitted", "to", "the", "CyDex", "CVR", "holders.", "<tag3>"], "wordsA": ["We", "paid", "$31.2", "million", "in", "cash,", "of", "which", "$20.0", "million", "was", "financed,", "with", "an", "additional", "$4.3", "million", "to", "be", "paid", "on", "the", "one-year", "anniversary", "of", "the", "transaction."], "wordsB": ["Under", "this", "License", "Agreement,", "we", "received", "a", "$1.8", "million", "upfront", "payment,", "of", "which", "$0.9", "million", "was", "remitted", "to", "the", "CyDex", "CVR", "holders."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_12_item1_p56_s1", "idA": "886163_11_item1_p51_s2", "sentA": "We paid $31.2 million in cash, of which $20.0 million was financed, with an additional $4.3 million to be paid on the one-year anniversary of the transaction.", "sentB": "Research and Development Expenses Research and development expenses from continuing operations were $10.3 million, $22.1 million, and $39.9 million in 2011, 2010, and 2009, respectively, of which 99%, 61%, and 47%, respectively, were sponsored by us.", "type": 1, "words": ["<tag1>", "We", "paid", "$31.2", "million", "in", "cash,", "of", "which", "$20.0", "million", "was", "financed,", "with", "an", "additional", "$4.3", "million", "to", "be", "paid", "on", "the", "one-year", "anniversary", "of", "the", "transaction.", "<tag2>", "Research", "and", "Development", "Expenses", "Research", "and", "development", "expenses", "from", "continuing", "operations", "were", "$10.3", "million,", "$22.1", "million,", "and", "$39.9", "million", "in", "2011,", "2010,", "and", "2009,", "respectively,", "of", "which", "99%,", "61%,", "and", "47%,", "respectively,", "were", "sponsored", "by", "us.", "<tag3>"], "wordsA": ["We", "paid", "$31.2", "million", "in", "cash,", "of", "which", "$20.0", "million", "was", "financed,", "with", "an", "additional", "$4.3", "million", "to", "be", "paid", "on", "the", "one-year", "anniversary", "of", "the", "transaction."], "wordsB": ["Research", "and", "Development", "Expenses", "Research", "and", "development", "expenses", "from", "continuing", "operations", "were", "$10.3", "million,", "$22.1", "million,", "and", "$39.9", "million", "in", "2011,", "2010,", "and", "2009,", "respectively,", "of", "which", "99%,", "61%,", "and", "47%,", "respectively,", "were", "sponsored", "by", "us."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_12_item1_p4_s4", "idA": "886163_11_item1_p58_s1", "sentA": "MEDI-528 is currently in a 320-patient Phase II study for moderate-to-severe asthma.", "sentB": "CAPTISOL is a powerful formulation technology that has enabled five FDA approved products, including Pfizer s VFEND IV and Baxter International s Nexterone and is currently being used in a number of clinical-stage partner programs.", "type": 1, "words": ["<tag1>", "MEDI-528", "is", "currently", "in", "a", "320-patient", "Phase", "II", "study", "for", "moderate-to-severe", "asthma.", "<tag2>", "CAPTISOL", "is", "a", "powerful", "formulation", "technology", "that", "has", "enabled", "five", "FDA", "approved", "products,", "including", "Pfizer", "s", "VFEND", "IV", "and", "Baxter", "International", "s", "Nexterone", "and", "is", "currently", "being", "used", "in", "a", "number", "of", "clinical-stage", "partner", "programs.", "<tag3>"], "wordsA": ["MEDI-528", "is", "currently", "in", "a", "320-patient", "Phase", "II", "study", "for", "moderate-to-severe", "asthma."], "wordsB": ["CAPTISOL", "is", "a", "powerful", "formulation", "technology", "that", "has", "enabled", "five", "FDA", "approved", "products,", "including", "Pfizer", "s", "VFEND", "IV", "and", "Baxter", "International", "s", "Nexterone", "and", "is", "currently", "being", "used", "in", "a", "number", "of", "clinical-stage", "partner", "programs."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_12_item1_p55_s9", "idA": "886163_11_item1_p59_s1", "sentA": "Several of these interleukin molecules, including IL-9, are thought to play an important role in the pathogenesis of asthma.", "sentB": "For further discussion of these items, see below under Item 7.", "type": 1, "words": ["<tag1>", "Several", "of", "these", "interleukin", "molecules,", "including", "IL-9,", "are", "thought", "to", "play", "an", "important", "role", "in", "the", "pathogenesis", "of", "asthma.", "<tag2>", "For", "further", "discussion", "of", "these", "items,", "see", "below", "under", "Item", "7.", "<tag3>"], "wordsA": ["Several", "of", "these", "interleukin", "molecules,", "including", "IL-9,", "are", "thought", "to", "play", "an", "important", "role", "in", "the", "pathogenesis", "of", "asthma."], "wordsB": ["For", "further", "discussion", "of", "these", "items,", "see", "below", "under", "Item", "7."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_12_item1_p35_s0", "idA": "886163_11_item1_p5_s0", "sentA": "These programs address the unmet medical needs of patients for a broad spectrum of diseases including hepatitis, muscle wasting, Alzheimer s disease, dyslipidemia, diabetes, anemia, COPD, asthma, rheumatoid arthritis, oncology and osteoporosis.", "sentB": "Inhibition of IRAK4 activity has been implicated in multiple diseases including rheumatoid arthritis, systemic lupus erythematosus, gout, inflammatory bowel disease, asthma, and allergic rhinitis.", "type": 1, "words": ["<tag1>", "These", "programs", "address", "the", "unmet", "medical", "needs", "of", "patients", "for", "a", "broad", "spectrum", "of", "diseases", "including", "hepatitis,", "muscle", "wasting,", "Alzheimer", "s", "disease,", "dyslipidemia,", "diabetes,", "anemia,", "COPD,", "asthma,", "rheumatoid", "arthritis,", "oncology", "and", "osteoporosis.", "<tag2>", "Inhibition", "of", "IRAK4", "activity", "has", "been", "implicated", "in", "multiple", "diseases", "including", "rheumatoid", "arthritis,", "systemic", "lupus", "erythematosus,", "gout,", "inflammatory", "bowel", "disease,", "asthma,", "and", "allergic", "rhinitis.", "<tag3>"], "wordsA": ["These", "programs", "address", "the", "unmet", "medical", "needs", "of", "patients", "for", "a", "broad", "spectrum", "of", "diseases", "including", "hepatitis,", "muscle", "wasting,", "Alzheimer", "s", "disease,", "dyslipidemia,", "diabetes,", "anemia,", "COPD,", "asthma,", "rheumatoid", "arthritis,", "oncology", "and", "osteoporosis."], "wordsB": ["Inhibition", "of", "IRAK4", "activity", "has", "been", "implicated", "in", "multiple", "diseases", "including", "rheumatoid", "arthritis,", "systemic", "lupus", "erythematosus,", "gout,", "inflammatory", "bowel", "disease,", "asthma,", "and", "allergic", "rhinitis."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_12_item1_p58_s1", "idA": "886163_11_item1_p62_s3", "sentA": "By virtue of the novation agreement, Proximagen becomes a party to the 2004 agreement in place of Swedish Orphan Biovitrum AB with respect to the CXCR4 compounds.", "sentB": "Furthermore, academic institutions, government agencies and other public and private organizations conducting research may seek patent protection with respect to potentially competing products or technologies and may establish collaborative arrangements with our competitors.", "type": 1, "words": ["<tag1>", "By", "virtue", "of", "the", "novation", "agreement,", "Proximagen", "becomes", "a", "party", "to", "the", "2004", "agreement", "in", "place", "of", "Swedish", "Orphan", "Biovitrum", "AB", "with", "respect", "to", "the", "CXCR4", "compounds.", "<tag2>", "Furthermore,", "academic", "institutions,", "government", "agencies", "and", "other", "public", "and", "private", "organizations", "conducting", "research", "may", "seek", "patent", "protection", "with", "respect", "to", "potentially", "competing", "products", "or", "technologies", "and", "may", "establish", "collaborative", "arrangements", "with", "our", "competitors.", "<tag3>"], "wordsA": ["By", "virtue", "of", "the", "novation", "agreement,", "Proximagen", "becomes", "a", "party", "to", "the", "2004", "agreement", "in", "place", "of", "Swedish", "Orphan", "Biovitrum", "AB", "with", "respect", "to", "the", "CXCR4", "compounds."], "wordsB": ["Furthermore,", "academic", "institutions,", "government", "agencies", "and", "other", "public", "and", "private", "organizations", "conducting", "research", "may", "seek", "patent", "protection", "with", "respect", "to", "potentially", "competing", "products", "or", "technologies", "and", "may", "establish", "collaborative", "arrangements", "with", "our", "competitors."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_12_item1_p61_s2", "idA": "886163_11_item1_p63_s1", "sentA": "Under the terms of the agreement, we received $1 million at the close of the transaction.", "sentB": "There are often comparable regulations that apply at the state level.", "type": 1, "words": ["<tag1>", "Under", "the", "terms", "of", "the", "agreement,", "we", "received", "$1", "million", "at", "the", "close", "of", "the", "transaction.", "<tag2>", "There", "are", "often", "comparable", "regulations", "that", "apply", "at", "the", "state", "level.", "<tag3>"], "wordsA": ["Under", "the", "terms", "of", "the", "agreement,", "we", "received", "$1", "million", "at", "the", "close", "of", "the", "transaction."], "wordsB": ["There", "are", "often", "comparable", "regulations", "that", "apply", "at", "the", "state", "level."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_12_item1_p45_s1", "idA": "886163_11_item1_p63_s2", "sentA": "In addition we will receive $800,000 over the following two years and 10% of all revenues from third party collaborations for three years.", "sentB": "Under the License Agreement, we will receive upfront and research support payments, and potentially can receive additional payments if SAGE exercises certain product commercialization options.", "type": 1, "words": ["<tag1>", "In", "addition", "we", "will", "receive", "$800,000", "over", "the", "following", "two", "years", "and", "10%", "of", "all", "revenues", "from", "third", "party", "collaborations", "for", "three", "years.", "<tag2>", "Under", "the", "License", "Agreement,", "we", "will", "receive", "upfront", "and", "research", "support", "payments,", "and", "potentially", "can", "receive", "additional", "payments", "if", "SAGE", "exercises", "certain", "product", "commercialization", "options.", "<tag3>"], "wordsA": ["In", "addition", "we", "will", "receive", "$800,000", "over", "the", "following", "two", "years", "and", "10%", "of", "all", "revenues", "from", "third", "party", "collaborations", "for", "three", "years."], "wordsB": ["Under", "the", "License", "Agreement,", "we", "will", "receive", "upfront", "and", "research", "support", "payments,", "and", "potentially", "can", "receive", "additional", "payments", "if", "SAGE", "exercises", "certain", "product", "commercialization", "options."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_12_item1_p59_s2", "idA": "886163_11_item1_p66_s1", "sentA": "The sublicensee is now responsible for the worldwide development, registration and commercialization of Tanaproget.", "sentB": "Our competitive position also depends upon our ability to attract and retain qualified personnel, obtain patent protection or otherwise develop proprietary products or processes, and secure sufficient capital resources for the often substantial period between technological conception and commercial sales.", "type": 1, "words": ["<tag1>", "The", "sublicensee", "is", "now", "responsible", "for", "the", "worldwide", "development,", "registration", "and", "commercialization", "of", "Tanaproget.", "<tag2>", "Our", "competitive", "position", "also", "depends", "upon", "our", "ability", "to", "attract", "and", "retain", "qualified", "personnel,", "obtain", "patent", "protection", "or", "otherwise", "develop", "proprietary", "products", "or", "processes,", "and", "secure", "sufficient", "capital", "resources", "for", "the", "often", "substantial", "period", "between", "technological", "conception", "and", "commercial", "sales.", "<tag3>"], "wordsA": ["The", "sublicensee", "is", "now", "responsible", "for", "the", "worldwide", "development,", "registration", "and", "commercialization", "of", "Tanaproget."], "wordsB": ["Our", "competitive", "position", "also", "depends", "upon", "our", "ability", "to", "attract", "and", "retain", "qualified", "personnel,", "obtain", "patent", "protection", "or", "otherwise", "develop", "proprietary", "products", "or", "processes,", "and", "secure", "sufficient", "capital", "resources", "for", "the", "often", "substantial", "period", "between", "technological", "conception", "and", "commercial", "sales."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_12_item1_p41_s1", "idA": "886163_11_item1_p67_s0", "sentA": "In January 2011, we entered into a strategic relationship with Chiva Pharmaceuticals, Inc., or Chiva, to develop multiple of our assets and technology in China and potentially worldwide.", "sentB": "Chiva was granted licenses to begin immediate development in China of our two clinical-stage HepDirect programs, Pradefovir for hepatitis B and MB01733 for hepatocellular carcinoma.", "type": 1, "words": ["<tag1>", "In", "January", "2011,", "we", "entered", "into", "a", "strategic", "relationship", "with", "Chiva", "Pharmaceuticals,", "Inc.,", "or", "Chiva,", "to", "develop", "multiple", "of", "our", "assets", "and", "technology", "in", "China", "and", "potentially", "worldwide.", "<tag2>", "Chiva", "was", "granted", "licenses", "to", "begin", "immediate", "development", "in", "China", "of", "our", "two", "clinical-stage", "HepDirect", "programs,", "Pradefovir", "for", "hepatitis", "B", "and", "MB01733", "for", "hepatocellular", "carcinoma.", "<tag3>"], "wordsA": ["In", "January", "2011,", "we", "entered", "into", "a", "strategic", "relationship", "with", "Chiva", "Pharmaceuticals,", "Inc.,", "or", "Chiva,", "to", "develop", "multiple", "of", "our", "assets", "and", "technology", "in", "China", "and", "potentially", "worldwide."], "wordsB": ["Chiva", "was", "granted", "licenses", "to", "begin", "immediate", "development", "in", "China", "of", "our", "two", "clinical-stage", "HepDirect", "programs,", "Pradefovir", "for", "hepatitis", "B", "and", "MB01733", "for", "hepatocellular", "carcinoma."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_12_item1_p45_s5", "idA": "886163_11_item1_p67_s0", "sentA": "In January 2011, we entered into a strategic relationship with Chiva Pharmaceuticals, Inc., or Chiva, to develop multiple of our assets and technology in China and potentially worldwide.", "sentB": "Under the License Agreement, we granted to Lilly an exclusive, nontransferable license to such intellectual property rights that will enable Lilly to develop and potentially commercialize CAPTISOL-enabled intravenous oncology therapeutics.", "type": 1, "words": ["<tag1>", "In", "January", "2011,", "we", "entered", "into", "a", "strategic", "relationship", "with", "Chiva", "Pharmaceuticals,", "Inc.,", "or", "Chiva,", "to", "develop", "multiple", "of", "our", "assets", "and", "technology", "in", "China", "and", "potentially", "worldwide.", "<tag2>", "Under", "the", "License", "Agreement,", "we", "granted", "to", "Lilly", "an", "exclusive,", "nontransferable", "license", "to", "such", "intellectual", "property", "rights", "that", "will", "enable", "Lilly", "to", "develop", "and", "potentially", "commercialize", "CAPTISOL-enabled", "intravenous", "oncology", "therapeutics.", "<tag3>"], "wordsA": ["In", "January", "2011,", "we", "entered", "into", "a", "strategic", "relationship", "with", "Chiva", "Pharmaceuticals,", "Inc.,", "or", "Chiva,", "to", "develop", "multiple", "of", "our", "assets", "and", "technology", "in", "China", "and", "potentially", "worldwide."], "wordsB": ["Under", "the", "License", "Agreement,", "we", "granted", "to", "Lilly", "an", "exclusive,", "nontransferable", "license", "to", "such", "intellectual", "property", "rights", "that", "will", "enable", "Lilly", "to", "develop", "and", "potentially", "commercialize", "CAPTISOL-enabled", "intravenous", "oncology", "therapeutics."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_12_item1_p45_s12", "idA": "886163_11_item1_p68_s4", "sentA": "In addition, we have the potential to receive a 10% equity position in Chiva and will also receive an undisclosed percentage of any sublicensing revenue generated from sublicensing of collaboration compounds to third parties in a major world market.", "sentB": "In addition, we received a pre-payment of $2.5 million, to be applied as a credit toward the first $2.5 million of CAPTISOL supplied under the Agreement.", "type": 1, "words": ["<tag1>", "In", "addition,", "we", "have", "the", "potential", "to", "receive", "a", "10%", "equity", "position", "in", "Chiva", "and", "will", "also", "receive", "an", "undisclosed", "percentage", "of", "any", "sublicensing", "revenue", "generated", "from", "sublicensing", "of", "collaboration", "compounds", "to", "third", "parties", "in", "a", "major", "world", "market.", "<tag2>", "In", "addition,", "we", "received", "a", "pre-payment", "of", "$2.5", "million,", "to", "be", "applied", "as", "a", "credit", "toward", "the", "first", "$2.5", "million", "of", "CAPTISOL", "supplied", "under", "the", "Agreement.", "<tag3>"], "wordsA": ["In", "addition,", "we", "have", "the", "potential", "to", "receive", "a", "10%", "equity", "position", "in", "Chiva", "and", "will", "also", "receive", "an", "undisclosed", "percentage", "of", "any", "sublicensing", "revenue", "generated", "from", "sublicensing", "of", "collaboration", "compounds", "to", "third", "parties", "in", "a", "major", "world", "market."], "wordsB": ["In", "addition,", "we", "received", "a", "pre-payment", "of", "$2.5", "million,", "to", "be", "applied", "as", "a", "credit", "toward", "the", "first", "$2.5", "million", "of", "CAPTISOL", "supplied", "under", "the", "Agreement."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_12_item1_p45_s10", "idA": "886163_11_item1_p73_s1", "sentA": "HepDirect may improve efficacy and/or safety of certain drugs and can be applied to marketed or new drug products.", "sentB": "Under the Agreement, we granted a license in specified territories, with sub-license rights, to such intellectual property rights that will enable the manufacture and sale of certain finished drug products of which CAPTISOL is a component.", "type": 1, "words": ["<tag1>", "HepDirect", "may", "improve", "efficacy", "and/or", "safety", "of", "certain", "drugs", "and", "can", "be", "applied", "to", "marketed", "or", "new", "drug", "products.", "<tag2>", "Under", "the", "Agreement,", "we", "granted", "a", "license", "in", "specified", "territories,", "with", "sub-license", "rights,", "to", "such", "intellectual", "property", "rights", "that", "will", "enable", "the", "manufacture", "and", "sale", "of", "certain", "finished", "drug", "products", "of", "which", "CAPTISOL", "is", "a", "component.", "<tag3>"], "wordsA": ["HepDirect", "may", "improve", "efficacy", "and/or", "safety", "of", "certain", "drugs", "and", "can", "be", "applied", "to", "marketed", "or", "new", "drug", "products."], "wordsB": ["Under", "the", "Agreement,", "we", "granted", "a", "license", "in", "specified", "territories,", "with", "sub-license", "rights,", "to", "such", "intellectual", "property", "rights", "that", "will", "enable", "the", "manufacture", "and", "sale", "of", "certain", "finished", "drug", "products", "of", "which", "CAPTISOL", "is", "a", "component."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_12_item1_p65_s0", "idA": "886163_11_item1_p75_s0", "sentA": "Intracellular receptors are involved in the actions of non-peptide hormones and drugs such as selective estrogen receptor modulators, or SERMs, and SARMs.", "sentB": "Human Resources As of February 1, 2012, we had 21 full-time employees, of whom 7 are involved directly in scientific research and development activities.", "type": 1, "words": ["<tag1>", "Intracellular", "receptors", "are", "involved", "in", "the", "actions", "of", "non-peptide", "hormones", "and", "drugs", "such", "as", "selective", "estrogen", "receptor", "modulators,", "or", "SERMs,", "and", "SARMs.", "<tag2>", "Human", "Resources", "As", "of", "February", "1,", "2012,", "we", "had", "21", "full-time", "employees,", "of", "whom", "7", "are", "involved", "directly", "in", "scientific", "research", "and", "development", "activities.", "<tag3>"], "wordsA": ["Intracellular", "receptors", "are", "involved", "in", "the", "actions", "of", "non-peptide", "hormones", "and", "drugs", "such", "as", "selective", "estrogen", "receptor", "modulators,", "or", "SERMs,", "and", "SARMs."], "wordsB": ["Human", "Resources", "As", "of", "February", "1,", "2012,", "we", "had", "21", "full-time", "employees,", "of", "whom", "7", "are", "involved", "directly", "in", "scientific", "research", "and", "development", "activities."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_12_item1_p27_s1", "idA": "886163_11_item1_p79_s4", "sentA": "In addition, if Hovione cannot supply our requirements of Captisol due to an uncured force majeure event or if the unit price of Captisol exceeds a set figure, we may obtain Captisol from a third party.", "sentB": "In addition, we will also supply both the clinical and commercial requirements of CAPTISOL for this program, and if the intravenous formulation is approved for commercialization, we will be the exclusive supplier of the product.", "type": 1, "words": ["<tag1>", "In", "addition,", "if", "Hovione", "cannot", "supply", "our", "requirements", "of", "Captisol", "due", "to", "an", "uncured", "force", "majeure", "event", "or", "if", "the", "unit", "price", "of", "Captisol", "exceeds", "a", "set", "figure,", "we", "may", "obtain", "Captisol", "from", "a", "third", "party.", "<tag2>", "In", "addition,", "we", "will", "also", "supply", "both", "the", "clinical", "and", "commercial", "requirements", "of", "CAPTISOL", "for", "this", "program,", "and", "if", "the", "intravenous", "formulation", "is", "approved", "for", "commercialization,", "we", "will", "be", "the", "exclusive", "supplier", "of", "the", "product.", "<tag3>"], "wordsA": ["In", "addition,", "if", "Hovione", "cannot", "supply", "our", "requirements", "of", "Captisol", "due", "to", "an", "uncured", "force", "majeure", "event", "or", "if", "the", "unit", "price", "of", "Captisol", "exceeds", "a", "set", "figure,", "we", "may", "obtain", "Captisol", "from", "a", "third", "party."], "wordsB": ["In", "addition,", "we", "will", "also", "supply", "both", "the", "clinical", "and", "commercial", "requirements", "of", "CAPTISOL", "for", "this", "program,", "and", "if", "the", "intravenous", "formulation", "is", "approved", "for", "commercialization,", "we", "will", "be", "the", "exclusive", "supplier", "of", "the", "product."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_12_item1_p43_s2", "idA": "886163_11_item1_p79_s5", "sentA": "In the January 2008 amendment to the supply agreement, we and Hovione agreed to remove the obligation of Hovione to hold additional quantities of Captisol inventory on our behalf.", "sentB": "The companies also agreed to mutual exclusivity terms.", "type": 1, "words": ["<tag1>", "In", "the", "January", "2008", "amendment", "to", "the", "supply", "agreement,", "we", "and", "Hovione", "agreed", "to", "remove", "the", "obligation", "of", "Hovione", "to", "hold", "additional", "quantities", "of", "Captisol", "inventory", "on", "our", "behalf.", "<tag2>", "The", "companies", "also", "agreed", "to", "mutual", "exclusivity", "terms.", "<tag3>"], "wordsA": ["In", "the", "January", "2008", "amendment", "to", "the", "supply", "agreement,", "we", "and", "Hovione", "agreed", "to", "remove", "the", "obligation", "of", "Hovione", "to", "hold", "additional", "quantities", "of", "Captisol", "inventory", "on", "our", "behalf."], "wordsB": ["The", "companies", "also", "agreed", "to", "mutual", "exclusivity", "terms."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_12_item1_p59_s0", "idA": "886163_11_item1_p7_s3", "sentA": "The principal elements of our strategy are set forth below.", "sentB": "Many of our existing or potential competitors, particularly large pharmaceutical companies, have greater financial, technical and human resources than we do and may be better equipped to develop, manufacture and market products.", "type": 1, "words": ["<tag1>", "The", "principal", "elements", "of", "our", "strategy", "are", "set", "forth", "below.", "<tag2>", "Many", "of", "our", "existing", "or", "potential", "competitors,", "particularly", "large", "pharmaceutical", "companies,", "have", "greater", "financial,", "technical", "and", "human", "resources", "than", "we", "do", "and", "may", "be", "better", "equipped", "to", "develop,", "manufacture", "and", "market", "products.", "<tag3>"], "wordsA": ["The", "principal", "elements", "of", "our", "strategy", "are", "set", "forth", "below."], "wordsB": ["Many", "of", "our", "existing", "or", "potential", "competitors,", "particularly", "large", "pharmaceutical", "companies,", "have", "greater", "financial,", "technical", "and", "human", "resources", "than", "we", "do", "and", "may", "be", "better", "equipped", "to", "develop,", "manufacture", "and", "market", "products."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_12_item1_p61_s1", "idA": "886163_11_item1_p7_s3", "sentA": "The principal elements of our strategy are set forth below.", "sentB": "The Federal Food, Drug and Cosmetic Act and the Public Health Service Act govern the testing, manufacture, safety, efficacy, labeling, storage, record keeping, approval, advertising and promotion of our products.", "type": 1, "words": ["<tag1>", "The", "principal", "elements", "of", "our", "strategy", "are", "set", "forth", "below.", "<tag2>", "The", "Federal", "Food,", "Drug", "and", "Cosmetic", "Act", "and", "the", "Public", "Health", "Service", "Act", "govern", "the", "testing,", "manufacture,", "safety,", "efficacy,", "labeling,", "storage,", "record", "keeping,", "approval,", "advertising", "and", "promotion", "of", "our", "products.", "<tag3>"], "wordsA": ["The", "principal", "elements", "of", "our", "strategy", "are", "set", "forth", "below."], "wordsB": ["The", "Federal", "Food,", "Drug", "and", "Cosmetic", "Act", "and", "the", "Public", "Health", "Service", "Act", "govern", "the", "testing,", "manufacture,", "safety,", "efficacy,", "labeling,", "storage,", "record", "keeping,", "approval,", "advertising", "and", "promotion", "of", "our", "products."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_13_item1_p9_s1", "idA": "886163_12_item1_p10_s0", "sentA": "PROMACTA (GSK) GSK s PROMACTA (Eltrombopag) is the first oral thrombopoietin (TPO) receptor agonist therapy for the treatment of adult patients with chronic ITP.", "sentB": "Promacta is the first supportive care treatment available to patients who are ineligible or poor candidates for interferon-based therapy due to their low blood platelet counts.", "type": 1, "words": ["<tag1>", "PROMACTA", "(GSK)", "GSK", "s", "PROMACTA", "(Eltrombopag)", "is", "the", "first", "oral", "thrombopoietin", "(TPO)", "receptor", "agonist", "therapy", "for", "the", "treatment", "of", "adult", "patients", "with", "chronic", "ITP.", "<tag2>", "Promacta", "is", "the", "first", "supportive", "care", "treatment", "available", "to", "patients", "who", "are", "ineligible", "or", "poor", "candidates", "for", "interferon-based", "therapy", "due", "to", "their", "low", "blood", "platelet", "counts.", "<tag3>"], "wordsA": ["PROMACTA", "(GSK)", "GSK", "s", "PROMACTA", "(Eltrombopag)", "is", "the", "first", "oral", "thrombopoietin", "(TPO)", "receptor", "agonist", "therapy", "for", "the", "treatment", "of", "adult", "patients", "with", "chronic", "ITP."], "wordsB": ["Promacta", "is", "the", "first", "supportive", "care", "treatment", "available", "to", "patients", "who", "are", "ineligible", "or", "poor", "candidates", "for", "interferon-based", "therapy", "due", "to", "their", "low", "blood", "platelet", "counts."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_13_item1_p32_s0", "idA": "886163_12_item1_p11_s1", "sentA": "In February 2011, the FDA granted GSK full approval status for PROMACTA in the US following the submission of long term safety data from post-marketing clinical studies, as well as the completion of other commitments that verify the clinical benefit to patients.", "sentB": "CLL is a slow-progressing disease, affecting the blood and bone marrow, as well as the lymph nodes or other organs, and is the most common type of leukemia affecting adults.", "type": 1, "words": ["<tag1>", "In", "February", "2011,", "the", "FDA", "granted", "GSK", "full", "approval", "status", "for", "PROMACTA", "in", "the", "US", "following", "the", "submission", "of", "long", "term", "safety", "data", "from", "post-marketing", "clinical", "studies,", "as", "well", "as", "the", "completion", "of", "other", "commitments", "that", "verify", "the", "clinical", "benefit", "to", "patients.", "<tag2>", "CLL", "is", "a", "slow-progressing", "disease,", "affecting", "the", "blood", "and", "bone", "marrow,", "as", "well", "as", "the", "lymph", "nodes", "or", "other", "organs,", "and", "is", "the", "most", "common", "type", "of", "leukemia", "affecting", "adults.", "<tag3>"], "wordsA": ["In", "February", "2011,", "the", "FDA", "granted", "GSK", "full", "approval", "status", "for", "PROMACTA", "in", "the", "US", "following", "the", "submission", "of", "long", "term", "safety", "data", "from", "post-marketing", "clinical", "studies,", "as", "well", "as", "the", "completion", "of", "other", "commitments", "that", "verify", "the", "clinical", "benefit", "to", "patients."], "wordsB": ["CLL", "is", "a", "slow-progressing", "disease,", "affecting", "the", "blood", "and", "bone", "marrow,", "as", "well", "as", "the", "lymph", "nodes", "or", "other", "organs,", "and", "is", "the", "most", "common", "type", "of", "leukemia", "affecting", "adults."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_13_item1_p46_s2", "idA": "886163_12_item1_p14_s3", "sentA": "Royalties are paid at a rate of 5% on sales up to $200 million and a higher rate above $200 million.", "sentB": "In animal models, LGD-4033 demonstrated anabolic activity in muscles, anti-resorptive and anabolic activity in bones and a robust selectivity for muscle and bone versus prostate and sebaceous glands.", "type": 1, "words": ["<tag1>", "Royalties", "are", "paid", "at", "a", "rate", "of", "5%", "on", "sales", "up", "to", "$200", "million", "and", "a", "higher", "rate", "above", "$200", "million.", "<tag2>", "In", "animal", "models,", "LGD-4033", "demonstrated", "anabolic", "activity", "in", "muscles,", "anti-resorptive", "and", "anabolic", "activity", "in", "bones", "and", "a", "robust", "selectivity", "for", "muscle", "and", "bone", "versus", "prostate", "and", "sebaceous", "glands.", "<tag3>"], "wordsA": ["Royalties", "are", "paid", "at", "a", "rate", "of", "5%", "on", "sales", "up", "to", "$200", "million", "and", "a", "higher", "rate", "above", "$200", "million."], "wordsB": ["In", "animal", "models,", "LGD-4033", "demonstrated", "anabolic", "activity", "in", "muscles,", "anti-resorptive", "and", "anabolic", "activity", "in", "bones", "and", "a", "robust", "selectivity", "for", "muscle", "and", "bone", "versus", "prostate", "and", "sebaceous", "glands."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_13_item1_p33_s0", "idA": "886163_12_item1_p18_s0", "sentA": "VIVIANT, a selective estrogen receptor modulator (SERM), is a result of the successful research collaboration between Wyeth (now a subsidiary of Pfizer) and us that began in 1994.", "sentB": "Dinaciclib is derived from a collaboration initiated in 1998 by Pharmacopeia (now a wholly owned subsidiary of Ligand).", "type": 1, "words": ["<tag1>", "VIVIANT,", "a", "selective", "estrogen", "receptor", "modulator", "(SERM),", "is", "a", "result", "of", "the", "successful", "research", "collaboration", "between", "Wyeth", "(now", "a", "subsidiary", "of", "Pfizer)", "and", "us", "that", "began", "in", "1994.", "<tag2>", "Dinaciclib", "is", "derived", "from", "a", "collaboration", "initiated", "in", "1998", "by", "Pharmacopeia", "(now", "a", "wholly", "owned", "subsidiary", "of", "Ligand).", "<tag3>"], "wordsA": ["VIVIANT,", "a", "selective", "estrogen", "receptor", "modulator", "(SERM),", "is", "a", "result", "of", "the", "successful", "research", "collaboration", "between", "Wyeth", "(now", "a", "subsidiary", "of", "Pfizer)", "and", "us", "that", "began", "in", "1994."], "wordsB": ["Dinaciclib", "is", "derived", "from", "a", "collaboration", "initiated", "in", "1998", "by", "Pharmacopeia", "(now", "a", "wholly", "owned", "subsidiary", "of", "Ligand)."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_13_item1_p46_s0", "idA": "886163_12_item1_p18_s0", "sentA": "VIVIANT, a selective estrogen receptor modulator (SERM), is a result of the successful research collaboration between Wyeth (now a subsidiary of Pfizer) and us that began in 1994.", "sentB": "Our LGD-4033 is a non-steroidal selective androgen receptor modulator (SARM) that is expected to produce the therapeutic benefits of testosterone with improved safety, tolerability and patient acceptance due to a tissue-selective mechanism of action and an oral route of administration.", "type": 1, "words": ["<tag1>", "VIVIANT,", "a", "selective", "estrogen", "receptor", "modulator", "(SERM),", "is", "a", "result", "of", "the", "successful", "research", "collaboration", "between", "Wyeth", "(now", "a", "subsidiary", "of", "Pfizer)", "and", "us", "that", "began", "in", "1994.", "<tag2>", "Our", "LGD-4033", "is", "a", "non-steroidal", "selective", "androgen", "receptor", "modulator", "(SARM)", "that", "is", "expected", "to", "produce", "the", "therapeutic", "benefits", "of", "testosterone", "with", "improved", "safety,", "tolerability", "and", "patient", "acceptance", "due", "to", "a", "tissue-selective", "mechanism", "of", "action", "and", "an", "oral", "route", "of", "administration.", "<tag3>"], "wordsA": ["VIVIANT,", "a", "selective", "estrogen", "receptor", "modulator", "(SERM),", "is", "a", "result", "of", "the", "successful", "research", "collaboration", "between", "Wyeth", "(now", "a", "subsidiary", "of", "Pfizer)", "and", "us", "that", "began", "in", "1994."], "wordsB": ["Our", "LGD-4033", "is", "a", "non-steroidal", "selective", "androgen", "receptor", "modulator", "(SARM)", "that", "is", "expected", "to", "produce", "the", "therapeutic", "benefits", "of", "testosterone", "with", "improved", "safety,", "tolerability", "and", "patient", "acceptance", "due", "to", "a", "tissue-selective", "mechanism", "of", "action", "and", "an", "oral", "route", "of", "administration."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_13_item1_p47_s2", "idA": "886163_12_item1_p19_s0", "sentA": "We are entitled to receive tiered royalties on net sales of bazedoxifene.", "sentB": "Healthy male subjects were randomized to receive 0.1, 0.3 or 1.0 mg LGD-4033 or placebo once daily over 21 days.", "type": 1, "words": ["<tag1>", "We", "are", "entitled", "to", "receive", "tiered", "royalties", "on", "net", "sales", "of", "bazedoxifene.", "<tag2>", "Healthy", "male", "subjects", "were", "randomized", "to", "receive", "0.1,", "0.3", "or", "1.0", "mg", "LGD-4033", "or", "placebo", "once", "daily", "over", "21", "days.", "<tag3>"], "wordsA": ["We", "are", "entitled", "to", "receive", "tiered", "royalties", "on", "net", "sales", "of", "bazedoxifene."], "wordsB": ["Healthy", "male", "subjects", "were", "randomized", "to", "receive", "0.1,", "0.3", "or", "1.0", "mg", "LGD-4033", "or", "placebo", "once", "daily", "over", "21", "days."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_13_item1_p43_s1", "idA": "886163_12_item1_p23_s1", "sentA": "Onyx completed filing of the NDA in 2011 and was granted a standard review by the FDA, with a Prescription Drug User Fee Act (PDUFA) date set as July 27, 2012.", "sentB": "The undisclosed partner paid a $50,000 upfront option fee.", "type": 1, "words": ["<tag1>", "Onyx", "completed", "filing", "of", "the", "NDA", "in", "2011", "and", "was", "granted", "a", "standard", "review", "by", "the", "FDA,", "with", "a", "Prescription", "Drug", "User", "Fee", "Act", "(PDUFA)", "date", "set", "as", "July", "27,", "2012.", "<tag2>", "The", "undisclosed", "partner", "paid", "a", "$50,000", "upfront", "option", "fee.", "<tag3>"], "wordsA": ["Onyx", "completed", "filing", "of", "the", "NDA", "in", "2011", "and", "was", "granted", "a", "standard", "review", "by", "the", "FDA,", "with", "a", "Prescription", "Drug", "User", "Fee", "Act", "(PDUFA)", "date", "set", "as", "July", "27,", "2012."], "wordsB": ["The", "undisclosed", "partner", "paid", "a", "$50,000", "upfront", "option", "fee."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_13_item1_p18_s1", "idA": "886163_12_item1_p24_s1", "sentA": "Pfizer is now combining VIVIANT with Premarin to create a combination therapy called Aprela for the treatment of post-menopausal symptoms in women.", "sentB": "Pfizer is responsible for the registration and worldwide marketing of bazedoxifene, a synthetic drug specifically designed to reduce the risk of osteoporotic fractures while also protecting uterine tissue.", "type": 1, "words": ["<tag1>", "Pfizer", "is", "now", "combining", "VIVIANT", "with", "Premarin", "to", "create", "a", "combination", "therapy", "called", "Aprela", "for", "the", "treatment", "of", "post-menopausal", "symptoms", "in", "women.", "<tag2>", "Pfizer", "is", "responsible", "for", "the", "registration", "and", "worldwide", "marketing", "of", "bazedoxifene,", "a", "synthetic", "drug", "specifically", "designed", "to", "reduce", "the", "risk", "of", "osteoporotic", "fractures", "while", "also", "protecting", "uterine", "tissue.", "<tag3>"], "wordsA": ["Pfizer", "is", "now", "combining", "VIVIANT", "with", "Premarin", "to", "create", "a", "combination", "therapy", "called", "Aprela", "for", "the", "treatment", "of", "post-menopausal", "symptoms", "in", "women."], "wordsB": ["Pfizer", "is", "responsible", "for", "the", "registration", "and", "worldwide", "marketing", "of", "bazedoxifene,", "a", "synthetic", "drug", "specifically", "designed", "to", "reduce", "the", "risk", "of", "osteoporotic", "fractures", "while", "also", "protecting", "uterine", "tissue."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_13_item1_p47_s0", "idA": "886163_12_item1_p24_s2", "sentA": "Pfizer has completed PIII studies of Aprela and we expect an NDA filing in 2012.", "sentB": "Phase I single and multiple dose escalation studies of LGD-4033 were conducted in a total of 116 healthy male subjects.", "type": 1, "words": ["<tag1>", "Pfizer", "has", "completed", "PIII", "studies", "of", "Aprela", "and", "we", "expect", "an", "NDA", "filing", "in", "2012.", "<tag2>", "Phase", "I", "single", "and", "multiple", "dose", "escalation", "studies", "of", "LGD-4033", "were", "conducted", "in", "a", "total", "of", "116", "healthy", "male", "subjects.", "<tag3>"], "wordsA": ["Pfizer", "has", "completed", "PIII", "studies", "of", "Aprela", "and", "we", "expect", "an", "NDA", "filing", "in", "2012."], "wordsB": ["Phase", "I", "single", "and", "multiple", "dose", "escalation", "studies", "of", "LGD-4033", "were", "conducted", "in", "a", "total", "of", "116", "healthy", "male", "subjects."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_13_item1_p47_s4", "idA": "886163_12_item1_p2_s1", "sentA": "For example, there can be no assurance that our revenues or expenses will meet any expectations or follow any trend(s), that we will be able to retain our key employees or that we will be able to enter into any strategic partnerships or other transactions.", "sentB": "LGD-4033 is positioned to enter into Phase II development, and potential studies include evaluation of LGD-4033 in conditions such as muscle wasting associated with cancer (cachexia), acute rehabilitation (e.g. hip fracture), and acute illness.", "type": 1, "words": ["<tag1>", "For", "example,", "there", "can", "be", "no", "assurance", "that", "our", "revenues", "or", "expenses", "will", "meet", "any", "expectations", "or", "follow", "any", "trend(s),", "that", "we", "will", "be", "able", "to", "retain", "our", "key", "employees", "or", "that", "we", "will", "be", "able", "to", "enter", "into", "any", "strategic", "partnerships", "or", "other", "transactions.", "<tag2>", "LGD-4033", "is", "positioned", "to", "enter", "into", "Phase", "II", "development,", "and", "potential", "studies", "include", "evaluation", "of", "LGD-4033", "in", "conditions", "such", "as", "muscle", "wasting", "associated", "with", "cancer", "(cachexia),", "acute", "rehabilitation", "(e.g.", "hip", "fracture),", "and", "acute", "illness.", "<tag3>"], "wordsA": ["For", "example,", "there", "can", "be", "no", "assurance", "that", "our", "revenues", "or", "expenses", "will", "meet", "any", "expectations", "or", "follow", "any", "trend(s),", "that", "we", "will", "be", "able", "to", "retain", "our", "key", "employees", "or", "that", "we", "will", "be", "able", "to", "enter", "into", "any", "strategic", "partnerships", "or", "other", "transactions."], "wordsB": ["LGD-4033", "is", "positioned", "to", "enter", "into", "Phase", "II", "development,", "and", "potential", "studies", "include", "evaluation", "of", "LGD-4033", "in", "conditions", "such", "as", "muscle", "wasting", "associated", "with", "cancer", "(cachexia),", "acute", "rehabilitation", "(e.g.", "hip", "fracture),", "and", "acute", "illness."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_13_item1_p42_s0", "idA": "886163_12_item1_p30_s0", "sentA": "Internal Product Development Programs As summarized in the table below, we are developing several proprietary products for a variety of indications.", "sentB": "Delafloxacin is a novel hospital-focused fluoroquinolone antibiotic candidate with potency against a variety of quinolone-resistant Gram-positive and Gram-negative bacteria, including quinolone-resistant, methicillin-resistant Staphylococcus aureus (MRSA).", "type": 1, "words": ["<tag1>", "Internal", "Product", "Development", "Programs", "As", "summarized", "in", "the", "table", "below,", "we", "are", "developing", "several", "proprietary", "products", "for", "a", "variety", "of", "indications.", "<tag2>", "Delafloxacin", "is", "a", "novel", "hospital-focused", "fluoroquinolone", "antibiotic", "candidate", "with", "potency", "against", "a", "variety", "of", "quinolone-resistant", "Gram-positive", "and", "Gram-negative", "bacteria,", "including", "quinolone-resistant,", "methicillin-resistant", "Staphylococcus", "aureus", "(MRSA).", "<tag3>"], "wordsA": ["Internal", "Product", "Development", "Programs", "As", "summarized", "in", "the", "table", "below,", "we", "are", "developing", "several", "proprietary", "products", "for", "a", "variety", "of", "indications."], "wordsB": ["Delafloxacin", "is", "a", "novel", "hospital-focused", "fluoroquinolone", "antibiotic", "candidate", "with", "potency", "against", "a", "variety", "of", "quinolone-resistant", "Gram-positive", "and", "Gram-negative", "bacteria,", "including", "quinolone-resistant,", "methicillin-resistant", "Staphylococcus", "aureus", "(MRSA)."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_13_item1_p40_s1", "idA": "886163_12_item1_p34_s0", "sentA": "(IRAK4) inhibitors for the treatment of inflammatory and immune disorders.", "sentB": "Lundbeck is developing CE carbamazepine-IV for the management of acute seizure disorder for hospital or emergency settings.", "type": 1, "words": ["<tag1>", "(IRAK4)", "inhibitors", "for", "the", "treatment", "of", "inflammatory", "and", "immune", "disorders.", "<tag2>", "Lundbeck", "is", "developing", "CE", "carbamazepine-IV", "for", "the", "management", "of", "acute", "seizure", "disorder", "for", "hospital", "or", "emergency", "settings.", "<tag3>"], "wordsA": ["(IRAK4)", "inhibitors", "for", "the", "treatment", "of", "inflammatory", "and", "immune", "disorders."], "wordsB": ["Lundbeck", "is", "developing", "CE", "carbamazepine-IV", "for", "the", "management", "of", "acute", "seizure", "disorder", "for", "hospital", "or", "emergency", "settings."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_13_item1_p56_s2", "idA": "886163_12_item1_p36_s0", "sentA": "Glucagon Receptor Antagonist Research Program We are developing small molecule glucagon receptor antagonists for the treatment of Type 2 diabetes mellitus.", "sentB": "We have discovered a series of orally-available, small molecule partial agonists of the EPO receptor with unique mechanism of action that should provide additional benefit in the treatment of anemia with improved safety, tolerability, and patient acceptance due to the convenience of oral administration and the lack of excessive erythropoietic stimulation.", "type": 1, "words": ["<tag1>", "Glucagon", "Receptor", "Antagonist", "Research", "Program", "We", "are", "developing", "small", "molecule", "glucagon", "receptor", "antagonists", "for", "the", "treatment", "of", "Type", "2", "diabetes", "mellitus.", "<tag2>", "We", "have", "discovered", "a", "series", "of", "orally-available,", "small", "molecule", "partial", "agonists", "of", "the", "EPO", "receptor", "with", "unique", "mechanism", "of", "action", "that", "should", "provide", "additional", "benefit", "in", "the", "treatment", "of", "anemia", "with", "improved", "safety,", "tolerability,", "and", "patient", "acceptance", "due", "to", "the", "convenience", "of", "oral", "administration", "and", "the", "lack", "of", "excessive", "erythropoietic", "stimulation.", "<tag3>"], "wordsA": ["Glucagon", "Receptor", "Antagonist", "Research", "Program", "We", "are", "developing", "small", "molecule", "glucagon", "receptor", "antagonists", "for", "the", "treatment", "of", "Type", "2", "diabetes", "mellitus."], "wordsB": ["We", "have", "discovered", "a", "series", "of", "orally-available,", "small", "molecule", "partial", "agonists", "of", "the", "EPO", "receptor", "with", "unique", "mechanism", "of", "action", "that", "should", "provide", "additional", "benefit", "in", "the", "treatment", "of", "anemia", "with", "improved", "safety,", "tolerability,", "and", "patient", "acceptance", "due", "to", "the", "convenience", "of", "oral", "administration", "and", "the", "lack", "of", "excessive", "erythropoietic", "stimulation."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_13_item1_p49_s2", "idA": "886163_12_item1_p42_s0", "sentA": "CAPTISOL License and Supply Agreement with The Medicines Company to Develop CAPTISOL-Enabled Clopidogrel In June 2011, we entered into a CAPTISOL License and Supply Agreement with The Medicines Company for development and commercialization of CAPTISOL-enabled clopidogrel for use as an intravenous drug.", "sentB": "In completed Phase I studies, Captisol-enabled topiramate has demonstrated a faster onset of action than the orally administered drug.", "type": 1, "words": ["<tag1>", "CAPTISOL", "License", "and", "Supply", "Agreement", "with", "The", "Medicines", "Company", "to", "Develop", "CAPTISOL-Enabled", "Clopidogrel", "In", "June", "2011,", "we", "entered", "into", "a", "CAPTISOL", "License", "and", "Supply", "Agreement", "with", "The", "Medicines", "Company", "for", "development", "and", "commercialization", "of", "CAPTISOL-enabled", "clopidogrel", "for", "use", "as", "an", "intravenous", "drug.", "<tag2>", "In", "completed", "Phase", "I", "studies,", "Captisol-enabled", "topiramate", "has", "demonstrated", "a", "faster", "onset", "of", "action", "than", "the", "orally", "administered", "drug.", "<tag3>"], "wordsA": ["CAPTISOL", "License", "and", "Supply", "Agreement", "with", "The", "Medicines", "Company", "to", "Develop", "CAPTISOL-Enabled", "Clopidogrel", "In", "June", "2011,", "we", "entered", "into", "a", "CAPTISOL", "License", "and", "Supply", "Agreement", "with", "The", "Medicines", "Company", "for", "development", "and", "commercialization", "of", "CAPTISOL-enabled", "clopidogrel", "for", "use", "as", "an", "intravenous", "drug."], "wordsB": ["In", "completed", "Phase", "I", "studies,", "Captisol-enabled", "topiramate", "has", "demonstrated", "a", "faster", "onset", "of", "action", "than", "the", "orally", "administered", "drug."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_13_item1_p44_s3", "idA": "886163_12_item1_p43_s2", "sentA": "The companies also agreed to mutual exclusivity terms.", "sentB": "We also agreed to terminate the Fablyn license agreement and all assets related to Fablyn, including all relevant patents, know-how, properties, rights, interests and other tangible and intangible assets owned or controlled by Chiva were returned to us.", "type": 1, "words": ["<tag1>", "The", "companies", "also", "agreed", "to", "mutual", "exclusivity", "terms.", "<tag2>", "We", "also", "agreed", "to", "terminate", "the", "Fablyn", "license", "agreement", "and", "all", "assets", "related", "to", "Fablyn,", "including", "all", "relevant", "patents,", "know-how,", "properties,", "rights,", "interests", "and", "other", "tangible", "and", "intangible", "assets", "owned", "or", "controlled", "by", "Chiva", "were", "returned", "to", "us.", "<tag3>"], "wordsA": ["The", "companies", "also", "agreed", "to", "mutual", "exclusivity", "terms."], "wordsB": ["We", "also", "agreed", "to", "terminate", "the", "Fablyn", "license", "agreement", "and", "all", "assets", "related", "to", "Fablyn,", "including", "all", "relevant", "patents,", "know-how,", "properties,", "rights,", "interests", "and", "other", "tangible", "and", "intangible", "assets", "owned", "or", "controlled", "by", "Chiva", "were", "returned", "to", "us."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_13_item1_p44_s6", "idA": "886163_12_item1_p44_s3", "sentA": "We are also eligible to receive, under the License Agreement, both milestones and royalty payments on worldwide net sales of Fablyn.", "sentB": "Having reclaimed the rights to Fablyn per the settlement agreement, we will seek new potential partners or licensees for Fablyn.", "type": 1, "words": ["<tag1>", "We", "are", "also", "eligible", "to", "receive,", "under", "the", "License", "Agreement,", "both", "milestones", "and", "royalty", "payments", "on", "worldwide", "net", "sales", "of", "Fablyn.", "<tag2>", "Having", "reclaimed", "the", "rights", "to", "Fablyn", "per", "the", "settlement", "agreement,", "we", "will", "seek", "new", "potential", "partners", "or", "licensees", "for", "Fablyn.", "<tag3>"], "wordsA": ["We", "are", "also", "eligible", "to", "receive,", "under", "the", "License", "Agreement,", "both", "milestones", "and", "royalty", "payments", "on", "worldwide", "net", "sales", "of", "Fablyn."], "wordsB": ["Having", "reclaimed", "the", "rights", "to", "Fablyn", "per", "the", "settlement", "agreement,", "we", "will", "seek", "new", "potential", "partners", "or", "licensees", "for", "Fablyn."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_13_item1_p11_s2", "idA": "886163_12_item1_p45_s11", "sentA": "The terms of the Agreement call for us to receive a non-refundable license fee of $0.5 million.", "sentB": "We earned a milestone payment of $0.6 million upon FDA approval.", "type": 1, "words": ["<tag1>", "The", "terms", "of", "the", "Agreement", "call", "for", "us", "to", "receive", "a", "non-refundable", "license", "fee", "of", "$0.5", "million.", "<tag2>", "We", "earned", "a", "milestone", "payment", "of", "$0.6", "million", "upon", "FDA", "approval.", "<tag3>"], "wordsA": ["The", "terms", "of", "the", "Agreement", "call", "for", "us", "to", "receive", "a", "non-refundable", "license", "fee", "of", "$0.5", "million."], "wordsB": ["We", "earned", "a", "milestone", "payment", "of", "$0.6", "million", "upon", "FDA", "approval."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_13_item1_p44_s4", "idA": "886163_12_item1_p45_s8", "sentA": "Under the Supply Agreement, Lilly agreed to purchase from us its CAPTISOL requirements for the development of the compounds contemplated by the License Agreement, as well as any CAPTISOL required for any product that is successfully commercialized.", "sentB": "Under the settlement agreement, Chiva agreed to pay $0.1 million and we agreed to drop our claim for $1.7 million asserted in arbitration.", "type": 1, "words": ["<tag1>", "Under", "the", "Supply", "Agreement,", "Lilly", "agreed", "to", "purchase", "from", "us", "its", "CAPTISOL", "requirements", "for", "the", "development", "of", "the", "compounds", "contemplated", "by", "the", "License", "Agreement,", "as", "well", "as", "any", "CAPTISOL", "required", "for", "any", "product", "that", "is", "successfully", "commercialized.", "<tag2>", "Under", "the", "settlement", "agreement,", "Chiva", "agreed", "to", "pay", "$0.1", "million", "and", "we", "agreed", "to", "drop", "our", "claim", "for", "$1.7", "million", "asserted", "in", "arbitration.", "<tag3>"], "wordsA": ["Under", "the", "Supply", "Agreement,", "Lilly", "agreed", "to", "purchase", "from", "us", "its", "CAPTISOL", "requirements", "for", "the", "development", "of", "the", "compounds", "contemplated", "by", "the", "License", "Agreement,", "as", "well", "as", "any", "CAPTISOL", "required", "for", "any", "product", "that", "is", "successfully", "commercialized."], "wordsB": ["Under", "the", "settlement", "agreement,", "Chiva", "agreed", "to", "pay", "$0.1", "million", "and", "we", "agreed", "to", "drop", "our", "claim", "for", "$1.7", "million", "asserted", "in", "arbitration."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_13_item1_p55_s0", "idA": "886163_12_item1_p47_s1", "sentA": "Hematopoietic growth factor receptors are involved in the differentiation and proliferation of blood cell progenitors, the formation of new blood cells, and the action of drugs such as PROMACTA, Epogen and Neumega.", "sentB": "The lead compound, LG7455, activates the GCSF-GCSFR signaling pathway and induces the differentiation of human bone marrow cells into granulocytes.", "type": 1, "words": ["<tag1>", "Hematopoietic", "growth", "factor", "receptors", "are", "involved", "in", "the", "differentiation", "and", "proliferation", "of", "blood", "cell", "progenitors,", "the", "formation", "of", "new", "blood", "cells,", "and", "the", "action", "of", "drugs", "such", "as", "PROMACTA,", "Epogen", "and", "Neumega.", "<tag2>", "The", "lead", "compound,", "LG7455,", "activates", "the", "GCSF-GCSFR", "signaling", "pathway", "and", "induces", "the", "differentiation", "of", "human", "bone", "marrow", "cells", "into", "granulocytes.", "<tag3>"], "wordsA": ["Hematopoietic", "growth", "factor", "receptors", "are", "involved", "in", "the", "differentiation", "and", "proliferation", "of", "blood", "cell", "progenitors,", "the", "formation", "of", "new", "blood", "cells,", "and", "the", "action", "of", "drugs", "such", "as", "PROMACTA,", "Epogen", "and", "Neumega."], "wordsB": ["The", "lead", "compound,", "LG7455,", "activates", "the", "GCSF-GCSFR", "signaling", "pathway", "and", "induces", "the", "differentiation", "of", "human", "bone", "marrow", "cells", "into", "granulocytes."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_13_item1_p56_s0", "idA": "886163_12_item1_p47_s1", "sentA": "Hematopoietic growth factor receptors are involved in the differentiation and proliferation of blood cell progenitors, the formation of new blood cells, and the action of drugs such as PROMACTA, Epogen and Neumega.", "sentB": "Oral EPO Program Erythropoietin (EPO) acts on its receptor to stimulate the differentiation of bone marrow hematopoietic cells to form red blood cells.", "type": 1, "words": ["<tag1>", "Hematopoietic", "growth", "factor", "receptors", "are", "involved", "in", "the", "differentiation", "and", "proliferation", "of", "blood", "cell", "progenitors,", "the", "formation", "of", "new", "blood", "cells,", "and", "the", "action", "of", "drugs", "such", "as", "PROMACTA,", "Epogen", "and", "Neumega.", "<tag2>", "Oral", "EPO", "Program", "Erythropoietin", "(EPO)", "acts", "on", "its", "receptor", "to", "stimulate", "the", "differentiation", "of", "bone", "marrow", "hematopoietic", "cells", "to", "form", "red", "blood", "cells.", "<tag3>"], "wordsA": ["Hematopoietic", "growth", "factor", "receptors", "are", "involved", "in", "the", "differentiation", "and", "proliferation", "of", "blood", "cell", "progenitors,", "the", "formation", "of", "new", "blood", "cells,", "and", "the", "action", "of", "drugs", "such", "as", "PROMACTA,", "Epogen", "and", "Neumega."], "wordsB": ["Oral", "EPO", "Program", "Erythropoietin", "(EPO)", "acts", "on", "its", "receptor", "to", "stimulate", "the", "differentiation", "of", "bone", "marrow", "hematopoietic", "cells", "to", "form", "red", "blood", "cells."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_13_item1_p13_s0", "idA": "886163_12_item1_p4_s2", "sentA": "Since a portion of our business model is based on the goal of partnering with other pharmaceutical companies to commercialize and market our assets, a significant amount of our revenue is based largely on payments made to us by partners for royalties, milestones and license fees.", "sentB": "The indication for Kyprolis is based on response rate.", "type": 1, "words": ["<tag1>", "Since", "a", "portion", "of", "our", "business", "model", "is", "based", "on", "the", "goal", "of", "partnering", "with", "other", "pharmaceutical", "companies", "to", "commercialize", "and", "market", "our", "assets,", "a", "significant", "amount", "of", "our", "revenue", "is", "based", "largely", "on", "payments", "made", "to", "us", "by", "partners", "for", "royalties,", "milestones", "and", "license", "fees.", "<tag2>", "The", "indication", "for", "Kyprolis", "is", "based", "on", "response", "rate.", "<tag3>"], "wordsA": ["Since", "a", "portion", "of", "our", "business", "model", "is", "based", "on", "the", "goal", "of", "partnering", "with", "other", "pharmaceutical", "companies", "to", "commercialize", "and", "market", "our", "assets,", "a", "significant", "amount", "of", "our", "revenue", "is", "based", "largely", "on", "payments", "made", "to", "us", "by", "partners", "for", "royalties,", "milestones", "and", "license", "fees."], "wordsB": ["The", "indication", "for", "Kyprolis", "is", "based", "on", "response", "rate."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_13_item1_p23_s0", "idA": "886163_12_item1_p4_s4", "sentA": "CAPTISOL is a powerful formulation technology that has enabled five FDA approved products, including Pfizer s VFEND IV and Baxter International s Nexterone and is currently being used in a number of clinical-stage partner programs.", "sentB": "This program is currently enrolling patients in a pivotal clinical trial.", "type": 1, "words": ["<tag1>", "CAPTISOL", "is", "a", "powerful", "formulation", "technology", "that", "has", "enabled", "five", "FDA", "approved", "products,", "including", "Pfizer", "s", "VFEND", "IV", "and", "Baxter", "International", "s", "Nexterone", "and", "is", "currently", "being", "used", "in", "a", "number", "of", "clinical-stage", "partner", "programs.", "<tag2>", "This", "program", "is", "currently", "enrolling", "patients", "in", "a", "pivotal", "clinical", "trial.", "<tag3>"], "wordsA": ["CAPTISOL", "is", "a", "powerful", "formulation", "technology", "that", "has", "enabled", "five", "FDA", "approved", "products,", "including", "Pfizer", "s", "VFEND", "IV", "and", "Baxter", "International", "s", "Nexterone", "and", "is", "currently", "being", "used", "in", "a", "number", "of", "clinical-stage", "partner", "programs."], "wordsB": ["This", "program", "is", "currently", "enrolling", "patients", "in", "a", "pivotal", "clinical", "trial."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_13_item1_p37_s0", "idA": "886163_12_item1_p50_s0", "sentA": "HepDirect is a prodrug technology that targets delivery of certain drugs to the liver by using a proprietary chemical modification that renders a drug biologically inactive until cleaved by a liver-specific enzyme.", "sentB": "Amyloid-beta is formed when the larger amyloid precursor protein (APP) is cleaved by two enzymes, beta-secretase and gamma-secretase, which releases the amyloid-beta fragment.", "type": 1, "words": ["<tag1>", "HepDirect", "is", "a", "prodrug", "technology", "that", "targets", "delivery", "of", "certain", "drugs", "to", "the", "liver", "by", "using", "a", "proprietary", "chemical", "modification", "that", "renders", "a", "drug", "biologically", "inactive", "until", "cleaved", "by", "a", "liver-specific", "enzyme.", "<tag2>", "Amyloid-beta", "is", "formed", "when", "the", "larger", "amyloid", "precursor", "protein", "(APP)", "is", "cleaved", "by", "two", "enzymes,", "beta-secretase", "and", "gamma-secretase,", "which", "releases", "the", "amyloid-beta", "fragment.", "<tag3>"], "wordsA": ["HepDirect", "is", "a", "prodrug", "technology", "that", "targets", "delivery", "of", "certain", "drugs", "to", "the", "liver", "by", "using", "a", "proprietary", "chemical", "modification", "that", "renders", "a", "drug", "biologically", "inactive", "until", "cleaved", "by", "a", "liver-specific", "enzyme."], "wordsB": ["Amyloid-beta", "is", "formed", "when", "the", "larger", "amyloid", "precursor", "protein", "(APP)", "is", "cleaved", "by", "two", "enzymes,", "beta-secretase", "and", "gamma-secretase,", "which", "releases", "the", "amyloid-beta", "fragment."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_13_item1_p22_s2", "idA": "886163_12_item1_p55_s4", "sentA": "In December 2011, the contract was amended to allow certain bulk quantities of CAPTISOL to be distributed directly from Hovione.", "sentB": "The formulation avoids the use of propylene glycol, which has been reported to cause renal and cardiac side-effects that limit the ability to deliver higher quantities of therapeutic compounds.", "type": 1, "words": ["<tag1>", "In", "December", "2011,", "the", "contract", "was", "amended", "to", "allow", "certain", "bulk", "quantities", "of", "CAPTISOL", "to", "be", "distributed", "directly", "from", "Hovione.", "<tag2>", "The", "formulation", "avoids", "the", "use", "of", "propylene", "glycol,", "which", "has", "been", "reported", "to", "cause", "renal", "and", "cardiac", "side-effects", "that", "limit", "the", "ability", "to", "deliver", "higher", "quantities", "of", "therapeutic", "compounds.", "<tag3>"], "wordsA": ["In", "December", "2011,", "the", "contract", "was", "amended", "to", "allow", "certain", "bulk", "quantities", "of", "CAPTISOL", "to", "be", "distributed", "directly", "from", "Hovione."], "wordsB": ["The", "formulation", "avoids", "the", "use", "of", "propylene", "glycol,", "which", "has", "been", "reported", "to", "cause", "renal", "and", "cardiac", "side-effects", "that", "limit", "the", "ability", "to", "deliver", "higher", "quantities", "of", "therapeutic", "compounds."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_13_item1_p35_s0", "idA": "886163_12_item1_p59_s3", "sentA": "For a discussion of the risks associated with competition, see below under Item 1A. Risk Factors.", "sentB": "This disease is characterized by plaques of the toxic amyloid-beta protein within the brain.", "type": 1, "words": ["<tag1>", "For", "a", "discussion", "of", "the", "risks", "associated", "with", "competition,", "see", "below", "under", "Item", "1A.", "Risk", "Factors.", "<tag2>", "This", "disease", "is", "characterized", "by", "plaques", "of", "the", "toxic", "amyloid-beta", "protein", "within", "the", "brain.", "<tag3>"], "wordsA": ["For", "a", "discussion", "of", "the", "risks", "associated", "with", "competition,", "see", "below", "under", "Item", "1A.", "Risk", "Factors."], "wordsB": ["This", "disease", "is", "characterized", "by", "plaques", "of", "the", "toxic", "amyloid-beta", "protein", "within", "the", "brain."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_13_item1_p47_s3", "idA": "886163_12_item1_p62_s6", "sentA": "In addition, changes in existing regulations could have a material adverse effect to us.", "sentB": "Key findings of this study included: LGD-4033 was safe and well tolerated at all doses following daily oral administration for three weeks in young healthy males; no clinically significant dose-related adverse events were reported; no clinically significant changes in liver function tests, PSA, hematocrit or ECG were seen; positive dose-dependent trends in lean muscle mass increase were observed with drug-treated subjects; positive dose-dependent trends in functional exercise and strength measures were consistent with anabolic activity.", "type": 1, "words": ["<tag1>", "In", "addition,", "changes", "in", "existing", "regulations", "could", "have", "a", "material", "adverse", "effect", "to", "us.", "<tag2>", "Key", "findings", "of", "this", "study", "included:", "LGD-4033", "was", "safe", "and", "well", "tolerated", "at", "all", "doses", "following", "daily", "oral", "administration", "for", "three", "weeks", "in", "young", "healthy", "males;", "no", "clinically", "significant", "dose-related", "adverse", "events", "were", "reported;", "no", "clinically", "significant", "changes", "in", "liver", "function", "tests,", "PSA,", "hematocrit", "or", "ECG", "were", "seen;", "positive", "dose-dependent", "trends", "in", "lean", "muscle", "mass", "increase", "were", "observed", "with", "drug-treated", "subjects;", "positive", "dose-dependent", "trends", "in", "functional", "exercise", "and", "strength", "measures", "were", "consistent", "with", "anabolic", "activity.", "<tag3>"], "wordsA": ["In", "addition,", "changes", "in", "existing", "regulations", "could", "have", "a", "material", "adverse", "effect", "to", "us."], "wordsB": ["Key", "findings", "of", "this", "study", "included:", "LGD-4033", "was", "safe", "and", "well", "tolerated", "at", "all", "doses", "following", "daily", "oral", "administration", "for", "three", "weeks", "in", "young", "healthy", "males;", "no", "clinically", "significant", "dose-related", "adverse", "events", "were", "reported;", "no", "clinically", "significant", "changes", "in", "liver", "function", "tests,", "PSA,", "hematocrit", "or", "ECG", "were", "seen;", "positive", "dose-dependent", "trends", "in", "lean", "muscle", "mass", "increase", "were", "observed", "with", "drug-treated", "subjects;", "positive", "dose-dependent", "trends", "in", "functional", "exercise", "and", "strength", "measures", "were", "consistent", "with", "anabolic", "activity."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_13_item1_p54_s0", "idA": "886163_12_item1_p63_s5", "sentA": "We have developed and are developing a number of policies and procedures to ensure our compliance with these state laws, in addition to the federal regulations described above.", "sentB": "Oral Human Granulocyte Colony Stimulating Factor (GCSF) Program We have discovered a novel series of small molecules that selectively activate human granulocyte colony stimulating factor (GCSF) receptor function in a manner distinct from GCSF, but similar to the mechanism of small-molecule human thrombopoietin receptor (hTPOR) agonists, such as eltrombopag (Promacta ).", "type": 1, "words": ["<tag1>", "We", "have", "developed", "and", "are", "developing", "a", "number", "of", "policies", "and", "procedures", "to", "ensure", "our", "compliance", "with", "these", "state", "laws,", "in", "addition", "to", "the", "federal", "regulations", "described", "above.", "<tag2>", "Oral", "Human", "Granulocyte", "Colony", "Stimulating", "Factor", "(GCSF)", "Program", "We", "have", "discovered", "a", "novel", "series", "of", "small", "molecules", "that", "selectively", "activate", "human", "granulocyte", "colony", "stimulating", "factor", "(GCSF)", "receptor", "function", "in", "a", "manner", "distinct", "from", "GCSF,", "but", "similar", "to", "the", "mechanism", "of", "small-molecule", "human", "thrombopoietin", "receptor", "(hTPOR)", "agonists,", "such", "as", "eltrombopag", "(Promacta", ").", "<tag3>"], "wordsA": ["We", "have", "developed", "and", "are", "developing", "a", "number", "of", "policies", "and", "procedures", "to", "ensure", "our", "compliance", "with", "these", "state", "laws,", "in", "addition", "to", "the", "federal", "regulations", "described", "above."], "wordsB": ["Oral", "Human", "Granulocyte", "Colony", "Stimulating", "Factor", "(GCSF)", "Program", "We", "have", "discovered", "a", "novel", "series", "of", "small", "molecules", "that", "selectively", "activate", "human", "granulocyte", "colony", "stimulating", "factor", "(GCSF)", "receptor", "function", "in", "a", "manner", "distinct", "from", "GCSF,", "but", "similar", "to", "the", "mechanism", "of", "small-molecule", "human", "thrombopoietin", "receptor", "(hTPOR)", "agonists,", "such", "as", "eltrombopag", "(Promacta", ")."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_13_item1_p46_s1", "idA": "886163_12_item1_p64_s0", "sentA": "We believe that patents and other proprietary rights are important to our business.", "sentB": "We have discovered several novel orally active, non-steroidal SARM compounds, including LGD-4033, based on tissue-specific gene expression and other functional, cell-based technologies.", "type": 1, "words": ["<tag1>", "We", "believe", "that", "patents", "and", "other", "proprietary", "rights", "are", "important", "to", "our", "business.", "<tag2>", "We", "have", "discovered", "several", "novel", "orally", "active,", "non-steroidal", "SARM", "compounds,", "including", "LGD-4033,", "based", "on", "tissue-specific", "gene", "expression", "and", "other", "functional,", "cell-based", "technologies.", "<tag3>"], "wordsA": ["We", "believe", "that", "patents", "and", "other", "proprietary", "rights", "are", "important", "to", "our", "business."], "wordsB": ["We", "have", "discovered", "several", "novel", "orally", "active,", "non-steroidal", "SARM", "compounds,", "including", "LGD-4033,", "based", "on", "tissue-specific", "gene", "expression", "and", "other", "functional,", "cell-based", "technologies."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_13_item1_p20_s3", "idA": "886163_12_item1_p64_s7", "sentA": "Subject to compliance with the terms of the respective agreements, our rights under our licenses with our exclusive licensors extend for the life of the patents covering such developments.", "sentB": "For the year ended December 31, 2012, we received $0.3 million for the filing submissions with the FDA and the EMA.", "type": 1, "words": ["<tag1>", "Subject", "to", "compliance", "with", "the", "terms", "of", "the", "respective", "agreements,", "our", "rights", "under", "our", "licenses", "with", "our", "exclusive", "licensors", "extend", "for", "the", "life", "of", "the", "patents", "covering", "such", "developments.", "<tag2>", "For", "the", "year", "ended", "December", "31,", "2012,", "we", "received", "$0.3", "million", "for", "the", "filing", "submissions", "with", "the", "FDA", "and", "the", "EMA.", "<tag3>"], "wordsA": ["Subject", "to", "compliance", "with", "the", "terms", "of", "the", "respective", "agreements,", "our", "rights", "under", "our", "licenses", "with", "our", "exclusive", "licensors", "extend", "for", "the", "life", "of", "the", "patents", "covering", "such", "developments."], "wordsB": ["For", "the", "year", "ended", "December", "31,", "2012,", "we", "received", "$0.3", "million", "for", "the", "filing", "submissions", "with", "the", "FDA", "and", "the", "EMA."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_13_item1_p38_s0", "idA": "886163_12_item1_p9_s2", "sentA": "We perform extensive target profiling and base our selection of promising development candidates on product characteristics such as initial indications of safety and efficacy.", "sentB": "In December 2012, Merck initiated a Phase II/III clinical trial for its lead BACE inhibitor product candidate, MK-8931, evaluating its safety and efficacy in patients with mild-to-moderate Alzheimer's disease.", "type": 1, "words": ["<tag1>", "We", "perform", "extensive", "target", "profiling", "and", "base", "our", "selection", "of", "promising", "development", "candidates", "on", "product", "characteristics", "such", "as", "initial", "indications", "of", "safety", "and", "efficacy.", "<tag2>", "In", "December", "2012,", "Merck", "initiated", "a", "Phase", "II/III", "clinical", "trial", "for", "its", "lead", "BACE", "inhibitor", "product", "candidate,", "MK-8931,", "evaluating", "its", "safety", "and", "efficacy", "in", "patients", "with", "mild-to-moderate", "Alzheimer's", "disease.", "<tag3>"], "wordsA": ["We", "perform", "extensive", "target", "profiling", "and", "base", "our", "selection", "of", "promising", "development", "candidates", "on", "product", "characteristics", "such", "as", "initial", "indications", "of", "safety", "and", "efficacy."], "wordsB": ["In", "December", "2012,", "Merck", "initiated", "a", "Phase", "II/III", "clinical", "trial", "for", "its", "lead", "BACE", "inhibitor", "product", "candidate,", "MK-8931,", "evaluating", "its", "safety", "and", "efficacy", "in", "patients", "with", "mild-to-moderate", "Alzheimer's", "disease."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_13_item1_p47_s1", "idA": "886163_12_item1_p9_s4", "sentA": "Our goal is to partner our programs early in the development and regulatory life-cycle.", "sentB": "The safety, tolerability and preliminary efficacy of LGD-4033 was evaluated in the double-blind, placebo-controlled Phase I multiple ascending dose study.", "type": 1, "words": ["<tag1>", "Our", "goal", "is", "to", "partner", "our", "programs", "early", "in", "the", "development", "and", "regulatory", "life-cycle.", "<tag2>", "The", "safety,", "tolerability", "and", "preliminary", "efficacy", "of", "LGD-4033", "was", "evaluated", "in", "the", "double-blind,", "placebo-controlled", "Phase", "I", "multiple", "ascending", "dose", "study.", "<tag3>"], "wordsA": ["Our", "goal", "is", "to", "partner", "our", "programs", "early", "in", "the", "development", "and", "regulatory", "life-cycle."], "wordsB": ["The", "safety,", "tolerability", "and", "preliminary", "efficacy", "of", "LGD-4033", "was", "evaluated", "in", "the", "double-blind,", "placebo-controlled", "Phase", "I", "multiple", "ascending", "dose", "study."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_14_item1_p56_s1", "idA": "886163_13_item1_p0_s3", "sentA": "We recognized the important role of the drug reformulation segment in the pharmaceutical industry and in 2011 added Captisol to our technology portfolio.", "sentB": "IRAK4 plays an important role in the innate immune system and may also be important for cross-talk between the innate and adaptive immune systems.", "type": 1, "words": ["<tag1>", "We", "recognized", "the", "important", "role", "of", "the", "drug", "reformulation", "segment", "in", "the", "pharmaceutical", "industry", "and", "in", "2011", "added", "Captisol", "to", "our", "technology", "portfolio.", "<tag2>", "IRAK4", "plays", "an", "important", "role", "in", "the", "innate", "immune", "system", "and", "may", "also", "be", "important", "for", "cross-talk", "between", "the", "innate", "and", "adaptive", "immune", "systems.", "<tag3>"], "wordsA": ["We", "recognized", "the", "important", "role", "of", "the", "drug", "reformulation", "segment", "in", "the", "pharmaceutical", "industry", "and", "in", "2011", "added", "Captisol", "to", "our", "technology", "portfolio."], "wordsB": ["IRAK4", "plays", "an", "important", "role", "in", "the", "innate", "immune", "system", "and", "may", "also", "be", "important", "for", "cross-talk", "between", "the", "innate", "and", "adaptive", "immune", "systems."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_14_item1_p85_s3", "idA": "886163_13_item1_p10_s2", "sentA": "GSK has listed a patent in the FDA s Orange Book for Promacta with an expiration date in 2027.", "sentB": "The type of patent protection ( e.g ., composition of matter or use) for each patent listed in the Orange Book and the expiration dates for each patent listed in the Orange Book are provided in the following table.", "type": 1, "words": ["<tag1>", "GSK", "has", "listed", "a", "patent", "in", "the", "FDA", "s", "Orange", "Book", "for", "Promacta", "with", "an", "expiration", "date", "in", "2027.", "<tag2>", "The", "type", "of", "patent", "protection", "(", "e.g", ".,", "composition", "of", "matter", "or", "use)", "for", "each", "patent", "listed", "in", "the", "Orange", "Book", "and", "the", "expiration", "dates", "for", "each", "patent", "listed", "in", "the", "Orange", "Book", "are", "provided", "in", "the", "following", "table.", "<tag3>"], "wordsA": ["GSK", "has", "listed", "a", "patent", "in", "the", "FDA", "s", "Orange", "Book", "for", "Promacta", "with", "an", "expiration", "date", "in", "2027."], "wordsB": ["The", "type", "of", "patent", "protection", "(", "e.g", ".,", "composition", "of", "matter", "or", "use)", "for", "each", "patent", "listed", "in", "the", "Orange", "Book", "and", "the", "expiration", "dates", "for", "each", "patent", "listed", "in", "the", "Orange", "Book", "are", "provided", "in", "the", "following", "table."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_14_item1_p43_s0", "idA": "886163_13_item1_p18_s0", "sentA": "Viviant, a selective estrogen receptor modulator (SERM), is a result of the successful research collaboration between Wyeth (now a subsidiary of Pfizer) and us that began in 1994.", "sentB": "Lasofoxifene is an estrogen partial agonist for osteoporosis treatment and other diseases, discovered through the research collaboration between us and Pfizer.", "type": 1, "words": ["<tag1>", "Viviant,", "a", "selective", "estrogen", "receptor", "modulator", "(SERM),", "is", "a", "result", "of", "the", "successful", "research", "collaboration", "between", "Wyeth", "(now", "a", "subsidiary", "of", "Pfizer)", "and", "us", "that", "began", "in", "1994.", "<tag2>", "Lasofoxifene", "is", "an", "estrogen", "partial", "agonist", "for", "osteoporosis", "treatment", "and", "other", "diseases,", "discovered", "through", "the", "research", "collaboration", "between", "us", "and", "Pfizer.", "<tag3>"], "wordsA": ["Viviant,", "a", "selective", "estrogen", "receptor", "modulator", "(SERM),", "is", "a", "result", "of", "the", "successful", "research", "collaboration", "between", "Wyeth", "(now", "a", "subsidiary", "of", "Pfizer)", "and", "us", "that", "began", "in", "1994."], "wordsB": ["Lasofoxifene", "is", "an", "estrogen", "partial", "agonist", "for", "osteoporosis", "treatment", "and", "other", "diseases,", "discovered", "through", "the", "research", "collaboration", "between", "us", "and", "Pfizer."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_14_item1_p17_s1", "idA": "886163_13_item1_p19_s3", "sentA": "We are supplying Captisol to Baxter for use in accordance with the terms of the license agreement under a separate supply agreement.", "sentB": "Under this agreement we agreed to sell Captisol to Onyx for use with carfilzomib, and granted an exclusive product-specific license under our patent rights with respect to Captisol.", "type": 1, "words": ["<tag1>", "We", "are", "supplying", "Captisol", "to", "Baxter", "for", "use", "in", "accordance", "with", "the", "terms", "of", "the", "license", "agreement", "under", "a", "separate", "supply", "agreement.", "<tag2>", "Under", "this", "agreement", "we", "agreed", "to", "sell", "Captisol", "to", "Onyx", "for", "use", "with", "carfilzomib,", "and", "granted", "an", "exclusive", "product-specific", "license", "under", "our", "patent", "rights", "with", "respect", "to", "Captisol.", "<tag3>"], "wordsA": ["We", "are", "supplying", "Captisol", "to", "Baxter", "for", "use", "in", "accordance", "with", "the", "terms", "of", "the", "license", "agreement", "under", "a", "separate", "supply", "agreement."], "wordsB": ["Under", "this", "agreement", "we", "agreed", "to", "sell", "Captisol", "to", "Onyx", "for", "use", "with", "carfilzomib,", "and", "granted", "an", "exclusive", "product-specific", "license", "under", "our", "patent", "rights", "with", "respect", "to", "Captisol."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_14_item1_p13_s4", "idA": "886163_13_item1_p19_s4", "sentA": "Baxter has paid milestone payments and is obligated to pay royalties to us on sales of Nexterone through early 2029.", "sentB": "The obligation to pay royalties lasts during the life or the relevant patents or at a reduced rate for ten years from the first commercial sale, whichever is longer, on a country-by-country basis.", "type": 1, "words": ["<tag1>", "Baxter", "has", "paid", "milestone", "payments", "and", "is", "obligated", "to", "pay", "royalties", "to", "us", "on", "sales", "of", "Nexterone", "through", "early", "2029.", "<tag2>", "The", "obligation", "to", "pay", "royalties", "lasts", "during", "the", "life", "or", "the", "relevant", "patents", "or", "at", "a", "reduced", "rate", "for", "ten", "years", "from", "the", "first", "commercial", "sale,", "whichever", "is", "longer,", "on", "a", "country-by-country", "basis.", "<tag3>"], "wordsA": ["Baxter", "has", "paid", "milestone", "payments", "and", "is", "obligated", "to", "pay", "royalties", "to", "us", "on", "sales", "of", "Nexterone", "through", "early", "2029."], "wordsB": ["The", "obligation", "to", "pay", "royalties", "lasts", "during", "the", "life", "or", "the", "relevant", "patents", "or", "at", "a", "reduced", "rate", "for", "ten", "years", "from", "the", "first", "commercial", "sale,", "whichever", "is", "longer,", "on", "a", "country-by-country", "basis."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_14_item1_p44_s0", "idA": "886163_13_item1_p1_s1", "sentA": "The therapies in our development portfolio address the unmet medical needs of patients for a broad spectrum of diseases including hepatitis, muscle wasting, multiple myeloma, Alzheimer s disease, dyslipidemia, diabetes, anemia, epilepsy, FSGS and osteoporosis.", "sentB": "Ethicor plans to supply oral lasofoxifene as an unlicensed medicinal product, which may be requested by healthcare professionals to meet the clinical needs of patients when authorized medicines are unsuitable or contraindicated.", "type": 1, "words": ["<tag1>", "The", "therapies", "in", "our", "development", "portfolio", "address", "the", "unmet", "medical", "needs", "of", "patients", "for", "a", "broad", "spectrum", "of", "diseases", "including", "hepatitis,", "muscle", "wasting,", "multiple", "myeloma,", "Alzheimer", "s", "disease,", "dyslipidemia,", "diabetes,", "anemia,", "epilepsy,", "FSGS", "and", "osteoporosis.", "<tag2>", "Ethicor", "plans", "to", "supply", "oral", "lasofoxifene", "as", "an", "unlicensed", "medicinal", "product,", "which", "may", "be", "requested", "by", "healthcare", "professionals", "to", "meet", "the", "clinical", "needs", "of", "patients", "when", "authorized", "medicines", "are", "unsuitable", "or", "contraindicated.", "<tag3>"], "wordsA": ["The", "therapies", "in", "our", "development", "portfolio", "address", "the", "unmet", "medical", "needs", "of", "patients", "for", "a", "broad", "spectrum", "of", "diseases", "including", "hepatitis,", "muscle", "wasting,", "multiple", "myeloma,", "Alzheimer", "s", "disease,", "dyslipidemia,", "diabetes,", "anemia,", "epilepsy,", "FSGS", "and", "osteoporosis."], "wordsB": ["Ethicor", "plans", "to", "supply", "oral", "lasofoxifene", "as", "an", "unlicensed", "medicinal", "product,", "which", "may", "be", "requested", "by", "healthcare", "professionals", "to", "meet", "the", "clinical", "needs", "of", "patients", "when", "authorized", "medicines", "are", "unsuitable", "or", "contraindicated."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_14_item1_p15_s0", "idA": "886163_13_item1_p22_s5", "sentA": "We are also eligible to receive significant double-digit royalties on future net sales of the Captisol-enabled melphalan product.", "sentB": "*Net royalties due Ligand after payment to Rockefeller University.", "type": 1, "words": ["<tag1>", "We", "are", "also", "eligible", "to", "receive", "significant", "double-digit", "royalties", "on", "future", "net", "sales", "of", "the", "Captisol-enabled", "melphalan", "product.", "<tag2>", "*Net", "royalties", "due", "Ligand", "after", "payment", "to", "Rockefeller", "University.", "<tag3>"], "wordsA": ["We", "are", "also", "eligible", "to", "receive", "significant", "double-digit", "royalties", "on", "future", "net", "sales", "of", "the", "Captisol-enabled", "melphalan", "product."], "wordsB": ["*Net", "royalties", "due", "Ligand", "after", "payment", "to", "Rockefeller", "University."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_14_item1_p3_s0", "idA": "886163_13_item1_p22_s5", "sentA": "We are also eligible to receive significant double-digit royalties on future net sales of the Captisol-enabled melphalan product.", "sentB": "We were incorporated in Delaware in 1987.", "type": 1, "words": ["<tag1>", "We", "are", "also", "eligible", "to", "receive", "significant", "double-digit", "royalties", "on", "future", "net", "sales", "of", "the", "Captisol-enabled", "melphalan", "product.", "<tag2>", "We", "were", "incorporated", "in", "Delaware", "in", "1987.", "<tag3>"], "wordsA": ["We", "are", "also", "eligible", "to", "receive", "significant", "double-digit", "royalties", "on", "future", "net", "sales", "of", "the", "Captisol-enabled", "melphalan", "product."], "wordsB": ["We", "were", "incorporated", "in", "Delaware", "in", "1987."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_14_item1_p3_s1", "idA": "886163_13_item1_p22_s5", "sentA": "We are also eligible to receive significant double-digit royalties on future net sales of the Captisol-enabled melphalan product.", "sentB": "Our principal executive offices are located at 11119 North Torrey Pines Road, Suite 200, La Jolla, California, 92037.", "type": 1, "words": ["<tag1>", "We", "are", "also", "eligible", "to", "receive", "significant", "double-digit", "royalties", "on", "future", "net", "sales", "of", "the", "Captisol-enabled", "melphalan", "product.", "<tag2>", "Our", "principal", "executive", "offices", "are", "located", "at", "11119", "North", "Torrey", "Pines", "Road,", "Suite", "200,", "La", "Jolla,", "California,", "92037.", "<tag3>"], "wordsA": ["We", "are", "also", "eligible", "to", "receive", "significant", "double-digit", "royalties", "on", "future", "net", "sales", "of", "the", "Captisol-enabled", "melphalan", "product."], "wordsB": ["Our", "principal", "executive", "offices", "are", "located", "at", "11119", "North", "Torrey", "Pines", "Road,", "Suite", "200,", "La", "Jolla,", "California,", "92037."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_14_item1_p3_s2", "idA": "886163_13_item1_p22_s5", "sentA": "We are also eligible to receive significant double-digit royalties on future net sales of the Captisol-enabled melphalan product.", "sentB": "Our telephone number is (858) 550-7500.", "type": 1, "words": ["<tag1>", "We", "are", "also", "eligible", "to", "receive", "significant", "double-digit", "royalties", "on", "future", "net", "sales", "of", "the", "Captisol-enabled", "melphalan", "product.", "<tag2>", "Our", "telephone", "number", "is", "(858)", "550-7500.", "<tag3>"], "wordsA": ["We", "are", "also", "eligible", "to", "receive", "significant", "double-digit", "royalties", "on", "future", "net", "sales", "of", "the", "Captisol-enabled", "melphalan", "product."], "wordsB": ["Our", "telephone", "number", "is", "(858)", "550-7500."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_14_item1_p55_s1", "idA": "886163_13_item1_p23_s0", "sentA": "This program is currently enrolling patients in a pivotal clinical trial.", "sentB": "It also significantly increases peripheral blood neutrophils and demonstrated the first reported proof-of-concept for a small molecule GCSF receptor antagonist in a primate model.", "type": 1, "words": ["<tag1>", "This", "program", "is", "currently", "enrolling", "patients", "in", "a", "pivotal", "clinical", "trial.", "<tag2>", "It", "also", "significantly", "increases", "peripheral", "blood", "neutrophils", "and", "demonstrated", "the", "first", "reported", "proof-of-concept", "for", "a", "small", "molecule", "GCSF", "receptor", "antagonist", "in", "a", "primate", "model.", "<tag3>"], "wordsA": ["This", "program", "is", "currently", "enrolling", "patients", "in", "a", "pivotal", "clinical", "trial."], "wordsB": ["It", "also", "significantly", "increases", "peripheral", "blood", "neutrophils", "and", "demonstrated", "the", "first", "reported", "proof-of-concept", "for", "a", "small", "molecule", "GCSF", "receptor", "antagonist", "in", "a", "primate", "model."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_14_item1_p67_s0", "idA": "886163_13_item1_p25_s1", "sentA": "The Captisol-enabled clopidogrel formulation is designed to provide an intravenous option in situations where the administration of oral platelet inhibitors is not feasible or desirable.", "sentB": "MedCo recently conducted a pharmacokinetic and pharmacodynamic study of oral Clopidogrel and Captisol-enabled intravenous Clopidogrel in healthy volunteers.", "type": 1, "words": ["<tag1>", "The", "Captisol-enabled", "clopidogrel", "formulation", "is", "designed", "to", "provide", "an", "intravenous", "option", "in", "situations", "where", "the", "administration", "of", "oral", "platelet", "inhibitors", "is", "not", "feasible", "or", "desirable.", "<tag2>", "MedCo", "recently", "conducted", "a", "pharmacokinetic", "and", "pharmacodynamic", "study", "of", "oral", "Clopidogrel", "and", "Captisol-enabled", "intravenous", "Clopidogrel", "in", "healthy", "volunteers.", "<tag3>"], "wordsA": ["The", "Captisol-enabled", "clopidogrel", "formulation", "is", "designed", "to", "provide", "an", "intravenous", "option", "in", "situations", "where", "the", "administration", "of", "oral", "platelet", "inhibitors", "is", "not", "feasible", "or", "desirable."], "wordsB": ["MedCo", "recently", "conducted", "a", "pharmacokinetic", "and", "pharmacodynamic", "study", "of", "oral", "Clopidogrel", "and", "Captisol-enabled", "intravenous", "Clopidogrel", "in", "healthy", "volunteers."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_14_item1_p25_s1", "idA": "886163_13_item1_p2_s1", "sentA": "We have assembled a portfolio of over 70 fully-funded partner programs that are in all stages of development, from preclinical research to awaiting commercialization.", "sentB": "In April 2013, we acquired a portfolio of possible future royalty and milestone payment rights from Selexis SA, based on over 15 Selexis commercial license agreement programs with various pharmaceutical companies.", "type": 1, "words": ["<tag1>", "We", "have", "assembled", "a", "portfolio", "of", "over", "70", "fully-funded", "partner", "programs", "that", "are", "in", "all", "stages", "of", "development,", "from", "preclinical", "research", "to", "awaiting", "commercialization.", "<tag2>", "In", "April", "2013,", "we", "acquired", "a", "portfolio", "of", "possible", "future", "royalty", "and", "milestone", "payment", "rights", "from", "Selexis", "SA,", "based", "on", "over", "15", "Selexis", "commercial", "license", "agreement", "programs", "with", "various", "pharmaceutical", "companies.", "<tag3>"], "wordsA": ["We", "have", "assembled", "a", "portfolio", "of", "over", "70", "fully-funded", "partner", "programs", "that", "are", "in", "all", "stages", "of", "development,", "from", "preclinical", "research", "to", "awaiting", "commercialization."], "wordsB": ["In", "April", "2013,", "we", "acquired", "a", "portfolio", "of", "possible", "future", "royalty", "and", "milestone", "payment", "rights", "from", "Selexis", "SA,", "based", "on", "over", "15", "Selexis", "commercial", "license", "agreement", "programs", "with", "various", "pharmaceutical", "companies."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_14_item1_p25_s6", "idA": "886163_13_item1_p2_s1", "sentA": "We have assembled a portfolio of over 70 fully-funded partner programs that are in all stages of development, from preclinical research to awaiting commercialization.", "sentB": "The programs that we acquired in this transaction are based on Selexis technology platform for cell line development and scale-up to manufacturing of therapeutic proteins, and relate to pre-commercialized drugs that are currently being developed; the programs should thus require no funding or technological support from Ligand.", "type": 1, "words": ["<tag1>", "We", "have", "assembled", "a", "portfolio", "of", "over", "70", "fully-funded", "partner", "programs", "that", "are", "in", "all", "stages", "of", "development,", "from", "preclinical", "research", "to", "awaiting", "commercialization.", "<tag2>", "The", "programs", "that", "we", "acquired", "in", "this", "transaction", "are", "based", "on", "Selexis", "technology", "platform", "for", "cell", "line", "development", "and", "scale-up", "to", "manufacturing", "of", "therapeutic", "proteins,", "and", "relate", "to", "pre-commercialized", "drugs", "that", "are", "currently", "being", "developed;", "the", "programs", "should", "thus", "require", "no", "funding", "or", "technological", "support", "from", "Ligand.", "<tag3>"], "wordsA": ["We", "have", "assembled", "a", "portfolio", "of", "over", "70", "fully-funded", "partner", "programs", "that", "are", "in", "all", "stages", "of", "development,", "from", "preclinical", "research", "to", "awaiting", "commercialization."], "wordsB": ["The", "programs", "that", "we", "acquired", "in", "this", "transaction", "are", "based", "on", "Selexis", "technology", "platform", "for", "cell", "line", "development", "and", "scale-up", "to", "manufacturing", "of", "therapeutic", "proteins,", "and", "relate", "to", "pre-commercialized", "drugs", "that", "are", "currently", "being", "developed;", "the", "programs", "should", "thus", "require", "no", "funding", "or", "technological", "support", "from", "Ligand."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_14_item1_p29_s0", "idA": "886163_13_item1_p3_s0", "sentA": "We sell Captisol material to a broad range of customers.", "sentB": "On portion of sales less than $400 million 0.5 % On portion of sales in range of $400 million to $1 billion 1.5 % On portion of sales greater than $1 billion 2.5 % * Net royalties due Ligand after payment to Royalty Pharma.", "type": 1, "words": ["<tag1>", "We", "sell", "Captisol", "material", "to", "a", "broad", "range", "of", "customers.", "<tag2>", "On", "portion", "of", "sales", "less", "than", "$400", "million", "0.5", "%", "On", "portion", "of", "sales", "in", "range", "of", "$400", "million", "to", "$1", "billion", "1.5", "%", "On", "portion", "of", "sales", "greater", "than", "$1", "billion", "2.5", "%", "*", "Net", "royalties", "due", "Ligand", "after", "payment", "to", "Royalty", "Pharma.", "<tag3>"], "wordsA": ["We", "sell", "Captisol", "material", "to", "a", "broad", "range", "of", "customers."], "wordsB": ["On", "portion", "of", "sales", "less", "than", "$400", "million", "0.5", "%", "On", "portion", "of", "sales", "in", "range", "of", "$400", "million", "to", "$1", "billion", "1.5", "%", "On", "portion", "of", "sales", "greater", "than", "$1", "billion", "2.5", "%", "*", "Net", "royalties", "due", "Ligand", "after", "payment", "to", "Royalty", "Pharma."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_14_item1_p56_s2", "idA": "886163_13_item1_p3_s0", "sentA": "We sell Captisol material to a broad range of customers.", "sentB": "IRAK4 is a key signaling component downstream of both toll-like receptors and interleukin-1 receptors suggesting that it may have therapeutic value for a range of autoimmune and inflammatory conditions.", "type": 1, "words": ["<tag1>", "We", "sell", "Captisol", "material", "to", "a", "broad", "range", "of", "customers.", "<tag2>", "IRAK4", "is", "a", "key", "signaling", "component", "downstream", "of", "both", "toll-like", "receptors", "and", "interleukin-1", "receptors", "suggesting", "that", "it", "may", "have", "therapeutic", "value", "for", "a", "range", "of", "autoimmune", "and", "inflammatory", "conditions.", "<tag3>"], "wordsA": ["We", "sell", "Captisol", "material", "to", "a", "broad", "range", "of", "customers."], "wordsB": ["IRAK4", "is", "a", "key", "signaling", "component", "downstream", "of", "both", "toll-like", "receptors", "and", "interleukin-1", "receptors", "suggesting", "that", "it", "may", "have", "therapeutic", "value", "for", "a", "range", "of", "autoimmune", "and", "inflammatory", "conditions."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_14_item1_p85_s0", "idA": "886163_13_item1_p41_s0", "sentA": "The development and commercialization agreement for Captisol-enabled delafloxacin began in 2008 between Rib-X Pharmaceuticals and us for the use of Captisol in the formation of delafloxacin.", "sentB": "Kyprolis Patents protecting Kyprolis include those owned by Onyx Pharmaceuticals and those owned by Ligand.", "type": 1, "words": ["<tag1>", "The", "development", "and", "commercialization", "agreement", "for", "Captisol-enabled", "delafloxacin", "began", "in", "2008", "between", "Rib-X", "Pharmaceuticals", "and", "us", "for", "the", "use", "of", "Captisol", "in", "the", "formation", "of", "delafloxacin.", "<tag2>", "Kyprolis", "Patents", "protecting", "Kyprolis", "include", "those", "owned", "by", "Onyx", "Pharmaceuticals", "and", "those", "owned", "by", "Ligand.", "<tag3>"], "wordsA": ["The", "development", "and", "commercialization", "agreement", "for", "Captisol-enabled", "delafloxacin", "began", "in", "2008", "between", "Rib-X", "Pharmaceuticals", "and", "us", "for", "the", "use", "of", "Captisol", "in", "the", "formation", "of", "delafloxacin."], "wordsB": ["Kyprolis", "Patents", "protecting", "Kyprolis", "include", "those", "owned", "by", "Onyx", "Pharmaceuticals", "and", "those", "owned", "by", "Ligand."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_14_item1_p66_s1", "idA": "886163_13_item1_p44_s2", "sentA": "In October 2012, we entered into a settlement agreement and mutual release with Chiva, pursuant to which we resolved all disputes, including our primary claim in arbitration relating to payments due under the License Agreement.", "sentB": "In July 2013, we and MedCo mutually terminated the License Agreement dated June 1, 2011 and the related Supply Agreement dated June 1, 2011.", "type": 1, "words": ["<tag1>", "In", "October", "2012,", "we", "entered", "into", "a", "settlement", "agreement", "and", "mutual", "release", "with", "Chiva,", "pursuant", "to", "which", "we", "resolved", "all", "disputes,", "including", "our", "primary", "claim", "in", "arbitration", "relating", "to", "payments", "due", "under", "the", "License", "Agreement.", "<tag2>", "In", "July", "2013,", "we", "and", "MedCo", "mutually", "terminated", "the", "License", "Agreement", "dated", "June", "1,", "2011", "and", "the", "related", "Supply", "Agreement", "dated", "June", "1,", "2011.", "<tag3>"], "wordsA": ["In", "October", "2012,", "we", "entered", "into", "a", "settlement", "agreement", "and", "mutual", "release", "with", "Chiva,", "pursuant", "to", "which", "we", "resolved", "all", "disputes,", "including", "our", "primary", "claim", "in", "arbitration", "relating", "to", "payments", "due", "under", "the", "License", "Agreement."], "wordsB": ["In", "July", "2013,", "we", "and", "MedCo", "mutually", "terminated", "the", "License", "Agreement", "dated", "June", "1,", "2011", "and", "the", "related", "Supply", "Agreement", "dated", "June", "1,", "2011."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_14_item1_p82_s2", "idA": "886163_13_item1_p44_s5", "sentA": "Under the Fablyn license agreement, we have been paid and will retain $2.5 million in license fees.", "sentB": "The nominal patent expiration dates have been provided.", "type": 1, "words": ["<tag1>", "Under", "the", "Fablyn", "license", "agreement,", "we", "have", "been", "paid", "and", "will", "retain", "$2.5", "million", "in", "license", "fees.", "<tag2>", "The", "nominal", "patent", "expiration", "dates", "have", "been", "provided.", "<tag3>"], "wordsA": ["Under", "the", "Fablyn", "license", "agreement,", "we", "have", "been", "paid", "and", "will", "retain", "$2.5", "million", "in", "license", "fees."], "wordsB": ["The", "nominal", "patent", "expiration", "dates", "have", "been", "provided."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_14_item1_p88_s4", "idA": "886163_13_item1_p58_s1", "sentA": "Hematopoietic growth factor receptors are involved in the differentiation and proliferation of blood cell progenitors, the formation of new blood cells, and the action of drugs such as Promacta, Epogen and Neumega.", "sentB": "The type of patent protection ( e.g ., composition of matter or use) and the expiration dates for several issued patents covering Captisol are provided in the following table.", "type": 1, "words": ["<tag1>", "Hematopoietic", "growth", "factor", "receptors", "are", "involved", "in", "the", "differentiation", "and", "proliferation", "of", "blood", "cell", "progenitors,", "the", "formation", "of", "new", "blood", "cells,", "and", "the", "action", "of", "drugs", "such", "as", "Promacta,", "Epogen", "and", "Neumega.", "<tag2>", "The", "type", "of", "patent", "protection", "(", "e.g", ".,", "composition", "of", "matter", "or", "use)", "and", "the", "expiration", "dates", "for", "several", "issued", "patents", "covering", "Captisol", "are", "provided", "in", "the", "following", "table.", "<tag3>"], "wordsA": ["Hematopoietic", "growth", "factor", "receptors", "are", "involved", "in", "the", "differentiation", "and", "proliferation", "of", "blood", "cell", "progenitors,", "the", "formation", "of", "new", "blood", "cells,", "and", "the", "action", "of", "drugs", "such", "as", "Promacta,", "Epogen", "and", "Neumega."], "wordsB": ["The", "type", "of", "patent", "protection", "(", "e.g", ".,", "composition", "of", "matter", "or", "use)", "and", "the", "expiration", "dates", "for", "several", "issued", "patents", "covering", "Captisol", "are", "provided", "in", "the", "following", "table."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_14_item1_p84_s0", "idA": "886163_13_item1_p5_s0", "sentA": "We discover and develop compounds that are promising drug candidates.", "sentB": "Expiration dates of European and Japanese patents are calculated as 20 years from the earliest nonprovisional filing date to which priority is claimed, and do not take into account extensions that are or may be available in these jurisdictions.", "type": 1, "words": ["<tag1>", "We", "discover", "and", "develop", "compounds", "that", "are", "promising", "drug", "candidates.", "<tag2>", "Expiration", "dates", "of", "European", "and", "Japanese", "patents", "are", "calculated", "as", "20", "years", "from", "the", "earliest", "nonprovisional", "filing", "date", "to", "which", "priority", "is", "claimed,", "and", "do", "not", "take", "into", "account", "extensions", "that", "are", "or", "may", "be", "available", "in", "these", "jurisdictions.", "<tag3>"], "wordsA": ["We", "discover", "and", "develop", "compounds", "that", "are", "promising", "drug", "candidates."], "wordsB": ["Expiration", "dates", "of", "European", "and", "Japanese", "patents", "are", "calculated", "as", "20", "years", "from", "the", "earliest", "nonprovisional", "filing", "date", "to", "which", "priority", "is", "claimed,", "and", "do", "not", "take", "into", "account", "extensions", "that", "are", "or", "may", "be", "available", "in", "these", "jurisdictions."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_14_item1_p86_s0", "idA": "886163_13_item1_p5_s0", "sentA": "We discover and develop compounds that are promising drug candidates.", "sentB": "Expiration dates of European and Japanese patents are calculated as 20 years from the earliest nonprovisional filing date to which priority is claimed, and do not take into account extensions that are or may be available in these jurisdictions.", "type": 1, "words": ["<tag1>", "We", "discover", "and", "develop", "compounds", "that", "are", "promising", "drug", "candidates.", "<tag2>", "Expiration", "dates", "of", "European", "and", "Japanese", "patents", "are", "calculated", "as", "20", "years", "from", "the", "earliest", "nonprovisional", "filing", "date", "to", "which", "priority", "is", "claimed,", "and", "do", "not", "take", "into", "account", "extensions", "that", "are", "or", "may", "be", "available", "in", "these", "jurisdictions.", "<tag3>"], "wordsA": ["We", "discover", "and", "develop", "compounds", "that", "are", "promising", "drug", "candidates."], "wordsB": ["Expiration", "dates", "of", "European", "and", "Japanese", "patents", "are", "calculated", "as", "20", "years", "from", "the", "earliest", "nonprovisional", "filing", "date", "to", "which", "priority", "is", "claimed,", "and", "do", "not", "take", "into", "account", "extensions", "that", "are", "or", "may", "be", "available", "in", "these", "jurisdictions."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_14_item1_p89_s0", "idA": "886163_13_item1_p5_s0", "sentA": "We discover and develop compounds that are promising drug candidates.", "sentB": "Expiration date of European and Japanese patents are calculated as 20 years from the earliest nonprovisional filing date to which priority is claimed, and do not take into account extensions that are or may be available in these jurisdictions.", "type": 1, "words": ["<tag1>", "We", "discover", "and", "develop", "compounds", "that", "are", "promising", "drug", "candidates.", "<tag2>", "Expiration", "date", "of", "European", "and", "Japanese", "patents", "are", "calculated", "as", "20", "years", "from", "the", "earliest", "nonprovisional", "filing", "date", "to", "which", "priority", "is", "claimed,", "and", "do", "not", "take", "into", "account", "extensions", "that", "are", "or", "may", "be", "available", "in", "these", "jurisdictions.", "<tag3>"], "wordsA": ["We", "discover", "and", "develop", "compounds", "that", "are", "promising", "drug", "candidates."], "wordsB": ["Expiration", "date", "of", "European", "and", "Japanese", "patents", "are", "calculated", "as", "20", "years", "from", "the", "earliest", "nonprovisional", "filing", "date", "to", "which", "priority", "is", "claimed,", "and", "do", "not", "take", "into", "account", "extensions", "that", "are", "or", "may", "be", "available", "in", "these", "jurisdictions."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_14_item1_p67_s1", "idA": "886163_13_item1_p5_s1", "sentA": "We discover, synthesize and test numerous compounds to identify those that are most promising for clinical development.", "sentB": "The study indicated a potential difference in metabolism between the oral and intravenous routes of administration for Clopidogrel, and MedCo elected not to proceed with further development.", "type": 1, "words": ["<tag1>", "We", "discover,", "synthesize", "and", "test", "numerous", "compounds", "to", "identify", "those", "that", "are", "most", "promising", "for", "clinical", "development.", "<tag2>", "The", "study", "indicated", "a", "potential", "difference", "in", "metabolism", "between", "the", "oral", "and", "intravenous", "routes", "of", "administration", "for", "Clopidogrel,", "and", "MedCo", "elected", "not", "to", "proceed", "with", "further", "development.", "<tag3>"], "wordsA": ["We", "discover,", "synthesize", "and", "test", "numerous", "compounds", "to", "identify", "those", "that", "are", "most", "promising", "for", "clinical", "development."], "wordsB": ["The", "study", "indicated", "a", "potential", "difference", "in", "metabolism", "between", "the", "oral", "and", "intravenous", "routes", "of", "administration", "for", "Clopidogrel,", "and", "MedCo", "elected", "not", "to", "proceed", "with", "further", "development."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_14_item1_p35_s4", "idA": "886163_13_item1_p61_s6", "sentA": "In addition to its main manufacturing site in Loures, Portugal, Hovione will qualify a second site in Macau if our forecast requirements for Captisol exceed the capabilities of the Loures site.", "sentB": "In December 2013, Merck announced progression of the program to Phase 3 by advancing the Phase 2/3 trial to Phase 3 and by initiating a second Phase 3 trial.", "type": 1, "words": ["<tag1>", "In", "addition", "to", "its", "main", "manufacturing", "site", "in", "Loures,", "Portugal,", "Hovione", "will", "qualify", "a", "second", "site", "in", "Macau", "if", "our", "forecast", "requirements", "for", "Captisol", "exceed", "the", "capabilities", "of", "the", "Loures", "site.", "<tag2>", "In", "December", "2013,", "Merck", "announced", "progression", "of", "the", "program", "to", "Phase", "3", "by", "advancing", "the", "Phase", "2/3", "trial", "to", "Phase", "3", "and", "by", "initiating", "a", "second", "Phase", "3", "trial.", "<tag3>"], "wordsA": ["In", "addition", "to", "its", "main", "manufacturing", "site", "in", "Loures,", "Portugal,", "Hovione", "will", "qualify", "a", "second", "site", "in", "Macau", "if", "our", "forecast", "requirements", "for", "Captisol", "exceed", "the", "capabilities", "of", "the", "Loures", "site."], "wordsB": ["In", "December", "2013,", "Merck", "announced", "progression", "of", "the", "program", "to", "Phase", "3", "by", "advancing", "the", "Phase", "2/3", "trial", "to", "Phase", "3", "and", "by", "initiating", "a", "second", "Phase", "3", "trial."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_14_item1_p13_s1", "idA": "886163_13_item1_p61_s9", "sentA": "In 2008, we entered into an amendment to the supply agreement, under which we and Hovione agreed to reduce our minimum annual purchase requirement of Captisol and to extend the term of the agreement.", "sentB": "The purpose of the agreement was to engage in a joint research and development effort to discover and/or design small molecule compounds which act as modulators of certain signal transducers and activators of transcription, or STATS, to develop pharmaceutical products from such compounds and to commercialize products resulting from the joint research and development.", "type": 1, "words": ["<tag1>", "In", "2008,", "we", "entered", "into", "an", "amendment", "to", "the", "supply", "agreement,", "under", "which", "we", "and", "Hovione", "agreed", "to", "reduce", "our", "minimum", "annual", "purchase", "requirement", "of", "Captisol", "and", "to", "extend", "the", "term", "of", "the", "agreement.", "<tag2>", "The", "purpose", "of", "the", "agreement", "was", "to", "engage", "in", "a", "joint", "research", "and", "development", "effort", "to", "discover", "and/or", "design", "small", "molecule", "compounds", "which", "act", "as", "modulators", "of", "certain", "signal", "transducers", "and", "activators", "of", "transcription,", "or", "STATS,", "to", "develop", "pharmaceutical", "products", "from", "such", "compounds", "and", "to", "commercialize", "products", "resulting", "from", "the", "joint", "research", "and", "development.", "<tag3>"], "wordsA": ["In", "2008,", "we", "entered", "into", "an", "amendment", "to", "the", "supply", "agreement,", "under", "which", "we", "and", "Hovione", "agreed", "to", "reduce", "our", "minimum", "annual", "purchase", "requirement", "of", "Captisol", "and", "to", "extend", "the", "term", "of", "the", "agreement."], "wordsB": ["The", "purpose", "of", "the", "agreement", "was", "to", "engage", "in", "a", "joint", "research", "and", "development", "effort", "to", "discover", "and/or", "design", "small", "molecule", "compounds", "which", "act", "as", "modulators", "of", "certain", "signal", "transducers", "and", "activators", "of", "transcription,", "or", "STATS,", "to", "develop", "pharmaceutical", "products", "from", "such", "compounds", "and", "to", "commercialize", "products", "resulting", "from", "the", "joint", "research", "and", "development."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_14_item1_p25_s5", "idA": "886163_13_item1_p65_s1", "sentA": "Furthermore, academic institutions, government agencies and other public and private organizations conducting research may seek patent protection with respect to potentially competing products or technologies and may establish collaborative arrangements with our competitors.", "sentB": "Neither we nor Selexis has any ongoing termination rights with respect to our acquisition agreement.", "type": 1, "words": ["<tag1>", "Furthermore,", "academic", "institutions,", "government", "agencies", "and", "other", "public", "and", "private", "organizations", "conducting", "research", "may", "seek", "patent", "protection", "with", "respect", "to", "potentially", "competing", "products", "or", "technologies", "and", "may", "establish", "collaborative", "arrangements", "with", "our", "competitors.", "<tag2>", "Neither", "we", "nor", "Selexis", "has", "any", "ongoing", "termination", "rights", "with", "respect", "to", "our", "acquisition", "agreement.", "<tag3>"], "wordsA": ["Furthermore,", "academic", "institutions,", "government", "agencies", "and", "other", "public", "and", "private", "organizations", "conducting", "research", "may", "seek", "patent", "protection", "with", "respect", "to", "potentially", "competing", "products", "or", "technologies", "and", "may", "establish", "collaborative", "arrangements", "with", "our", "competitors."], "wordsB": ["Neither", "we", "nor", "Selexis", "has", "any", "ongoing", "termination", "rights", "with", "respect", "to", "our", "acquisition", "agreement."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_14_item1_p82_s0", "idA": "886163_13_item1_p65_s4", "sentA": "Our competitive position also depends upon our ability to attract and retain qualified personnel, obtain patent protection or otherwise develop proprietary products or processes, and secure sufficient capital resources for the often substantial period between technological conception and commercial sales.", "sentB": "Patents are issued or pending for the following key products or product families.", "type": 1, "words": ["<tag1>", "Our", "competitive", "position", "also", "depends", "upon", "our", "ability", "to", "attract", "and", "retain", "qualified", "personnel,", "obtain", "patent", "protection", "or", "otherwise", "develop", "proprietary", "products", "or", "processes,", "and", "secure", "sufficient", "capital", "resources", "for", "the", "often", "substantial", "period", "between", "technological", "conception", "and", "commercial", "sales.", "<tag2>", "Patents", "are", "issued", "or", "pending", "for", "the", "following", "key", "products", "or", "product", "families.", "<tag3>"], "wordsA": ["Our", "competitive", "position", "also", "depends", "upon", "our", "ability", "to", "attract", "and", "retain", "qualified", "personnel,", "obtain", "patent", "protection", "or", "otherwise", "develop", "proprietary", "products", "or", "processes,", "and", "secure", "sufficient", "capital", "resources", "for", "the", "often", "substantial", "period", "between", "technological", "conception", "and", "commercial", "sales."], "wordsB": ["Patents", "are", "issued", "or", "pending", "for", "the", "following", "key", "products", "or", "product", "families."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_14_item1_p83_s0", "idA": "886163_13_item1_p67_s0", "sentA": "In the United States, pharmaceuticals are subject to rigorous regulation by federal and various state authorities, including the FDA.", "sentB": "For each product or product family, the patents and/or applications referred to are in force in at least the United States, and for most products and product families, the patents and/or applications are also in force in European jurisdictions, Japan and other jurisdictions.", "type": 1, "words": ["<tag1>", "In", "the", "United", "States,", "pharmaceuticals", "are", "subject", "to", "rigorous", "regulation", "by", "federal", "and", "various", "state", "authorities,", "including", "the", "FDA.", "<tag2>", "For", "each", "product", "or", "product", "family,", "the", "patents", "and/or", "applications", "referred", "to", "are", "in", "force", "in", "at", "least", "the", "United", "States,", "and", "for", "most", "products", "and", "product", "families,", "the", "patents", "and/or", "applications", "are", "also", "in", "force", "in", "European", "jurisdictions,", "Japan", "and", "other", "jurisdictions.", "<tag3>"], "wordsA": ["In", "the", "United", "States,", "pharmaceuticals", "are", "subject", "to", "rigorous", "regulation", "by", "federal", "and", "various", "state", "authorities,", "including", "the", "FDA."], "wordsB": ["For", "each", "product", "or", "product", "family,", "the", "patents", "and/or", "applications", "referred", "to", "are", "in", "force", "in", "at", "least", "the", "United", "States,", "and", "for", "most", "products", "and", "product", "families,", "the", "patents", "and/or", "applications", "are", "also", "in", "force", "in", "European", "jurisdictions,", "Japan", "and", "other", "jurisdictions."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_14_item1_p83_s4", "idA": "886163_13_item1_p69_s5", "sentA": "In addition, changes in existing regulations could have a material adverse effect on us.", "sentB": "In addition, certain related patents in the commercially important jurisdictions of Europe and Japan are identified in the following table.", "type": 1, "words": ["<tag1>", "In", "addition,", "changes", "in", "existing", "regulations", "could", "have", "a", "material", "adverse", "effect", "on", "us.", "<tag2>", "In", "addition,", "certain", "related", "patents", "in", "the", "commercially", "important", "jurisdictions", "of", "Europe", "and", "Japan", "are", "identified", "in", "the", "following", "table.", "<tag3>"], "wordsA": ["In", "addition,", "changes", "in", "existing", "regulations", "could", "have", "a", "material", "adverse", "effect", "on", "us."], "wordsB": ["In", "addition,", "certain", "related", "patents", "in", "the", "commercially", "important", "jurisdictions", "of", "Europe", "and", "Japan", "are", "identified", "in", "the", "following", "table."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_14_item1_p85_s4", "idA": "886163_13_item1_p69_s5", "sentA": "In addition, changes in existing regulations could have a material adverse effect on us.", "sentB": "In addition, certain related patents in the commercially important jurisdictions of Europe and Japan are identified in the following table.", "type": 1, "words": ["<tag1>", "In", "addition,", "changes", "in", "existing", "regulations", "could", "have", "a", "material", "adverse", "effect", "on", "us.", "<tag2>", "In", "addition,", "certain", "related", "patents", "in", "the", "commercially", "important", "jurisdictions", "of", "Europe", "and", "Japan", "are", "identified", "in", "the", "following", "table.", "<tag3>"], "wordsA": ["In", "addition,", "changes", "in", "existing", "regulations", "could", "have", "a", "material", "adverse", "effect", "on", "us."], "wordsB": ["In", "addition,", "certain", "related", "patents", "in", "the", "commercially", "important", "jurisdictions", "of", "Europe", "and", "Japan", "are", "identified", "in", "the", "following", "table."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_14_item1_p25_s8", "idA": "886163_13_item1_p69_s6", "sentA": "We are also increasingly subject to regulation by the states.", "sentB": "The programs covered by the Selexis transaction include novel biologics programs with Merrimack (MM-121, MM-111, MM-302 and MM-151), Baxter (BAX69), Aveo, CSL and Glenmark and biosimilar programs with Coherus and Biocad.", "type": 1, "words": ["<tag1>", "We", "are", "also", "increasingly", "subject", "to", "regulation", "by", "the", "states.", "<tag2>", "The", "programs", "covered", "by", "the", "Selexis", "transaction", "include", "novel", "biologics", "programs", "with", "Merrimack", "(MM-121,", "MM-111,", "MM-302", "and", "MM-151),", "Baxter", "(BAX69),", "Aveo,", "CSL", "and", "Glenmark", "and", "biosimilar", "programs", "with", "Coherus", "and", "Biocad.", "<tag3>"], "wordsA": ["We", "are", "also", "increasingly", "subject", "to", "regulation", "by", "the", "states."], "wordsB": ["The", "programs", "covered", "by", "the", "Selexis", "transaction", "include", "novel", "biologics", "programs", "with", "Merrimack", "(MM-121,", "MM-111,", "MM-302", "and", "MM-151),", "Baxter", "(BAX69),", "Aveo,", "CSL", "and", "Glenmark", "and", "biosimilar", "programs", "with", "Coherus", "and", "Biocad."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_14_item1_p88_s1", "idA": "886163_13_item1_p70_s0", "sentA": "We believe that patents and other proprietary rights are important to our business.", "sentB": "Other patents and pending patent applications covering methods of making Captisol are owned by Ligand or by Pfizer.", "type": 1, "words": ["<tag1>", "We", "believe", "that", "patents", "and", "other", "proprietary", "rights", "are", "important", "to", "our", "business.", "<tag2>", "Other", "patents", "and", "pending", "patent", "applications", "covering", "methods", "of", "making", "Captisol", "are", "owned", "by", "Ligand", "or", "by", "Pfizer.", "<tag3>"], "wordsA": ["We", "believe", "that", "patents", "and", "other", "proprietary", "rights", "are", "important", "to", "our", "business."], "wordsB": ["Other", "patents", "and", "pending", "patent", "applications", "covering", "methods", "of", "making", "Captisol", "are", "owned", "by", "Ligand", "or", "by", "Pfizer."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_14_item1_p88_s3", "idA": "886163_13_item1_p70_s0", "sentA": "We believe that patents and other proprietary rights are important to our business.", "sentB": "Ligand also owns several patents and pending patent applications covering drug products containing Captisol as a component.", "type": 1, "words": ["<tag1>", "We", "believe", "that", "patents", "and", "other", "proprietary", "rights", "are", "important", "to", "our", "business.", "<tag2>", "Ligand", "also", "owns", "several", "patents", "and", "pending", "patent", "applications", "covering", "drug", "products", "containing", "Captisol", "as", "a", "component.", "<tag3>"], "wordsA": ["We", "believe", "that", "patents", "and", "other", "proprietary", "rights", "are", "important", "to", "our", "business."], "wordsB": ["Ligand", "also", "owns", "several", "patents", "and", "pending", "patent", "applications", "covering", "drug", "products", "containing", "Captisol", "as", "a", "component."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_14_item1_p88_s5", "idA": "886163_13_item1_p70_s0", "sentA": "We believe that patents and other proprietary rights are important to our business.", "sentB": "In addition, certain related patents and applications in the commercially important jurisdictions of Europe and Japan are listed in the following table.", "type": 1, "words": ["<tag1>", "We", "believe", "that", "patents", "and", "other", "proprietary", "rights", "are", "important", "to", "our", "business.", "<tag2>", "In", "addition,", "certain", "related", "patents", "and", "applications", "in", "the", "commercially", "important", "jurisdictions", "of", "Europe", "and", "Japan", "are", "listed", "in", "the", "following", "table.", "<tag3>"], "wordsA": ["We", "believe", "that", "patents", "and", "other", "proprietary", "rights", "are", "important", "to", "our", "business."], "wordsB": ["In", "addition,", "certain", "related", "patents", "and", "applications", "in", "the", "commercially", "important", "jurisdictions", "of", "Europe", "and", "Japan", "are", "listed", "in", "the", "following", "table."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_14_item1_p88_s0", "idA": "886163_13_item1_p70_s1", "sentA": "Our policy is to file patent applications to protect technology, inventions and improvements to our inventions that are considered important to the development of our business.", "sentB": "Captisol Patents and pending patent applications covering Captisol are owned by Ligand.", "type": 1, "words": ["<tag1>", "Our", "policy", "is", "to", "file", "patent", "applications", "to", "protect", "technology,", "inventions", "and", "improvements", "to", "our", "inventions", "that", "are", "considered", "important", "to", "the", "development", "of", "our", "business.", "<tag2>", "Captisol", "Patents", "and", "pending", "patent", "applications", "covering", "Captisol", "are", "owned", "by", "Ligand.", "<tag3>"], "wordsA": ["Our", "policy", "is", "to", "file", "patent", "applications", "to", "protect", "technology,", "inventions", "and", "improvements", "to", "our", "inventions", "that", "are", "considered", "important", "to", "the", "development", "of", "our", "business."], "wordsB": ["Captisol", "Patents", "and", "pending", "patent", "applications", "covering", "Captisol", "are", "owned", "by", "Ligand."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_14_item1_p88_s2", "idA": "886163_13_item1_p70_s6", "sentA": "The last to expire United States patents related to Captisol is not expected to expire until 2029.", "sentB": "The patents covering the Captisol product, if issued, with the latest expiration date would not be set to expire until 2033 ( see, e.g., WO 2013/130666 (contains composition of matter and use claims; filed Feb. 27, 2013)).", "type": 1, "words": ["<tag1>", "The", "last", "to", "expire", "United", "States", "patents", "related", "to", "Captisol", "is", "not", "expected", "to", "expire", "until", "2029.", "<tag2>", "The", "patents", "covering", "the", "Captisol", "product,", "if", "issued,", "with", "the", "latest", "expiration", "date", "would", "not", "be", "set", "to", "expire", "until", "2033", "(", "see,", "e.g.,", "WO", "2013/130666", "(contains", "composition", "of", "matter", "and", "use", "claims;", "filed", "Feb.", "27,", "2013)).", "<tag3>"], "wordsA": ["The", "last", "to", "expire", "United", "States", "patents", "related", "to", "Captisol", "is", "not", "expected", "to", "expire", "until", "2029."], "wordsB": ["The", "patents", "covering", "the", "Captisol", "product,", "if", "issued,", "with", "the", "latest", "expiration", "date", "would", "not", "be", "set", "to", "expire", "until", "2033", "(", "see,", "e.g.,", "WO", "2013/130666", "(contains", "composition", "of", "matter", "and", "use", "claims;", "filed", "Feb.", "27,", "2013))."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_14_item1_p24_s2", "idA": "886163_13_item1_p70_s7", "sentA": "Subject to compliance with the terms of the respective agreements, our rights to receive royalty payments under our licenses with our exclusive licensors extend for the life of the patents covering such developments.", "sentB": "Spectrum s obligation to pay royalties will expire at the end of the life of the relevant patents or when a competing product is launched, whichever is earlier, but in no event within ten years of the commercial launch.", "type": 1, "words": ["<tag1>", "Subject", "to", "compliance", "with", "the", "terms", "of", "the", "respective", "agreements,", "our", "rights", "to", "receive", "royalty", "payments", "under", "our", "licenses", "with", "our", "exclusive", "licensors", "extend", "for", "the", "life", "of", "the", "patents", "covering", "such", "developments.", "<tag2>", "Spectrum", "s", "obligation", "to", "pay", "royalties", "will", "expire", "at", "the", "end", "of", "the", "life", "of", "the", "relevant", "patents", "or", "when", "a", "competing", "product", "is", "launched,", "whichever", "is", "earlier,", "but", "in", "no", "event", "within", "ten", "years", "of", "the", "commercial", "launch.", "<tag3>"], "wordsA": ["Subject", "to", "compliance", "with", "the", "terms", "of", "the", "respective", "agreements,", "our", "rights", "to", "receive", "royalty", "payments", "under", "our", "licenses", "with", "our", "exclusive", "licensors", "extend", "for", "the", "life", "of", "the", "patents", "covering", "such", "developments."], "wordsB": ["Spectrum", "s", "obligation", "to", "pay", "royalties", "will", "expire", "at", "the", "end", "of", "the", "life", "of", "the", "relevant", "patents", "or", "when", "a", "competing", "product", "is", "launched,", "whichever", "is", "earlier,", "but", "in", "no", "event", "within", "ten", "years", "of", "the", "commercial", "launch."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_14_item1_p25_s4", "idA": "886163_13_item1_p70_s7", "sentA": "Subject to compliance with the terms of the respective agreements, our rights to receive royalty payments under our licenses with our exclusive licensors extend for the life of the patents covering such developments.", "sentB": "In return for the rights to these payment streams, we paid Selexis $3.5 million in an upfront cash payment, and expect to make a $1 million cash payment in April 2014 on the first anniversary of the acquisition.", "type": 1, "words": ["<tag1>", "Subject", "to", "compliance", "with", "the", "terms", "of", "the", "respective", "agreements,", "our", "rights", "to", "receive", "royalty", "payments", "under", "our", "licenses", "with", "our", "exclusive", "licensors", "extend", "for", "the", "life", "of", "the", "patents", "covering", "such", "developments.", "<tag2>", "In", "return", "for", "the", "rights", "to", "these", "payment", "streams,", "we", "paid", "Selexis", "$3.5", "million", "in", "an", "upfront", "cash", "payment,", "and", "expect", "to", "make", "a", "$1", "million", "cash", "payment", "in", "April", "2014", "on", "the", "first", "anniversary", "of", "the", "acquisition.", "<tag3>"], "wordsA": ["Subject", "to", "compliance", "with", "the", "terms", "of", "the", "respective", "agreements,", "our", "rights", "to", "receive", "royalty", "payments", "under", "our", "licenses", "with", "our", "exclusive", "licensors", "extend", "for", "the", "life", "of", "the", "patents", "covering", "such", "developments."], "wordsB": ["In", "return", "for", "the", "rights", "to", "these", "payment", "streams,", "we", "paid", "Selexis", "$3.5", "million", "in", "an", "upfront", "cash", "payment,", "and", "expect", "to", "make", "a", "$1", "million", "cash", "payment", "in", "April", "2014", "on", "the", "first", "anniversary", "of", "the", "acquisition."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_14_item1_p83_s1", "idA": "886163_13_item1_p7_s2", "sentA": "Additionally, it was reported in November 2011 that the Risk Evaluation and Mitgation Strategies (REMS) program that Promacta had been operating under in the US was being significantly reduced in scope by the FDA due to data that had been submitted by GSK demonstrating the long term safety of Promacta.", "sentB": "Promacta Patents covering Promacta are owned by GSK.", "type": 1, "words": ["<tag1>", "Additionally,", "it", "was", "reported", "in", "November", "2011", "that", "the", "Risk", "Evaluation", "and", "Mitgation", "Strategies", "(REMS)", "program", "that", "Promacta", "had", "been", "operating", "under", "in", "the", "US", "was", "being", "significantly", "reduced", "in", "scope", "by", "the", "FDA", "due", "to", "data", "that", "had", "been", "submitted", "by", "GSK", "demonstrating", "the", "long", "term", "safety", "of", "Promacta.", "<tag2>", "Promacta", "Patents", "covering", "Promacta", "are", "owned", "by", "GSK.", "<tag3>"], "wordsA": ["Additionally,", "it", "was", "reported", "in", "November", "2011", "that", "the", "Risk", "Evaluation", "and", "Mitgation", "Strategies", "(REMS)", "program", "that", "Promacta", "had", "been", "operating", "under", "in", "the", "US", "was", "being", "significantly", "reduced", "in", "scope", "by", "the", "FDA", "due", "to", "data", "that", "had", "been", "submitted", "by", "GSK", "demonstrating", "the", "long", "term", "safety", "of", "Promacta."], "wordsB": ["Promacta", "Patents", "covering", "Promacta", "are", "owned", "by", "GSK."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_14_item1_p45_s0", "idA": "886163_13_item1_p8_s1", "sentA": "That application is currently under review by the European Medicines Agency.", "sentB": "In the European Union, there are approximately 37 million women with osteoporosis.", "type": 1, "words": ["<tag1>", "That", "application", "is", "currently", "under", "review", "by", "the", "European", "Medicines", "Agency.", "<tag2>", "In", "the", "European", "Union,", "there", "are", "approximately", "37", "million", "women", "with", "osteoporosis.", "<tag3>"], "wordsA": ["That", "application", "is", "currently", "under", "review", "by", "the", "European", "Medicines", "Agency."], "wordsB": ["In", "the", "European", "Union,", "there", "are", "approximately", "37", "million", "women", "with", "osteoporosis."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_14_item1_p57_s0", "idA": "886163_13_item1_p9_s2", "sentA": "Promacta in combination with interferon-based therapy has been shown to improve a patient's chance of achieving a sustained virologic response (SVR) or viral cure.", "sentB": "Inhibition of IRAK4 activity has been implicated in multiple diseases including rheumatoid arthritis, systemic lupus erythematosus, gout, inflammatory bowel disease, asthma, and allergic rhinitis.", "type": 1, "words": ["<tag1>", "Promacta", "in", "combination", "with", "interferon-based", "therapy", "has", "been", "shown", "to", "improve", "a", "patient's", "chance", "of", "achieving", "a", "sustained", "virologic", "response", "(SVR)", "or", "viral", "cure.", "<tag2>", "Inhibition", "of", "IRAK4", "activity", "has", "been", "implicated", "in", "multiple", "diseases", "including", "rheumatoid", "arthritis,", "systemic", "lupus", "erythematosus,", "gout,", "inflammatory", "bowel", "disease,", "asthma,", "and", "allergic", "rhinitis.", "<tag3>"], "wordsA": ["Promacta", "in", "combination", "with", "interferon-based", "therapy", "has", "been", "shown", "to", "improve", "a", "patient's", "chance", "of", "achieving", "a", "sustained", "virologic", "response", "(SVR)", "or", "viral", "cure."], "wordsB": ["Inhibition", "of", "IRAK4", "activity", "has", "been", "implicated", "in", "multiple", "diseases", "including", "rheumatoid", "arthritis,", "systemic", "lupus", "erythematosus,", "gout,", "inflammatory", "bowel", "disease,", "asthma,", "and", "allergic", "rhinitis."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_15_item1_p12_s1", "idA": "886163_14_item1_p11_s2", "sentA": "Promacta in combination with interferon-based therapy has been shown to improve a patient s chance of achieving a sustained virologic response (SVR) or viral cure.", "sentB": "In June of 2014, GSK announced positive Phase 3 data for Promacta in pediatric ITP.", "type": 1, "words": ["<tag1>", "Promacta", "in", "combination", "with", "interferon-based", "therapy", "has", "been", "shown", "to", "improve", "a", "patient", "s", "chance", "of", "achieving", "a", "sustained", "virologic", "response", "(SVR)", "or", "viral", "cure.", "<tag2>", "In", "June", "of", "2014,", "GSK", "announced", "positive", "Phase", "3", "data", "for", "Promacta", "in", "pediatric", "ITP.", "<tag3>"], "wordsA": ["Promacta", "in", "combination", "with", "interferon-based", "therapy", "has", "been", "shown", "to", "improve", "a", "patient", "s", "chance", "of", "achieving", "a", "sustained", "virologic", "response", "(SVR)", "or", "viral", "cure."], "wordsB": ["In", "June", "of", "2014,", "GSK", "announced", "positive", "Phase", "3", "data", "for", "Promacta", "in", "pediatric", "ITP."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_15_item1_p11_s1", "idA": "886163_14_item1_p12_s0", "sentA": "Promacta is authorized for use in 95 countries.", "sentB": "Specifically, ITP is currently approved in 95 countries, the Hepatitic C-related indication is currently approved in 53 countries, and the severe aplastic anemia indication is approved in 3 counties.", "type": 1, "words": ["<tag1>", "Promacta", "is", "authorized", "for", "use", "in", "95", "countries.", "<tag2>", "Specifically,", "ITP", "is", "currently", "approved", "in", "95", "countries,", "the", "Hepatitic", "C-related", "indication", "is", "currently", "approved", "in", "53", "countries,", "and", "the", "severe", "aplastic", "anemia", "indication", "is", "approved", "in", "3", "counties.", "<tag3>"], "wordsA": ["Promacta", "is", "authorized", "for", "use", "in", "95", "countries."], "wordsB": ["Specifically,", "ITP", "is", "currently", "approved", "in", "95", "countries,", "the", "Hepatitic", "C-related", "indication", "is", "currently", "approved", "in", "53", "countries,", "and", "the", "severe", "aplastic", "anemia", "indication", "is", "approved", "in", "3", "counties."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_15_item1_p20_s0", "idA": "886163_14_item1_p18_s1", "sentA": "Kyprolis is formulated with Ligand s Captisol technology and is used for the treatment of patients with multiple myeloma who have received at least two prior therapies, including bortezomib and an immunomodulatory agent, and have demonstrated disease progression on or within 60 days of completion of the last therapy.", "sentB": "patients with relapsed multiple myeloma, with a clinically relevant 31% decrease in the risk of disease progression or death and an increase of 8.7 months in the median progression free survival (26.3 months in the carfilzomib group vs. 17.6 months in the control group).", "type": 1, "words": ["<tag1>", "Kyprolis", "is", "formulated", "with", "Ligand", "s", "Captisol", "technology", "and", "is", "used", "for", "the", "treatment", "of", "patients", "with", "multiple", "myeloma", "who", "have", "received", "at", "least", "two", "prior", "therapies,", "including", "bortezomib", "and", "an", "immunomodulatory", "agent,", "and", "have", "demonstrated", "disease", "progression", "on", "or", "within", "60", "days", "of", "completion", "of", "the", "last", "therapy.", "<tag2>", "patients", "with", "relapsed", "multiple", "myeloma,", "with", "a", "clinically", "relevant", "31%", "decrease", "in", "the", "risk", "of", "disease", "progression", "or", "death", "and", "an", "increase", "of", "8.7", "months", "in", "the", "median", "progression", "free", "survival", "(26.3", "months", "in", "the", "carfilzomib", "group", "vs.", "17.6", "months", "in", "the", "control", "group).", "<tag3>"], "wordsA": ["Kyprolis", "is", "formulated", "with", "Ligand", "s", "Captisol", "technology", "and", "is", "used", "for", "the", "treatment", "of", "patients", "with", "multiple", "myeloma", "who", "have", "received", "at", "least", "two", "prior", "therapies,", "including", "bortezomib", "and", "an", "immunomodulatory", "agent,", "and", "have", "demonstrated", "disease", "progression", "on", "or", "within", "60", "days", "of", "completion", "of", "the", "last", "therapy."], "wordsB": ["patients", "with", "relapsed", "multiple", "myeloma,", "with", "a", "clinically", "relevant", "31%", "decrease", "in", "the", "risk", "of", "disease", "progression", "or", "death", "and", "an", "increase", "of", "8.7", "months", "in", "the", "median", "progression", "free", "survival", "(26.3", "months", "in", "the", "carfilzomib", "group", "vs.", "17.6", "months", "in", "the", "control", "group)."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_15_item1_p13_s0", "idA": "886163_14_item1_p25_s0", "sentA": "This program has completed enrollment in a pivotal clinical trial.", "sentB": "In April of 2014, GSK and Novartis announced that Novartis was acquiring the Promacta franchise from GSK in a $14.5 billion transaction for GSK s oncology business.", "type": 1, "words": ["<tag1>", "This", "program", "has", "completed", "enrollment", "in", "a", "pivotal", "clinical", "trial.", "<tag2>", "In", "April", "of", "2014,", "GSK", "and", "Novartis", "announced", "that", "Novartis", "was", "acquiring", "the", "Promacta", "franchise", "from", "GSK", "in", "a", "$14.5", "billion", "transaction", "for", "GSK", "s", "oncology", "business.", "<tag3>"], "wordsA": ["This", "program", "has", "completed", "enrollment", "in", "a", "pivotal", "clinical", "trial."], "wordsB": ["In", "April", "of", "2014,", "GSK", "and", "Novartis", "announced", "that", "Novartis", "was", "acquiring", "the", "Promacta", "franchise", "from", "GSK", "in", "a", "$14.5", "billion", "transaction", "for", "GSK", "s", "oncology", "business."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_15_item1_p29_s6", "idA": "886163_14_item1_p25_s0", "sentA": "This program has completed enrollment in a pivotal clinical trial.", "sentB": "In February 2014, Actavis launched a generic form of Avinza which resulted in a significant decrease in product sales.", "type": 1, "words": ["<tag1>", "This", "program", "has", "completed", "enrollment", "in", "a", "pivotal", "clinical", "trial.", "<tag2>", "In", "February", "2014,", "Actavis", "launched", "a", "generic", "form", "of", "Avinza", "which", "resulted", "in", "a", "significant", "decrease", "in", "product", "sales.", "<tag3>"], "wordsA": ["This", "program", "has", "completed", "enrollment", "in", "a", "pivotal", "clinical", "trial."], "wordsB": ["In", "February", "2014,", "Actavis", "launched", "a", "generic", "form", "of", "Avinza", "which", "resulted", "in", "a", "significant", "decrease", "in", "product", "sales."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_15_item1_p7_s2", "idA": "886163_14_item1_p27_s0", "sentA": "Viviant was approved in 2009 by the European Commission (under the trade name Conbriza) for the treatment of postmenopausal osteoporosis in women at increased risk of fracture.", "sentB": "Individuals with low platelets can be at significant risk of bleeding or death.", "type": 1, "words": ["<tag1>", "Viviant", "was", "approved", "in", "2009", "by", "the", "European", "Commission", "(under", "the", "trade", "name", "Conbriza)", "for", "the", "treatment", "of", "postmenopausal", "osteoporosis", "in", "women", "at", "increased", "risk", "of", "fracture.", "<tag2>", "Individuals", "with", "low", "platelets", "can", "be", "at", "significant", "risk", "of", "bleeding", "or", "death.", "<tag3>"], "wordsA": ["Viviant", "was", "approved", "in", "2009", "by", "the", "European", "Commission", "(under", "the", "trade", "name", "Conbriza)", "for", "the", "treatment", "of", "postmenopausal", "osteoporosis", "in", "women", "at", "increased", "risk", "of", "fracture."], "wordsB": ["Individuals", "with", "low", "platelets", "can", "be", "at", "significant", "risk", "of", "bleeding", "or", "death."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_15_item1_p19_s3", "idA": "886163_14_item1_p28_s1", "sentA": "Pfizer is responsible for the registration and worldwide marketing of bazedoxifene, a synthetic drug specifically designed to reduce the risk of osteoporotic fractures while also protecting uterine tissue.", "sentB": "Patients had received one to three prior regimens (on average, two).", "type": 1, "words": ["<tag1>", "Pfizer", "is", "responsible", "for", "the", "registration", "and", "worldwide", "marketing", "of", "bazedoxifene,", "a", "synthetic", "drug", "specifically", "designed", "to", "reduce", "the", "risk", "of", "osteoporotic", "fractures", "while", "also", "protecting", "uterine", "tissue.", "<tag2>", "Patients", "had", "received", "one", "to", "three", "prior", "regimens", "(on", "average,", "two).", "<tag3>"], "wordsA": ["Pfizer", "is", "responsible", "for", "the", "registration", "and", "worldwide", "marketing", "of", "bazedoxifene,", "a", "synthetic", "drug", "specifically", "designed", "to", "reduce", "the", "risk", "of", "osteoporotic", "fractures", "while", "also", "protecting", "uterine", "tissue."], "wordsB": ["Patients", "had", "received", "one", "to", "three", "prior", "regimens", "(on", "average,", "two)."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_15_item1_p32_s1", "idA": "886163_14_item1_p28_s1", "sentA": "Pfizer is responsible for the registration and worldwide marketing of bazedoxifene, a synthetic drug specifically designed to reduce the risk of osteoporotic fractures while also protecting uterine tissue.", "sentB": "Spectrum anticipates the review will be completed in approximately 10 months.", "type": 1, "words": ["<tag1>", "Pfizer", "is", "responsible", "for", "the", "registration", "and", "worldwide", "marketing", "of", "bazedoxifene,", "a", "synthetic", "drug", "specifically", "designed", "to", "reduce", "the", "risk", "of", "osteoporotic", "fractures", "while", "also", "protecting", "uterine", "tissue.", "<tag2>", "Spectrum", "anticipates", "the", "review", "will", "be", "completed", "in", "approximately", "10", "months.", "<tag3>"], "wordsA": ["Pfizer", "is", "responsible", "for", "the", "registration", "and", "worldwide", "marketing", "of", "bazedoxifene,", "a", "synthetic", "drug", "specifically", "designed", "to", "reduce", "the", "risk", "of", "osteoporotic", "fractures", "while", "also", "protecting", "uterine", "tissue."], "wordsB": ["Spectrum", "anticipates", "the", "review", "will", "be", "completed", "in", "approximately", "10", "months."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_15_item1_p47_s1", "idA": "886163_14_item1_p28_s1", "sentA": "Pfizer is responsible for the registration and worldwide marketing of bazedoxifene, a synthetic drug specifically designed to reduce the risk of osteoporotic fractures while also protecting uterine tissue.", "sentB": "The partnership is centered on improving targeted lipid-lowering activity of Omega-3 fatty acids.", "type": 1, "words": ["<tag1>", "Pfizer", "is", "responsible", "for", "the", "registration", "and", "worldwide", "marketing", "of", "bazedoxifene,", "a", "synthetic", "drug", "specifically", "designed", "to", "reduce", "the", "risk", "of", "osteoporotic", "fractures", "while", "also", "protecting", "uterine", "tissue.", "<tag2>", "The", "partnership", "is", "centered", "on", "improving", "targeted", "lipid-lowering", "activity", "of", "Omega-3", "fatty", "acids.", "<tag3>"], "wordsA": ["Pfizer", "is", "responsible", "for", "the", "registration", "and", "worldwide", "marketing", "of", "bazedoxifene,", "a", "synthetic", "drug", "specifically", "designed", "to", "reduce", "the", "risk", "of", "osteoporotic", "fractures", "while", "also", "protecting", "uterine", "tissue."], "wordsB": ["The", "partnership", "is", "centered", "on", "improving", "targeted", "lipid-lowering", "activity", "of", "Omega-3", "fatty", "acids."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_15_item1_p29_s7", "idA": "886163_14_item1_p28_s2", "sentA": "Pfizer has combined bazedoxifene (discussed above) with the active ingredient in Premarin to create Duavee , a combination therapy for the treatment of post-menopausal symptoms in women.", "sentB": "Pfizer has informed us that they have stopped selling Avinza to wholesalers.", "type": 1, "words": ["<tag1>", "Pfizer", "has", "combined", "bazedoxifene", "(discussed", "above)", "with", "the", "active", "ingredient", "in", "Premarin", "to", "create", "Duavee", ",", "a", "combination", "therapy", "for", "the", "treatment", "of", "post-menopausal", "symptoms", "in", "women.", "<tag2>", "Pfizer", "has", "informed", "us", "that", "they", "have", "stopped", "selling", "Avinza", "to", "wholesalers.", "<tag3>"], "wordsA": ["Pfizer", "has", "combined", "bazedoxifene", "(discussed", "above)", "with", "the", "active", "ingredient", "in", "Premarin", "to", "create", "Duavee", ",", "a", "combination", "therapy", "for", "the", "treatment", "of", "post-menopausal", "symptoms", "in", "women."], "wordsB": ["Pfizer", "has", "informed", "us", "that", "they", "have", "stopped", "selling", "Avinza", "to", "wholesalers."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_15_item1_p23_s1", "idA": "886163_14_item1_p31_s2", "sentA": "In 2010, Nexterone was approved by the FDA and launched in the United States in 2011.", "sentB": "The drug has also been launched in Germany, Italy, Greece, Switzerland, Netherlands, and South Korea.", "type": 1, "words": ["<tag1>", "In", "2010,", "Nexterone", "was", "approved", "by", "the", "FDA", "and", "launched", "in", "the", "United", "States", "in", "2011.", "<tag2>", "The", "drug", "has", "also", "been", "launched", "in", "Germany,", "Italy,", "Greece,", "Switzerland,", "Netherlands,", "and", "South", "Korea.", "<tag3>"], "wordsA": ["In", "2010,", "Nexterone", "was", "approved", "by", "the", "FDA", "and", "launched", "in", "the", "United", "States", "in", "2011."], "wordsB": ["The", "drug", "has", "also", "been", "launched", "in", "Germany,", "Italy,", "Greece,", "Switzerland,", "Netherlands,", "and", "South", "Korea."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_15_item1_p9_s1", "idA": "886163_14_item1_p32_s1", "sentA": "Merck has completed a Phase 3 study for this program and it filed a 505(b)(2) in 2013 for approval in the United States and European Union to market the drug.", "sentB": "Following the initial approval in 2008, and given Promacta s broad medical applicability, GSK has developed and currently received approvals for the drug in three different indications.", "type": 1, "words": ["<tag1>", "Merck", "has", "completed", "a", "Phase", "3", "study", "for", "this", "program", "and", "it", "filed", "a", "505(b)(2)", "in", "2013", "for", "approval", "in", "the", "United", "States", "and", "European", "Union", "to", "market", "the", "drug.", "<tag2>", "Following", "the", "initial", "approval", "in", "2008,", "and", "given", "Promacta", "s", "broad", "medical", "applicability,", "GSK", "has", "developed", "and", "currently", "received", "approvals", "for", "the", "drug", "in", "three", "different", "indications.", "<tag3>"], "wordsA": ["Merck", "has", "completed", "a", "Phase", "3", "study", "for", "this", "program", "and", "it", "filed", "a", "505(b)(2)", "in", "2013", "for", "approval", "in", "the", "United", "States", "and", "European", "Union", "to", "market", "the", "drug."], "wordsB": ["Following", "the", "initial", "approval", "in", "2008,", "and", "given", "Promacta", "s", "broad", "medical", "applicability,", "GSK", "has", "developed", "and", "currently", "received", "approvals", "for", "the", "drug", "in", "three", "different", "indications."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_15_item1_p39_s5", "idA": "886163_14_item1_p38_s0", "sentA": "Certain patient groups with severely compromised renal function exhibit extreme proteinuria resulting in progression to dialysis and a high mortality rate.", "sentB": "The data showed a greater than 70% response rate, observed in two patient groups.", "type": 1, "words": ["<tag1>", "Certain", "patient", "groups", "with", "severely", "compromised", "renal", "function", "exhibit", "extreme", "proteinuria", "resulting", "in", "progression", "to", "dialysis", "and", "a", "high", "mortality", "rate.", "<tag2>", "The", "data", "showed", "a", "greater", "than", "70%", "response", "rate,", "observed", "in", "two", "patient", "groups.", "<tag3>"], "wordsA": ["Certain", "patient", "groups", "with", "severely", "compromised", "renal", "function", "exhibit", "extreme", "proteinuria", "resulting", "in", "progression", "to", "dialysis", "and", "a", "high", "mortality", "rate."], "wordsB": ["The", "data", "showed", "a", "greater", "than", "70%", "response", "rate,", "observed", "in", "two", "patient", "groups."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_15_item1_p58_s1", "idA": "886163_14_item1_p42_s3", "sentA": "Azure may terminate the license agreement at any time upon six months prior notice.", "sentB": "The therapeutic programs covered in the license agreement include our Selective Androgen Receptor Modulator or SARM program for acute rehabilitation post-hip fracture, a Thyroid Hormone Receptor- (TR ) Agonist program for metabolic and lipid disorders such as X-linked adrenoleukodystrophy and hypercholesterolemia, an FBPase inhibitor program for type 2 diabetes, an Erythropoietin Receptor or EPOR Agonist program for anemia, and an Enterocyte-Directed Diacylglycerol Acyltransferase-1 or DGAT-1 inhibitor program for metabolic disorders.", "type": 1, "words": ["<tag1>", "Azure", "may", "terminate", "the", "license", "agreement", "at", "any", "time", "upon", "six", "months", "prior", "notice.", "<tag2>", "The", "therapeutic", "programs", "covered", "in", "the", "license", "agreement", "include", "our", "Selective", "Androgen", "Receptor", "Modulator", "or", "SARM", "program", "for", "acute", "rehabilitation", "post-hip", "fracture,", "a", "Thyroid", "Hormone", "Receptor-", "(TR", ")", "Agonist", "program", "for", "metabolic", "and", "lipid", "disorders", "such", "as", "X-linked", "adrenoleukodystrophy", "and", "hypercholesterolemia,", "an", "FBPase", "inhibitor", "program", "for", "type", "2", "diabetes,", "an", "Erythropoietin", "Receptor", "or", "EPOR", "Agonist", "program", "for", "anemia,", "and", "an", "Enterocyte-Directed", "Diacylglycerol", "Acyltransferase-1", "or", "DGAT-1", "inhibitor", "program", "for", "metabolic", "disorders.", "<tag3>"], "wordsA": ["Azure", "may", "terminate", "the", "license", "agreement", "at", "any", "time", "upon", "six", "months", "prior", "notice."], "wordsB": ["The", "therapeutic", "programs", "covered", "in", "the", "license", "agreement", "include", "our", "Selective", "Androgen", "Receptor", "Modulator", "or", "SARM", "program", "for", "acute", "rehabilitation", "post-hip", "fracture,", "a", "Thyroid", "Hormone", "Receptor-", "(TR", ")", "Agonist", "program", "for", "metabolic", "and", "lipid", "disorders", "such", "as", "X-linked", "adrenoleukodystrophy", "and", "hypercholesterolemia,", "an", "FBPase", "inhibitor", "program", "for", "type", "2", "diabetes,", "an", "Erythropoietin", "Receptor", "or", "EPOR", "Agonist", "program", "for", "anemia,", "and", "an", "Enterocyte-Directed", "Diacylglycerol", "Acyltransferase-1", "or", "DGAT-1", "inhibitor", "program", "for", "metabolic", "disorders."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_15_item1_p11_s0", "idA": "886163_14_item1_p55_s2", "sentA": "Further optimization of the LG7455 structure series could lead to a first-in-class, once-daily, oral medication for the treatment of congenital, chronic or chemotherapy-induced neutropenia.", "sentB": "GSK has been and continues to pursue globalization of the brand and currently markets Promacta in multiple countries for the three approved indications.", "type": 1, "words": ["<tag1>", "Further", "optimization", "of", "the", "LG7455", "structure", "series", "could", "lead", "to", "a", "first-in-class,", "once-daily,", "oral", "medication", "for", "the", "treatment", "of", "congenital,", "chronic", "or", "chemotherapy-induced", "neutropenia.", "<tag2>", "GSK", "has", "been", "and", "continues", "to", "pursue", "globalization", "of", "the", "brand", "and", "currently", "markets", "Promacta", "in", "multiple", "countries", "for", "the", "three", "approved", "indications.", "<tag3>"], "wordsA": ["Further", "optimization", "of", "the", "LG7455", "structure", "series", "could", "lead", "to", "a", "first-in-class,", "once-daily,", "oral", "medication", "for", "the", "treatment", "of", "congenital,", "chronic", "or", "chemotherapy-induced", "neutropenia."], "wordsB": ["GSK", "has", "been", "and", "continues", "to", "pursue", "globalization", "of", "the", "brand", "and", "currently", "markets", "Promacta", "in", "multiple", "countries", "for", "the", "three", "approved", "indications."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_15_item1_p48_s0", "idA": "886163_14_item1_p7_s1", "sentA": "Captisol is a well validated chemically-modified cyclodextrin that improves the solubility, stability, and pharmacokinetics of many drugs.", "sentB": "Lipid-lowering is a major therapeutic area with growing, global unmet needs.", "type": 1, "words": ["<tag1>", "Captisol", "is", "a", "well", "validated", "chemically-modified", "cyclodextrin", "that", "improves", "the", "solubility,", "stability,", "and", "pharmacokinetics", "of", "many", "drugs.", "<tag2>", "Lipid-lowering", "is", "a", "major", "therapeutic", "area", "with", "growing,", "global", "unmet", "needs.", "<tag3>"], "wordsA": ["Captisol", "is", "a", "well", "validated", "chemically-modified", "cyclodextrin", "that", "improves", "the", "solubility,", "stability,", "and", "pharmacokinetics", "of", "many", "drugs."], "wordsB": ["Lipid-lowering", "is", "a", "major", "therapeutic", "area", "with", "growing,", "global", "unmet", "needs."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_15_item1_p20_s3", "idA": "886163_14_item1_p80_s6", "sentA": "We are also increasingly subject to regulation by the states.", "sentB": "Amgen also announced that Kyprolis received Orphan Designation and Accelerated Assessment by the EMA.", "type": 1, "words": ["<tag1>", "We", "are", "also", "increasingly", "subject", "to", "regulation", "by", "the", "states.", "<tag2>", "Amgen", "also", "announced", "that", "Kyprolis", "received", "Orphan", "Designation", "and", "Accelerated", "Assessment", "by", "the", "EMA.", "<tag3>"], "wordsA": ["We", "are", "also", "increasingly", "subject", "to", "regulation", "by", "the", "states."], "wordsB": ["Amgen", "also", "announced", "that", "Kyprolis", "received", "Orphan", "Designation", "and", "Accelerated", "Assessment", "by", "the", "EMA."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_15_item1_p59_s0", "idA": "886163_14_item1_p81_s1", "sentA": "Our policy is to file patent applications to protect technology, inventions and improvements to our inventions that are considered important to the development of our business.", "sentB": "Viking is a clinical-stage biopharmaceutical company focused on the development of novel, first-in-class or best-in-class therapies for metabolic and endocrine disorders.", "type": 1, "words": ["<tag1>", "Our", "policy", "is", "to", "file", "patent", "applications", "to", "protect", "technology,", "inventions", "and", "improvements", "to", "our", "inventions", "that", "are", "considered", "important", "to", "the", "development", "of", "our", "business.", "<tag2>", "Viking", "is", "a", "clinical-stage", "biopharmaceutical", "company", "focused", "on", "the", "development", "of", "novel,", "first-in-class", "or", "best-in-class", "therapies", "for", "metabolic", "and", "endocrine", "disorders.", "<tag3>"], "wordsA": ["Our", "policy", "is", "to", "file", "patent", "applications", "to", "protect", "technology,", "inventions", "and", "improvements", "to", "our", "inventions", "that", "are", "considered", "important", "to", "the", "development", "of", "our", "business."], "wordsB": ["Viking", "is", "a", "clinical-stage", "biopharmaceutical", "company", "focused", "on", "the", "development", "of", "novel,", "first-in-class", "or", "best-in-class", "therapies", "for", "metabolic", "and", "endocrine", "disorders."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_15_item1_p9_s2", "idA": "886163_14_item1_p83_s1", "sentA": "Promacta Patents covering Promacta are owned by GSK.", "sentB": "The currently approved indications for Promacta are ITP, Hepatitis-C associated thrombocytopenia and severe aplastic anemia.", "type": 1, "words": ["<tag1>", "Promacta", "Patents", "covering", "Promacta", "are", "owned", "by", "GSK.", "<tag2>", "The", "currently", "approved", "indications", "for", "Promacta", "are", "ITP,", "Hepatitis-C", "associated", "thrombocytopenia", "and", "severe", "aplastic", "anemia.", "<tag3>"], "wordsA": ["Promacta", "Patents", "covering", "Promacta", "are", "owned", "by", "GSK."], "wordsB": ["The", "currently", "approved", "indications", "for", "Promacta", "are", "ITP,", "Hepatitis-C", "associated", "thrombocytopenia", "and", "severe", "aplastic", "anemia."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_15_item1_p77_s1", "idA": "886163_14_item1_p88_s0", "sentA": "Captisol Patents and pending patent applications covering Captisol are owned by Ligand.", "sentB": "Manufacturing operations for Captisol are currently performed in both of Hovione's Portugal and Ireland sites.", "type": 1, "words": ["<tag1>", "Captisol", "Patents", "and", "pending", "patent", "applications", "covering", "Captisol", "are", "owned", "by", "Ligand.", "<tag2>", "Manufacturing", "operations", "for", "Captisol", "are", "currently", "performed", "in", "both", "of", "Hovione's", "Portugal", "and", "Ireland", "sites.", "<tag3>"], "wordsA": ["Captisol", "Patents", "and", "pending", "patent", "applications", "covering", "Captisol", "are", "owned", "by", "Ligand."], "wordsB": ["Manufacturing", "operations", "for", "Captisol", "are", "currently", "performed", "in", "both", "of", "Hovione's", "Portugal", "and", "Ireland", "sites."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_15_item1_p77_s2", "idA": "886163_14_item1_p88_s0", "sentA": "Captisol Patents and pending patent applications covering Captisol are owned by Ligand.", "sentB": "Distribution operations for Captisol are currently performed from Hovione's US, Portugal and Ireland sites.", "type": 1, "words": ["<tag1>", "Captisol", "Patents", "and", "pending", "patent", "applications", "covering", "Captisol", "are", "owned", "by", "Ligand.", "<tag2>", "Distribution", "operations", "for", "Captisol", "are", "currently", "performed", "from", "Hovione's", "US,", "Portugal", "and", "Ireland", "sites.", "<tag3>"], "wordsA": ["Captisol", "Patents", "and", "pending", "patent", "applications", "covering", "Captisol", "are", "owned", "by", "Ligand."], "wordsB": ["Distribution", "operations", "for", "Captisol", "are", "currently", "performed", "from", "Hovione's", "US,", "Portugal", "and", "Ireland", "sites."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_15_item1_p78_s0", "idA": "886163_14_item1_p89_s2", "sentA": "Subject to compliance with the terms of the respective agreements, our rights to receive royalty payments under our licenses with our exclusive licensors typically extend for the life of the patents covering such developments.", "sentB": "Once manufactured, Captisol has a shelf life of 60 months (5 years).", "type": 1, "words": ["<tag1>", "Subject", "to", "compliance", "with", "the", "terms", "of", "the", "respective", "agreements,", "our", "rights", "to", "receive", "royalty", "payments", "under", "our", "licenses", "with", "our", "exclusive", "licensors", "typically", "extend", "for", "the", "life", "of", "the", "patents", "covering", "such", "developments.", "<tag2>", "Once", "manufactured,", "Captisol", "has", "a", "shelf", "life", "of", "60", "months", "(5", "years).", "<tag3>"], "wordsA": ["Subject", "to", "compliance", "with", "the", "terms", "of", "the", "respective", "agreements,", "our", "rights", "to", "receive", "royalty", "payments", "under", "our", "licenses", "with", "our", "exclusive", "licensors", "typically", "extend", "for", "the", "life", "of", "the", "patents", "covering", "such", "developments."], "wordsB": ["Once", "manufactured,", "Captisol", "has", "a", "shelf", "life", "of", "60", "months", "(5", "years)."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_15_item1_p39_s2", "idA": "886163_14_item1_p8_s0", "sentA": "We discover and develop compounds that are promising drug candidates.", "sentB": "Fast track designation is granted by the FDA to facilitate the development and expedite the review of drug candidates that are intended to treat serious or life-threatening conditions and demonstrate the potential to address unmet medical needs.", "type": 1, "words": ["<tag1>", "We", "discover", "and", "develop", "compounds", "that", "are", "promising", "drug", "candidates.", "<tag2>", "Fast", "track", "designation", "is", "granted", "by", "the", "FDA", "to", "facilitate", "the", "development", "and", "expedite", "the", "review", "of", "drug", "candidates", "that", "are", "intended", "to", "treat", "serious", "or", "life-threatening", "conditions", "and", "demonstrate", "the", "potential", "to", "address", "unmet", "medical", "needs.", "<tag3>"], "wordsA": ["We", "discover", "and", "develop", "compounds", "that", "are", "promising", "drug", "candidates."], "wordsB": ["Fast", "track", "designation", "is", "granted", "by", "the", "FDA", "to", "facilitate", "the", "development", "and", "expedite", "the", "review", "of", "drug", "candidates", "that", "are", "intended", "to", "treat", "serious", "or", "life-threatening", "conditions", "and", "demonstrate", "the", "potential", "to", "address", "unmet", "medical", "needs."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_15_item1_p12_s0", "idA": "886163_14_item1_p91_s0", "sentA": "Human Resources As of February 1, 2014, we had 20 full-time employees, of whom 6 are involved directly in scientific research and development activities.", "sentB": "As of February 2015, there are 43 open clinical trials related to Promacta (listed as recruiting or open, and not yet recruiting) on the clinicaltrials.gov website.", "type": 1, "words": ["<tag1>", "Human", "Resources", "As", "of", "February", "1,", "2014,", "we", "had", "20", "full-time", "employees,", "of", "whom", "6", "are", "involved", "directly", "in", "scientific", "research", "and", "development", "activities.", "<tag2>", "As", "of", "February", "2015,", "there", "are", "43", "open", "clinical", "trials", "related", "to", "Promacta", "(listed", "as", "recruiting", "or", "open,", "and", "not", "yet", "recruiting)", "on", "the", "clinicaltrials.gov", "website.", "<tag3>"], "wordsA": ["Human", "Resources", "As", "of", "February", "1,", "2014,", "we", "had", "20", "full-time", "employees,", "of", "whom", "6", "are", "involved", "directly", "in", "scientific", "research", "and", "development", "activities."], "wordsB": ["As", "of", "February", "2015,", "there", "are", "43", "open", "clinical", "trials", "related", "to", "Promacta", "(listed", "as", "recruiting", "or", "open,", "and", "not", "yet", "recruiting)", "on", "the", "clinicaltrials.gov", "website."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_16_item1_p15_s0", "idA": "886163_15_item1_p10_s0", "sentA": "Promacta is known as Revolade in the EU.", "sentB": "Global license and supply agreements with RODES, Inc. (now known as Sedor) for intramuscular (IM)/IV meloxicam, IM/IV fosphenytoin, and intranasal budesonide.", "type": 1, "words": ["<tag1>", "Promacta", "is", "known", "as", "Revolade", "in", "the", "EU.", "<tag2>", "Global", "license", "and", "supply", "agreements", "with", "RODES,", "Inc.", "(now", "known", "as", "Sedor)", "for", "intramuscular", "(IM)/IV", "meloxicam,", "IM/IV", "fosphenytoin,", "and", "intranasal", "budesonide.", "<tag3>"], "wordsA": ["Promacta", "is", "known", "as", "Revolade", "in", "the", "EU."], "wordsB": ["Global", "license", "and", "supply", "agreements", "with", "RODES,", "Inc.", "(now", "known", "as", "Sedor)", "for", "intramuscular", "(IM)/IV", "meloxicam,", "IM/IV", "fosphenytoin,", "and", "intranasal", "budesonide."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_16_item1_p10_s0", "idA": "886163_15_item1_p20_s2", "sentA": "The U.S. submission is designed to support conversion from accelerated approval to full FDA approval and also expand the current approved indication for the drug.", "sentB": "Zydus Cadila announced the approval and launch of Exemptia, a biosimilar of adalimumab, in India.", "type": 1, "words": ["<tag1>", "The", "U.S.", "submission", "is", "designed", "to", "support", "conversion", "from", "accelerated", "approval", "to", "full", "FDA", "approval", "and", "also", "expand", "the", "current", "approved", "indication", "for", "the", "drug.", "<tag2>", "Zydus", "Cadila", "announced", "the", "approval", "and", "launch", "of", "Exemptia,", "a", "biosimilar", "of", "adalimumab,", "in", "India.", "<tag3>"], "wordsA": ["The", "U.S.", "submission", "is", "designed", "to", "support", "conversion", "from", "accelerated", "approval", "to", "full", "FDA", "approval", "and", "also", "expand", "the", "current", "approved", "indication", "for", "the", "drug."], "wordsB": ["Zydus", "Cadila", "announced", "the", "approval", "and", "launch", "of", "Exemptia,", "a", "biosimilar", "of", "adalimumab,", "in", "India."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_16_item1_p24_s2", "idA": "886163_15_item1_p22_s0", "sentA": "In 2010, our partner Pfizer launched Viviant (bazedoxifene) in Japan for the treatment of postmenopausal osteoporosis.", "sentB": "Ligand also filed a DMF in Japan in 2015.", "type": 1, "words": ["<tag1>", "In", "2010,", "our", "partner", "Pfizer", "launched", "Viviant", "(bazedoxifene)", "in", "Japan", "for", "the", "treatment", "of", "postmenopausal", "osteoporosis.", "<tag2>", "Ligand", "also", "filed", "a", "DMF", "in", "Japan", "in", "2015.", "<tag3>"], "wordsA": ["In", "2010,", "our", "partner", "Pfizer", "launched", "Viviant", "(bazedoxifene)", "in", "Japan", "for", "the", "treatment", "of", "postmenopausal", "osteoporosis."], "wordsB": ["Ligand", "also", "filed", "a", "DMF", "in", "Japan", "in", "2015."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_16_item1_p45_s15", "idA": "886163_15_item1_p22_s1", "sentA": "The drug is also marketed in Spain under the brand name Conbriza through a co-promotion with Almirall, an international pharmaceutical company based in Spain.", "sentB": "Our partner, Zydus Cadila s Vivitra (trastuzumab biosimilar) is marketed in India for breast cancer.", "type": 1, "words": ["<tag1>", "The", "drug", "is", "also", "marketed", "in", "Spain", "under", "the", "brand", "name", "Conbriza", "through", "a", "co-promotion", "with", "Almirall,", "an", "international", "pharmaceutical", "company", "based", "in", "Spain.", "<tag2>", "Our", "partner,", "Zydus", "Cadila", "s", "Vivitra", "(trastuzumab", "biosimilar)", "is", "marketed", "in", "India", "for", "breast", "cancer.", "<tag3>"], "wordsA": ["The", "drug", "is", "also", "marketed", "in", "Spain", "under", "the", "brand", "name", "Conbriza", "through", "a", "co-promotion", "with", "Almirall,", "an", "international", "pharmaceutical", "company", "based", "in", "Spain."], "wordsB": ["Our", "partner,", "Zydus", "Cadila", "s", "Vivitra", "(trastuzumab", "biosimilar)", "is", "marketed", "in", "India", "for", "breast", "cancer."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_16_item1_p28_s1", "idA": "886163_15_item1_p29_s8", "sentA": "We expect future royalties from Avinza to stop in the second quarter of 2015 and that any remaining royalty payments for Avinza will be minimal.", "sentB": "The LTP Technology works by chemically modifying biologically active molecules into an inactive prodrug, which will be administered to a patient and later activated by specific enzymes in the liver.", "type": 1, "words": ["<tag1>", "We", "expect", "future", "royalties", "from", "Avinza", "to", "stop", "in", "the", "second", "quarter", "of", "2015", "and", "that", "any", "remaining", "royalty", "payments", "for", "Avinza", "will", "be", "minimal.", "<tag2>", "The", "LTP", "Technology", "works", "by", "chemically", "modifying", "biologically", "active", "molecules", "into", "an", "inactive", "prodrug,", "which", "will", "be", "administered", "to", "a", "patient", "and", "later", "activated", "by", "specific", "enzymes", "in", "the", "liver.", "<tag3>"], "wordsA": ["We", "expect", "future", "royalties", "from", "Avinza", "to", "stop", "in", "the", "second", "quarter", "of", "2015", "and", "that", "any", "remaining", "royalty", "payments", "for", "Avinza", "will", "be", "minimal."], "wordsB": ["The", "LTP", "Technology", "works", "by", "chemically", "modifying", "biologically", "active", "molecules", "into", "an", "inactive", "prodrug,", "which", "will", "be", "administered", "to", "a", "patient", "and", "later", "activated", "by", "specific", "enzymes", "in", "the", "liver."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_16_item1_p21_s1", "idA": "886163_15_item1_p31_s1", "sentA": "We are eligible to receive over $50 million in potential milestone payments under this agreement, and we are also eligible to receive royalties on future net sales of the Captisol-enabled melphalan product at a royalty rate of 20%.", "sentB": "The trial results also demonstrated a robust, dose-dependent reduction of fasting plasma glucose.", "type": 1, "words": ["<tag1>", "We", "are", "eligible", "to", "receive", "over", "$50", "million", "in", "potential", "milestone", "payments", "under", "this", "agreement,", "and", "we", "are", "also", "eligible", "to", "receive", "royalties", "on", "future", "net", "sales", "of", "the", "Captisol-enabled", "melphalan", "product", "at", "a", "royalty", "rate", "of", "20%.", "<tag2>", "The", "trial", "results", "also", "demonstrated", "a", "robust,", "dose-dependent", "reduction", "of", "fasting", "plasma", "glucose.", "<tag3>"], "wordsA": ["We", "are", "eligible", "to", "receive", "over", "$50", "million", "in", "potential", "milestone", "payments", "under", "this", "agreement,", "and", "we", "are", "also", "eligible", "to", "receive", "royalties", "on", "future", "net", "sales", "of", "the", "Captisol-enabled", "melphalan", "product", "at", "a", "royalty", "rate", "of", "20%."], "wordsB": ["The", "trial", "results", "also", "demonstrated", "a", "robust,", "dose-dependent", "reduction", "of", "fasting", "plasma", "glucose."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_16_item1_p26_s1", "idA": "886163_15_item1_p31_s1", "sentA": "We are eligible to receive over $50 million in potential milestone payments under this agreement, and we are also eligible to receive royalties on future net sales of the Captisol-enabled melphalan product at a royalty rate of 20%.", "sentB": "OmniAb includes three complementary and globally-branded platforms named OmniRat, OmniMouse and OmniFlic.", "type": 1, "words": ["<tag1>", "We", "are", "eligible", "to", "receive", "over", "$50", "million", "in", "potential", "milestone", "payments", "under", "this", "agreement,", "and", "we", "are", "also", "eligible", "to", "receive", "royalties", "on", "future", "net", "sales", "of", "the", "Captisol-enabled", "melphalan", "product", "at", "a", "royalty", "rate", "of", "20%.", "<tag2>", "OmniAb", "includes", "three", "complementary", "and", "globally-branded", "platforms", "named", "OmniRat,", "OmniMouse", "and", "OmniFlic.", "<tag3>"], "wordsA": ["We", "are", "eligible", "to", "receive", "over", "$50", "million", "in", "potential", "milestone", "payments", "under", "this", "agreement,", "and", "we", "are", "also", "eligible", "to", "receive", "royalties", "on", "future", "net", "sales", "of", "the", "Captisol-enabled", "melphalan", "product", "at", "a", "royalty", "rate", "of", "20%."], "wordsB": ["OmniAb", "includes", "three", "complementary", "and", "globally-branded", "platforms", "named", "OmniRat,", "OmniMouse", "and", "OmniFlic."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_16_item1_p72_s0", "idA": "886163_15_item1_p35_s2", "sentA": "A BACE inhibitor is expected to reduce amyloid-beta generation in Alzheimer s disease patients.", "sentB": "SAR-125844 recently completed a first-in-human, open-label, non-randomized, single agent, Phase 1 study in advanced/refractory solid tumor patients.", "type": 1, "words": ["<tag1>", "A", "BACE", "inhibitor", "is", "expected", "to", "reduce", "amyloid-beta", "generation", "in", "Alzheimer", "s", "disease", "patients.", "<tag2>", "SAR-125844", "recently", "completed", "a", "first-in-human,", "open-label,", "non-randomized,", "single", "agent,", "Phase", "1", "study", "in", "advanced/refractory", "solid", "tumor", "patients.", "<tag3>"], "wordsA": ["A", "BACE", "inhibitor", "is", "expected", "to", "reduce", "amyloid-beta", "generation", "in", "Alzheimer", "s", "disease", "patients."], "wordsB": ["SAR-125844", "recently", "completed", "a", "first-in-human,", "open-label,", "non-randomized,", "single", "agent,", "Phase", "1", "study", "in", "advanced/refractory", "solid", "tumor", "patients."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_16_item1_p60_s0", "idA": "886163_15_item1_p43_s1", "sentA": "In 2015, Melinta reported positive top-line results on the first of two planned Phase 3 clinical trials of delafoxacin for the treatment of acute bacterial skin and skin structure infections (ABSSSI), including infections caused by MRSA.", "sentB": "Carbella is for the management of acute seizure disorder for hospital or emergency settings.", "type": 1, "words": ["<tag1>", "In", "2015,", "Melinta", "reported", "positive", "top-line", "results", "on", "the", "first", "of", "two", "planned", "Phase", "3", "clinical", "trials", "of", "delafoxacin", "for", "the", "treatment", "of", "acute", "bacterial", "skin", "and", "skin", "structure", "infections", "(ABSSSI),", "including", "infections", "caused", "by", "MRSA.", "<tag2>", "Carbella", "is", "for", "the", "management", "of", "acute", "seizure", "disorder", "for", "hospital", "or", "emergency", "settings.", "<tag3>"], "wordsA": ["In", "2015,", "Melinta", "reported", "positive", "top-line", "results", "on", "the", "first", "of", "two", "planned", "Phase", "3", "clinical", "trials", "of", "delafoxacin", "for", "the", "treatment", "of", "acute", "bacterial", "skin", "and", "skin", "structure", "infections", "(ABSSSI),", "including", "infections", "caused", "by", "MRSA."], "wordsB": ["Carbella", "is", "for", "the", "management", "of", "acute", "seizure", "disorder", "for", "hospital", "or", "emergency", "settings."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_16_item1_p72_s1", "idA": "886163_15_item1_p43_s1", "sentA": "In 2015, Melinta reported positive top-line results on the first of two planned Phase 3 clinical trials of delafoxacin for the treatment of acute bacterial skin and skin structure infections (ABSSSI), including infections caused by MRSA.", "sentB": "Our partner, Coherus Biosciences is conducting Phase 3 / BLA-enabling clinical trials for CHS-0214 (etanercept biosimilar) for rheumatoid arthritis.", "type": 1, "words": ["<tag1>", "In", "2015,", "Melinta", "reported", "positive", "top-line", "results", "on", "the", "first", "of", "two", "planned", "Phase", "3", "clinical", "trials", "of", "delafoxacin", "for", "the", "treatment", "of", "acute", "bacterial", "skin", "and", "skin", "structure", "infections", "(ABSSSI),", "including", "infections", "caused", "by", "MRSA.", "<tag2>", "Our", "partner,", "Coherus", "Biosciences", "is", "conducting", "Phase", "3", "/", "BLA-enabling", "clinical", "trials", "for", "CHS-0214", "(etanercept", "biosimilar)", "for", "rheumatoid", "arthritis.", "<tag3>"], "wordsA": ["In", "2015,", "Melinta", "reported", "positive", "top-line", "results", "on", "the", "first", "of", "two", "planned", "Phase", "3", "clinical", "trials", "of", "delafoxacin", "for", "the", "treatment", "of", "acute", "bacterial", "skin", "and", "skin", "structure", "infections", "(ABSSSI),", "including", "infections", "caused", "by", "MRSA."], "wordsB": ["Our", "partner,", "Coherus", "Biosciences", "is", "conducting", "Phase", "3", "/", "BLA-enabling", "clinical", "trials", "for", "CHS-0214", "(etanercept", "biosimilar)", "for", "rheumatoid", "arthritis."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_16_item1_p71_s0", "idA": "886163_15_item1_p48_s0", "sentA": "Lipid-lowering is a major therapeutic area with growing, global unmet needs.", "sentB": "SAR-125844 is a potent, selective and reversible ATP-competitive MET tyrosine kinase inhibitor for IV administration.", "type": 1, "words": ["<tag1>", "Lipid-lowering", "is", "a", "major", "therapeutic", "area", "with", "growing,", "global", "unmet", "needs.", "<tag2>", "SAR-125844", "is", "a", "potent,", "selective", "and", "reversible", "ATP-competitive", "MET", "tyrosine", "kinase", "inhibitor", "for", "IV", "administration.", "<tag3>"], "wordsA": ["Lipid-lowering", "is", "a", "major", "therapeutic", "area", "with", "growing,", "global", "unmet", "needs."], "wordsB": ["SAR-125844", "is", "a", "potent,", "selective", "and", "reversible", "ATP-competitive", "MET", "tyrosine", "kinase", "inhibitor", "for", "IV", "administration."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_16_item1_p20_s0", "idA": "886163_15_item1_p49_s3", "sentA": "In return for the rights to these payment streams, we paid Selexis $4.5 million.", "sentB": "Ligand acquired financial rights to more than 15 additional development stage programs from Selexis for $4 million in cash.", "type": 1, "words": ["<tag1>", "In", "return", "for", "the", "rights", "to", "these", "payment", "streams,", "we", "paid", "Selexis", "$4.5", "million.", "<tag2>", "Ligand", "acquired", "financial", "rights", "to", "more", "than", "15", "additional", "development", "stage", "programs", "from", "Selexis", "for", "$4", "million", "in", "cash.", "<tag3>"], "wordsA": ["In", "return", "for", "the", "rights", "to", "these", "payment", "streams,", "we", "paid", "Selexis", "$4.5", "million."], "wordsB": ["Ligand", "acquired", "financial", "rights", "to", "more", "than", "15", "additional", "development", "stage", "programs", "from", "Selexis", "for", "$4", "million", "in", "cash."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_16_item1_p30_s2", "idA": "886163_15_item1_p4_s2", "sentA": "Fully-funded programs are those for which our partners pay all of the development and commercialization costs.", "sentB": "The technology creates advantages over traditional approaches including accelerated development and manufacturing times, high yields and increased compound stability.", "type": 1, "words": ["<tag1>", "Fully-funded", "programs", "are", "those", "for", "which", "our", "partners", "pay", "all", "of", "the", "development", "and", "commercialization", "costs.", "<tag2>", "The", "technology", "creates", "advantages", "over", "traditional", "approaches", "including", "accelerated", "development", "and", "manufacturing", "times,", "high", "yields", "and", "increased", "compound", "stability.", "<tag3>"], "wordsA": ["Fully-funded", "programs", "are", "those", "for", "which", "our", "partners", "pay", "all", "of", "the", "development", "and", "commercialization", "costs."], "wordsB": ["The", "technology", "creates", "advantages", "over", "traditional", "approaches", "including", "accelerated", "development", "and", "manufacturing", "times,", "high", "yields", "and", "increased", "compound", "stability."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_16_item1_p33_s2", "idA": "886163_15_item1_p50_s2", "sentA": "CURx has made certain milestone payments to us already and may be required to pay us an aggregate of an additional $19.6 million, net of amounts owed to third parties upon the achievement of specified milestones.", "sentB": "For information about the royalties owed to Ligand for these programs, see Royalties later in this business section.", "type": 1, "words": ["<tag1>", "CURx", "has", "made", "certain", "milestone", "payments", "to", "us", "already", "and", "may", "be", "required", "to", "pay", "us", "an", "aggregate", "of", "an", "additional", "$19.6", "million,", "net", "of", "amounts", "owed", "to", "third", "parties", "upon", "the", "achievement", "of", "specified", "milestones.", "<tag2>", "For", "information", "about", "the", "royalties", "owed", "to", "Ligand", "for", "these", "programs,", "see", "Royalties", "later", "in", "this", "business", "section.", "<tag3>"], "wordsA": ["CURx", "has", "made", "certain", "milestone", "payments", "to", "us", "already", "and", "may", "be", "required", "to", "pay", "us", "an", "aggregate", "of", "an", "additional", "$19.6", "million,", "net", "of", "amounts", "owed", "to", "third", "parties", "upon", "the", "achievement", "of", "specified", "milestones."], "wordsB": ["For", "information", "about", "the", "royalties", "owed", "to", "Ligand", "for", "these", "programs,", "see", "Royalties", "later", "in", "this", "business", "section."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_16_item1_p46_s3", "idA": "886163_15_item1_p50_s2", "sentA": "CURx has made certain milestone payments to us already and may be required to pay us an aggregate of an additional $19.6 million, net of amounts owed to third parties upon the achievement of specified milestones.", "sentB": "For information about the royalties owed to Ligand for these programs, see Royalties later in this Business Overview section.", "type": 1, "words": ["<tag1>", "CURx", "has", "made", "certain", "milestone", "payments", "to", "us", "already", "and", "may", "be", "required", "to", "pay", "us", "an", "aggregate", "of", "an", "additional", "$19.6", "million,", "net", "of", "amounts", "owed", "to", "third", "parties", "upon", "the", "achievement", "of", "specified", "milestones.", "<tag2>", "For", "information", "about", "the", "royalties", "owed", "to", "Ligand", "for", "these", "programs,", "see", "Royalties", "later", "in", "this", "Business", "Overview", "section.", "<tag3>"], "wordsA": ["CURx", "has", "made", "certain", "milestone", "payments", "to", "us", "already", "and", "may", "be", "required", "to", "pay", "us", "an", "aggregate", "of", "an", "additional", "$19.6", "million,", "net", "of", "amounts", "owed", "to", "third", "parties", "upon", "the", "achievement", "of", "specified", "milestones."], "wordsB": ["For", "information", "about", "the", "royalties", "owed", "to", "Ligand", "for", "these", "programs,", "see", "Royalties", "later", "in", "this", "Business", "Overview", "section."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_16_item1_p86_s0", "idA": "886163_15_item1_p50_s2", "sentA": "CURx has made certain milestone payments to us already and may be required to pay us an aggregate of an additional $19.6 million, net of amounts owed to third parties upon the achievement of specified milestones.", "sentB": "*Royalty rates are shown net of sublicense payments.", "type": 1, "words": ["<tag1>", "CURx", "has", "made", "certain", "milestone", "payments", "to", "us", "already", "and", "may", "be", "required", "to", "pay", "us", "an", "aggregate", "of", "an", "additional", "$19.6", "million,", "net", "of", "amounts", "owed", "to", "third", "parties", "upon", "the", "achievement", "of", "specified", "milestones.", "<tag2>", "*Royalty", "rates", "are", "shown", "net", "of", "sublicense", "payments.", "<tag3>"], "wordsA": ["CURx", "has", "made", "certain", "milestone", "payments", "to", "us", "already", "and", "may", "be", "required", "to", "pay", "us", "an", "aggregate", "of", "an", "additional", "$19.6", "million,", "net", "of", "amounts", "owed", "to", "third", "parties", "upon", "the", "achievement", "of", "specified", "milestones."], "wordsB": ["*Royalty", "rates", "are", "shown", "net", "of", "sublicense", "payments."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_16_item1_p29_s0", "idA": "886163_15_item1_p58_s0", "sentA": "In May 2014, we entered into an exclusive global license agreement with Viking Therapeutics Inc. or Viking for the rights to five programs.", "sentB": "Ligand acquired economic rights to over 30 SUREtechnology Platform programs from Selexis in two separate transactions in 2013 and 2015, granting Ligand rights to downstream economics on novel biologics and biosimilars programs.", "type": 1, "words": ["<tag1>", "In", "May", "2014,", "we", "entered", "into", "an", "exclusive", "global", "license", "agreement", "with", "Viking", "Therapeutics", "Inc.", "or", "Viking", "for", "the", "rights", "to", "five", "programs.", "<tag2>", "Ligand", "acquired", "economic", "rights", "to", "over", "30", "SUREtechnology", "Platform", "programs", "from", "Selexis", "in", "two", "separate", "transactions", "in", "2013", "and", "2015,", "granting", "Ligand", "rights", "to", "downstream", "economics", "on", "novel", "biologics", "and", "biosimilars", "programs.", "<tag3>"], "wordsA": ["In", "May", "2014,", "we", "entered", "into", "an", "exclusive", "global", "license", "agreement", "with", "Viking", "Therapeutics", "Inc.", "or", "Viking", "for", "the", "rights", "to", "five", "programs."], "wordsB": ["Ligand", "acquired", "economic", "rights", "to", "over", "30", "SUREtechnology", "Platform", "programs", "from", "Selexis", "in", "two", "separate", "transactions", "in", "2013", "and", "2015,", "granting", "Ligand", "rights", "to", "downstream", "economics", "on", "novel", "biologics", "and", "biosimilars", "programs."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_16_item1_p26_s3", "idA": "886163_15_item1_p5_s3", "sentA": "We generate revenue by selling Captisol material to our partners that have either licensed our proprietary Captisol-enabled drugs or have taken a license to use Captisol with their own internal programs.", "sentB": "Fully-human OmniAb antibodies provide advantages to our partners in that fully-human antibodies have reduced immunogenicity, streamline development timelines and costs, and accelerate novel antibody discovery.", "type": 1, "words": ["<tag1>", "We", "generate", "revenue", "by", "selling", "Captisol", "material", "to", "our", "partners", "that", "have", "either", "licensed", "our", "proprietary", "Captisol-enabled", "drugs", "or", "have", "taken", "a", "license", "to", "use", "Captisol", "with", "their", "own", "internal", "programs.", "<tag2>", "Fully-human", "OmniAb", "antibodies", "provide", "advantages", "to", "our", "partners", "in", "that", "fully-human", "antibodies", "have", "reduced", "immunogenicity,", "streamline", "development", "timelines", "and", "costs,", "and", "accelerate", "novel", "antibody", "discovery.", "<tag3>"], "wordsA": ["We", "generate", "revenue", "by", "selling", "Captisol", "material", "to", "our", "partners", "that", "have", "either", "licensed", "our", "proprietary", "Captisol-enabled", "drugs", "or", "have", "taken", "a", "license", "to", "use", "Captisol", "with", "their", "own", "internal", "programs."], "wordsB": ["Fully-human", "OmniAb", "antibodies", "provide", "advantages", "to", "our", "partners", "in", "that", "fully-human", "antibodies", "have", "reduced", "immunogenicity,", "streamline", "development", "timelines", "and", "costs,", "and", "accelerate", "novel", "antibody", "discovery."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_16_item1_p62_s1", "idA": "886163_15_item1_p60_s0", "sentA": "Viking is responsible for all development activities under the license.", "sentB": "Our partner Viking is developing VK5211, a novel, potentially best-in-class SARM for patients recovering from hip-fracture.", "type": 1, "words": ["<tag1>", "Viking", "is", "responsible", "for", "all", "development", "activities", "under", "the", "license.", "<tag2>", "Our", "partner", "Viking", "is", "developing", "VK5211,", "a", "novel,", "potentially", "best-in-class", "SARM", "for", "patients", "recovering", "from", "hip-fracture.", "<tag3>"], "wordsA": ["Viking", "is", "responsible", "for", "all", "development", "activities", "under", "the", "license."], "wordsB": ["Our", "partner", "Viking", "is", "developing", "VK5211,", "a", "novel,", "potentially", "best-in-class", "SARM", "for", "patients", "recovering", "from", "hip-fracture."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_16_item1_p66_s0", "idA": "886163_15_item1_p60_s0", "sentA": "Viking is responsible for all development activities under the license.", "sentB": "Viking is developing VK2809, a novel selective TR- agonist with potential in multiple indications, including hypercholesterolemia, dyslipidemia, NASH, and X-ALD.", "type": 1, "words": ["<tag1>", "Viking", "is", "responsible", "for", "all", "development", "activities", "under", "the", "license.", "<tag2>", "Viking", "is", "developing", "VK2809,", "a", "novel", "selective", "TR-", "agonist", "with", "potential", "in", "multiple", "indications,", "including", "hypercholesterolemia,", "dyslipidemia,", "NASH,", "and", "X-ALD.", "<tag3>"], "wordsA": ["Viking", "is", "responsible", "for", "all", "development", "activities", "under", "the", "license."], "wordsB": ["Viking", "is", "developing", "VK2809,", "a", "novel", "selective", "TR-", "agonist", "with", "potential", "in", "multiple", "indications,", "including", "hypercholesterolemia,", "dyslipidemia,", "NASH,", "and", "X-ALD."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_16_item1_p23_s1", "idA": "886163_15_item1_p65_s0", "sentA": "In October 2013, the FDA accepted our Investigational New Drug, or IND, application for our proprietary Glucagon receptor antagonist product (LGD-6972) candidate for the treatment of diabetes.", "sentB": "Captisol can enable faster and more efficient development paths for our partners, given its known regulatory acceptance.", "type": 1, "words": ["<tag1>", "In", "October", "2013,", "the", "FDA", "accepted", "our", "Investigational", "New", "Drug,", "or", "IND,", "application", "for", "our", "proprietary", "Glucagon", "receptor", "antagonist", "product", "(LGD-6972)", "candidate", "for", "the", "treatment", "of", "diabetes.", "<tag2>", "Captisol", "can", "enable", "faster", "and", "more", "efficient", "development", "paths", "for", "our", "partners,", "given", "its", "known", "regulatory", "acceptance.", "<tag3>"], "wordsA": ["In", "October", "2013,", "the", "FDA", "accepted", "our", "Investigational", "New", "Drug,", "or", "IND,", "application", "for", "our", "proprietary", "Glucagon", "receptor", "antagonist", "product", "(LGD-6972)", "candidate", "for", "the", "treatment", "of", "diabetes."], "wordsB": ["Captisol", "can", "enable", "faster", "and", "more", "efficient", "development", "paths", "for", "our", "partners,", "given", "its", "known", "regulatory", "acceptance."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_16_item1_p21_s0", "idA": "886163_15_item1_p65_s3", "sentA": "In the fourth quarter of 2014, we initiated a Phase 1b trial, and expect results in the second quarter of 2015.", "sentB": "Ligand announced results from a Phase 1b trial of LGD-6972 that demonstrated favorable safety, tolerability and pharmacokinetics in normal healthy volunteers and in subjects with type 2 diabetes mellitus.", "type": 1, "words": ["<tag1>", "In", "the", "fourth", "quarter", "of", "2014,", "we", "initiated", "a", "Phase", "1b", "trial,", "and", "expect", "results", "in", "the", "second", "quarter", "of", "2015.", "<tag2>", "Ligand", "announced", "results", "from", "a", "Phase", "1b", "trial", "of", "LGD-6972", "that", "demonstrated", "favorable", "safety,", "tolerability", "and", "pharmacokinetics", "in", "normal", "healthy", "volunteers", "and", "in", "subjects", "with", "type", "2", "diabetes", "mellitus.", "<tag3>"], "wordsA": ["In", "the", "fourth", "quarter", "of", "2014,", "we", "initiated", "a", "Phase", "1b", "trial,", "and", "expect", "results", "in", "the", "second", "quarter", "of", "2015."], "wordsB": ["Ligand", "announced", "results", "from", "a", "Phase", "1b", "trial", "of", "LGD-6972", "that", "demonstrated", "favorable", "safety,", "tolerability", "and", "pharmacokinetics", "in", "normal", "healthy", "volunteers", "and", "in", "subjects", "with", "type", "2", "diabetes", "mellitus."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_16_item1_p0_s3", "idA": "886163_15_item1_p68_s1", "sentA": "The LTP technology is designed to improve the activity and/or safety of existing drugs, develop new agents to treat certain liver disease, and treat diseases caused by homeostasis imbalance of circulating molecules controlled by the liver and is especially applicable to metabolic and cardiovascular indications, among others.", "sentB": "We have contributed novel research and technologies for approved medicines that treat cancer, osteoporosis, fungal infections and low blood platelets, among others.", "type": 1, "words": ["<tag1>", "The", "LTP", "technology", "is", "designed", "to", "improve", "the", "activity", "and/or", "safety", "of", "existing", "drugs,", "develop", "new", "agents", "to", "treat", "certain", "liver", "disease,", "and", "treat", "diseases", "caused", "by", "homeostasis", "imbalance", "of", "circulating", "molecules", "controlled", "by", "the", "liver", "and", "is", "especially", "applicable", "to", "metabolic", "and", "cardiovascular", "indications,", "among", "others.", "<tag2>", "We", "have", "contributed", "novel", "research", "and", "technologies", "for", "approved", "medicines", "that", "treat", "cancer,", "osteoporosis,", "fungal", "infections", "and", "low", "blood", "platelets,", "among", "others.", "<tag3>"], "wordsA": ["The", "LTP", "technology", "is", "designed", "to", "improve", "the", "activity", "and/or", "safety", "of", "existing", "drugs,", "develop", "new", "agents", "to", "treat", "certain", "liver", "disease,", "and", "treat", "diseases", "caused", "by", "homeostasis", "imbalance", "of", "circulating", "molecules", "controlled", "by", "the", "liver", "and", "is", "especially", "applicable", "to", "metabolic", "and", "cardiovascular", "indications,", "among", "others."], "wordsB": ["We", "have", "contributed", "novel", "research", "and", "technologies", "for", "approved", "medicines", "that", "treat", "cancer,", "osteoporosis,", "fungal", "infections", "and", "low", "blood", "platelets,", "among", "others."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_16_item1_p92_s5", "idA": "886163_15_item1_p6_s0", "sentA": "We discover and develop compounds that are promising drug candidates.", "sentB": "Our Captisol business may face competition from other suppliers of similar cyclodextrin excipients or other technologies that are aimed to increase solubility or stability of APIs.", "type": 1, "words": ["<tag1>", "We", "discover", "and", "develop", "compounds", "that", "are", "promising", "drug", "candidates.", "<tag2>", "Our", "Captisol", "business", "may", "face", "competition", "from", "other", "suppliers", "of", "similar", "cyclodextrin", "excipients", "or", "other", "technologies", "that", "are", "aimed", "to", "increase", "solubility", "or", "stability", "of", "APIs.", "<tag3>"], "wordsA": ["We", "discover", "and", "develop", "compounds", "that", "are", "promising", "drug", "candidates."], "wordsB": ["Our", "Captisol", "business", "may", "face", "competition", "from", "other", "suppliers", "of", "similar", "cyclodextrin", "excipients", "or", "other", "technologies", "that", "are", "aimed", "to", "increase", "solubility", "or", "stability", "of", "APIs."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_16_item1_p92_s6", "idA": "886163_15_item1_p6_s0", "sentA": "We discover and develop compounds that are promising drug candidates.", "sentB": "Our OmniAb antibody technology faces competition from suppliers of other transgenic animal systems that are also available for antibody drug discovery.", "type": 1, "words": ["<tag1>", "We", "discover", "and", "develop", "compounds", "that", "are", "promising", "drug", "candidates.", "<tag2>", "Our", "OmniAb", "antibody", "technology", "faces", "competition", "from", "suppliers", "of", "other", "transgenic", "animal", "systems", "that", "are", "also", "available", "for", "antibody", "drug", "discovery.", "<tag3>"], "wordsA": ["We", "discover", "and", "develop", "compounds", "that", "are", "promising", "drug", "candidates."], "wordsB": ["Our", "OmniAb", "antibody", "technology", "faces", "competition", "from", "suppliers", "of", "other", "transgenic", "animal", "systems", "that", "are", "also", "available", "for", "antibody", "drug", "discovery."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_16_item1_p0_s1", "idA": "886163_15_item1_p72_s0", "sentA": "Intracellular receptors are involved in the actions of non-peptide hormones and drugs such as SERMs and SARMs.", "sentB": "Over our more than 25 year history, we have employed research technologies such as nuclear receptor assays, high throughput computer screening, formulation science, liver targeted pro-drug technologies and antibody discovery technologies to assist companies in their work toward securing prescription drug approvals.", "type": 1, "words": ["<tag1>", "Intracellular", "receptors", "are", "involved", "in", "the", "actions", "of", "non-peptide", "hormones", "and", "drugs", "such", "as", "SERMs", "and", "SARMs.", "<tag2>", "Over", "our", "more", "than", "25", "year", "history,", "we", "have", "employed", "research", "technologies", "such", "as", "nuclear", "receptor", "assays,", "high", "throughput", "computer", "screening,", "formulation", "science,", "liver", "targeted", "pro-drug", "technologies", "and", "antibody", "discovery", "technologies", "to", "assist", "companies", "in", "their", "work", "toward", "securing", "prescription", "drug", "approvals.", "<tag3>"], "wordsA": ["Intracellular", "receptors", "are", "involved", "in", "the", "actions", "of", "non-peptide", "hormones", "and", "drugs", "such", "as", "SERMs", "and", "SARMs."], "wordsB": ["Over", "our", "more", "than", "25", "year", "history,", "we", "have", "employed", "research", "technologies", "such", "as", "nuclear", "receptor", "assays,", "high", "throughput", "computer", "screening,", "formulation", "science,", "liver", "targeted", "pro-drug", "technologies", "and", "antibody", "discovery", "technologies", "to", "assist", "companies", "in", "their", "work", "toward", "securing", "prescription", "drug", "approvals."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_16_item1_p28_s0", "idA": "886163_15_item1_p75_s0", "sentA": "HepDirect is a prodrug technology that targets delivery of certain drugs to the liver by using a proprietary chemical modification that renders a drug biologically inactive until cleaved by a liver-specific enzyme.", "sentB": "A prodrug is a biologically inactive compound that can be metabolized in the body to produce an active drug.", "type": 1, "words": ["<tag1>", "HepDirect", "is", "a", "prodrug", "technology", "that", "targets", "delivery", "of", "certain", "drugs", "to", "the", "liver", "by", "using", "a", "proprietary", "chemical", "modification", "that", "renders", "a", "drug", "biologically", "inactive", "until", "cleaved", "by", "a", "liver-specific", "enzyme.", "<tag2>", "A", "prodrug", "is", "a", "biologically", "inactive", "compound", "that", "can", "be", "metabolized", "in", "the", "body", "to", "produce", "an", "active", "drug.", "<tag3>"], "wordsA": ["HepDirect", "is", "a", "prodrug", "technology", "that", "targets", "delivery", "of", "certain", "drugs", "to", "the", "liver", "by", "using", "a", "proprietary", "chemical", "modification", "that", "renders", "a", "drug", "biologically", "inactive", "until", "cleaved", "by", "a", "liver-specific", "enzyme."], "wordsB": ["A", "prodrug", "is", "a", "biologically", "inactive", "compound", "that", "can", "be", "metabolized", "in", "the", "body", "to", "produce", "an", "active", "drug."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_16_item1_p43_s1", "idA": "886163_15_item1_p77_s4", "sentA": "We pay Hovione unit prices, in U.S. dollars, for all Captisol supplied, which prices may be adjusted for fluctuation in currency exchange rates, change in raw material prices and change in the Portuguese consumer price index.", "sentB": "Kyprolis was initially approved in the U.S. in 2012, and Amgen continues to invest significantly in Kyprolis to further expand its label and geography.", "type": 1, "words": ["<tag1>", "We", "pay", "Hovione", "unit", "prices,", "in", "U.S.", "dollars,", "for", "all", "Captisol", "supplied,", "which", "prices", "may", "be", "adjusted", "for", "fluctuation", "in", "currency", "exchange", "rates,", "change", "in", "raw", "material", "prices", "and", "change", "in", "the", "Portuguese", "consumer", "price", "index.", "<tag2>", "Kyprolis", "was", "initially", "approved", "in", "the", "U.S.", "in", "2012,", "and", "Amgen", "continues", "to", "invest", "significantly", "in", "Kyprolis", "to", "further", "expand", "its", "label", "and", "geography.", "<tag3>"], "wordsA": ["We", "pay", "Hovione", "unit", "prices,", "in", "U.S.", "dollars,", "for", "all", "Captisol", "supplied,", "which", "prices", "may", "be", "adjusted", "for", "fluctuation", "in", "currency", "exchange", "rates,", "change", "in", "raw", "material", "prices", "and", "change", "in", "the", "Portuguese", "consumer", "price", "index."], "wordsB": ["Kyprolis", "was", "initially", "approved", "in", "the", "U.S.", "in", "2012,", "and", "Amgen", "continues", "to", "invest", "significantly", "in", "Kyprolis", "to", "further", "expand", "its", "label", "and", "geography."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_16_item1_p63_s0", "idA": "886163_15_item1_p78_s9", "sentA": "We may terminate the agreement for extended supply interruption, regulatory action related to Captisol or other specified events.", "sentB": "SARMs retain the beneficial properties of androgens without undesired side-effects of steroids or other less selective androgens.", "type": 1, "words": ["<tag1>", "We", "may", "terminate", "the", "agreement", "for", "extended", "supply", "interruption,", "regulatory", "action", "related", "to", "Captisol", "or", "other", "specified", "events.", "<tag2>", "SARMs", "retain", "the", "beneficial", "properties", "of", "androgens", "without", "undesired", "side-effects", "of", "steroids", "or", "other", "less", "selective", "androgens.", "<tag3>"], "wordsA": ["We", "may", "terminate", "the", "agreement", "for", "extended", "supply", "interruption,", "regulatory", "action", "related", "to", "Captisol", "or", "other", "specified", "events."], "wordsB": ["SARMs", "retain", "the", "beneficial", "properties", "of", "androgens", "without", "undesired", "side-effects", "of", "steroids", "or", "other", "less", "selective", "androgens."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_16_item1_p79_s0", "idA": "886163_15_item1_p7_s0", "sentA": "Promacta (GSK) GSK s Promacta (eltrombopag) is an oral medicine that increases the number of platelets in the blood.", "sentB": "MM-302 is an antibody-drug conjugated liposomal doxorubicin that was developed using the Selexis SUREtechnology Platform.", "type": 1, "words": ["<tag1>", "Promacta", "(GSK)", "GSK", "s", "Promacta", "(eltrombopag)", "is", "an", "oral", "medicine", "that", "increases", "the", "number", "of", "platelets", "in", "the", "blood.", "<tag2>", "MM-302", "is", "an", "antibody-drug", "conjugated", "liposomal", "doxorubicin", "that", "was", "developed", "using", "the", "Selexis", "SUREtechnology", "Platform.", "<tag3>"], "wordsA": ["Promacta", "(GSK)", "GSK", "s", "Promacta", "(eltrombopag)", "is", "an", "oral", "medicine", "that", "increases", "the", "number", "of", "platelets", "in", "the", "blood."], "wordsB": ["MM-302", "is", "an", "antibody-drug", "conjugated", "liposomal", "doxorubicin", "that", "was", "developed", "using", "the", "Selexis", "SUREtechnology", "Platform."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_16_item1_p28_s4", "idA": "886163_15_item1_p80_s0", "sentA": "Some of the drugs we and our collaborative partners are developing may compete with existing therapies or other drugs in development by other companies.", "sentB": "Currently 3 partners are utilizing the LTP Technology or related platform(s).", "type": 1, "words": ["<tag1>", "Some", "of", "the", "drugs", "we", "and", "our", "collaborative", "partners", "are", "developing", "may", "compete", "with", "existing", "therapies", "or", "other", "drugs", "in", "development", "by", "other", "companies.", "<tag2>", "Currently", "3", "partners", "are", "utilizing", "the", "LTP", "Technology", "or", "related", "platform(s).", "<tag3>"], "wordsA": ["Some", "of", "the", "drugs", "we", "and", "our", "collaborative", "partners", "are", "developing", "may", "compete", "with", "existing", "therapies", "or", "other", "drugs", "in", "development", "by", "other", "companies."], "wordsB": ["Currently", "3", "partners", "are", "utilizing", "the", "LTP", "Technology", "or", "related", "platform(s)."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_16_item1_p111_s4", "idA": "886163_15_item1_p84_s1", "sentA": "There are often comparable regulations that apply at the state level.", "sentB": "Any document we file may be inspected, at the SEC s public reference room at 100 F Street NE, Washington, DC 20549, or at the SEC s internet address at www.sec.gov.", "type": 1, "words": ["<tag1>", "There", "are", "often", "comparable", "regulations", "that", "apply", "at", "the", "state", "level.", "<tag2>", "Any", "document", "we", "file", "may", "be", "inspected,", "at", "the", "SEC", "s", "public", "reference", "room", "at", "100", "F", "Street", "NE,", "Washington,", "DC", "20549,", "or", "at", "the", "SEC", "s", "internet", "address", "at", "www.sec.gov.", "<tag3>"], "wordsA": ["There", "are", "often", "comparable", "regulations", "that", "apply", "at", "the", "state", "level."], "wordsB": ["Any", "document", "we", "file", "may", "be", "inspected,", "at", "the", "SEC", "s", "public", "reference", "room", "at", "100", "F", "Street", "NE,", "Washington,", "DC", "20549,", "or", "at", "the", "SEC", "s", "internet", "address", "at", "www.sec.gov."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_16_item1_p31_s1", "idA": "886163_15_item1_p85_s2", "sentA": "In addition to obtaining FDA approval for each product, each domestic drug-manufacturing establishment must be registered with the FDA and, in California, with the Food and Drug Branch of California.", "sentB": "In addition to these 70 Companies, we have over 15 additional undisclosed partners and licensees, mostly biotech companies.", "type": 1, "words": ["<tag1>", "In", "addition", "to", "obtaining", "FDA", "approval", "for", "each", "product,", "each", "domestic", "drug-manufacturing", "establishment", "must", "be", "registered", "with", "the", "FDA", "and,", "in", "California,", "with", "the", "Food", "and", "Drug", "Branch", "of", "California.", "<tag2>", "In", "addition", "to", "these", "70", "Companies,", "we", "have", "over", "15", "additional", "undisclosed", "partners", "and", "licensees,", "mostly", "biotech", "companies.", "<tag3>"], "wordsA": ["In", "addition", "to", "obtaining", "FDA", "approval", "for", "each", "product,", "each", "domestic", "drug-manufacturing", "establishment", "must", "be", "registered", "with", "the", "FDA", "and,", "in", "California,", "with", "the", "Food", "and", "Drug", "Branch", "of", "California."], "wordsB": ["In", "addition", "to", "these", "70", "Companies,", "we", "have", "over", "15", "additional", "undisclosed", "partners", "and", "licensees,", "mostly", "biotech", "companies."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_16_item1_p111_s1", "idA": "886163_15_item1_p86_s0", "sentA": "We believe that patents and other proprietary rights are important to our business.", "sentB": "Investor Information Financial and other information about us is available on our website at www.ligand.com.", "type": 1, "words": ["<tag1>", "We", "believe", "that", "patents", "and", "other", "proprietary", "rights", "are", "important", "to", "our", "business.", "<tag2>", "Investor", "Information", "Financial", "and", "other", "information", "about", "us", "is", "available", "on", "our", "website", "at", "www.ligand.com.", "<tag3>"], "wordsA": ["We", "believe", "that", "patents", "and", "other", "proprietary", "rights", "are", "important", "to", "our", "business."], "wordsB": ["Investor", "Information", "Financial", "and", "other", "information", "about", "us", "is", "available", "on", "our", "website", "at", "www.ligand.com."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_16_item1_p31_s0", "idA": "886163_15_item1_p88_s4", "sentA": "In addition, certain related patents in the commercially important jurisdictions of Europe and Japan are identified in the following table.", "sentB": "Partners and Licensees The following table lists our disclosed partners and licensees.", "type": 1, "words": ["<tag1>", "In", "addition,", "certain", "related", "patents", "in", "the", "commercially", "important", "jurisdictions", "of", "Europe", "and", "Japan", "are", "identified", "in", "the", "following", "table.", "<tag2>", "Partners", "and", "Licensees", "The", "following", "table", "lists", "our", "disclosed", "partners", "and", "licensees.", "<tag3>"], "wordsA": ["In", "addition,", "certain", "related", "patents", "in", "the", "commercially", "important", "jurisdictions", "of", "Europe", "and", "Japan", "are", "identified", "in", "the", "following", "table."], "wordsB": ["Partners", "and", "Licensees", "The", "following", "table", "lists", "our", "disclosed", "partners", "and", "licensees."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_16_item1_p47_s2", "idA": "886163_15_item1_p90_s1", "sentA": "The United States patent listed in the Orange Book relating to Kyprolis with the latest expiration date is not expected to expire until 2027.", "sentB": "Spectrum has indicated that next FDA action date is May 2016.", "type": 1, "words": ["<tag1>", "The", "United", "States", "patent", "listed", "in", "the", "Orange", "Book", "relating", "to", "Kyprolis", "with", "the", "latest", "expiration", "date", "is", "not", "expected", "to", "expire", "until", "2027.", "<tag2>", "Spectrum", "has", "indicated", "that", "next", "FDA", "action", "date", "is", "May", "2016.", "<tag3>"], "wordsA": ["The", "United", "States", "patent", "listed", "in", "the", "Orange", "Book", "relating", "to", "Kyprolis", "with", "the", "latest", "expiration", "date", "is", "not", "expected", "to", "expire", "until", "2027."], "wordsB": ["Spectrum", "has", "indicated", "that", "next", "FDA", "action", "date", "is", "May", "2016."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_16_item1_p111_s2", "idA": "886163_15_item1_p9_s0", "sentA": "Promacta was first approved by the U.S. Food and Drug Administration, or FDA, in 2008 under an accelerated approval for the treatment of thrombocytopenia in patients with chronic immune (idiopathic) thrombocytopenic purpura, or ITP, who have had an insufficient response to corticosteroids, immunoglobulins or splenectomy.", "sentB": "We make available on our website copies of our Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, current reports on Form 8-K and amendments to those reports filed or furnished pursuant to Section 13(a) or 15(d) of the Exchange Act as soon as reasonably practicable after we electronically file such material with, or furnish it to, the U.S. Securities and Exchange Commission (SEC).", "type": 1, "words": ["<tag1>", "Promacta", "was", "first", "approved", "by", "the", "U.S.", "Food", "and", "Drug", "Administration,", "or", "FDA,", "in", "2008", "under", "an", "accelerated", "approval", "for", "the", "treatment", "of", "thrombocytopenia", "in", "patients", "with", "chronic", "immune", "(idiopathic)", "thrombocytopenic", "purpura,", "or", "ITP,", "who", "have", "had", "an", "insufficient", "response", "to", "corticosteroids,", "immunoglobulins", "or", "splenectomy.", "<tag2>", "We", "make", "available", "on", "our", "website", "copies", "of", "our", "Annual", "Report", "on", "Form", "10-K,", "Quarterly", "Reports", "on", "Form", "10-Q,", "current", "reports", "on", "Form", "8-K", "and", "amendments", "to", "those", "reports", "filed", "or", "furnished", "pursuant", "to", "Section", "13(a)", "or", "15(d)", "of", "the", "Exchange", "Act", "as", "soon", "as", "reasonably", "practicable", "after", "we", "electronically", "file", "such", "material", "with,", "or", "furnish", "it", "to,", "the", "U.S.", "Securities", "and", "Exchange", "Commission", "(SEC).", "<tag3>"], "wordsA": ["Promacta", "was", "first", "approved", "by", "the", "U.S.", "Food", "and", "Drug", "Administration,", "or", "FDA,", "in", "2008", "under", "an", "accelerated", "approval", "for", "the", "treatment", "of", "thrombocytopenia", "in", "patients", "with", "chronic", "immune", "(idiopathic)", "thrombocytopenic", "purpura,", "or", "ITP,", "who", "have", "had", "an", "insufficient", "response", "to", "corticosteroids,", "immunoglobulins", "or", "splenectomy."], "wordsB": ["We", "make", "available", "on", "our", "website", "copies", "of", "our", "Annual", "Report", "on", "Form", "10-K,", "Quarterly", "Reports", "on", "Form", "10-Q,", "current", "reports", "on", "Form", "8-K", "and", "amendments", "to", "those", "reports", "filed", "or", "furnished", "pursuant", "to", "Section", "13(a)", "or", "15(d)", "of", "the", "Exchange", "Act", "as", "soon", "as", "reasonably", "practicable", "after", "we", "electronically", "file", "such", "material", "with,", "or", "furnish", "it", "to,", "the", "U.S.", "Securities", "and", "Exchange", "Commission", "(SEC)."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_17_item1_p11_s0", "idA": "886163_16_item1_p104_s3", "sentA": "Ligand also owns several patents and pending patent applications covering drug products containing Captisol as a component.", "sentB": "On October 7, 2016, Lundbeck announced approval of Carnexiv IV as a short-term replacement therapy for oral carbamazepine formulations in adults with certain seizure types when oral administration is temporarily not feasible.", "type": 1, "words": ["<tag1>", "Ligand", "also", "owns", "several", "patents", "and", "pending", "patent", "applications", "covering", "drug", "products", "containing", "Captisol", "as", "a", "component.", "<tag2>", "On", "October", "7,", "2016,", "Lundbeck", "announced", "approval", "of", "Carnexiv", "IV", "as", "a", "short-term", "replacement", "therapy", "for", "oral", "carbamazepine", "formulations", "in", "adults", "with", "certain", "seizure", "types", "when", "oral", "administration", "is", "temporarily", "not", "feasible.", "<tag3>"], "wordsA": ["Ligand", "also", "owns", "several", "patents", "and", "pending", "patent", "applications", "covering", "drug", "products", "containing", "Captisol", "as", "a", "component."], "wordsB": ["On", "October", "7,", "2016,", "Lundbeck", "announced", "approval", "of", "Carnexiv", "IV", "as", "a", "short-term", "replacement", "therapy", "for", "oral", "carbamazepine", "formulations", "in", "adults", "with", "certain", "seizure", "types", "when", "oral", "administration", "is", "temporarily", "not", "feasible."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_17_item1_p80_s4", "idA": "886163_16_item1_p45_s10", "sentA": "NOXAFIL-IV is marketed in the United States, EU and Canada.", "sentB": "It is hoped that by attacking amyloid-beta plaque earlier in the disease, Verubecestat can still be effective.", "type": 1, "words": ["<tag1>", "NOXAFIL-IV", "is", "marketed", "in", "the", "United", "States,", "EU", "and", "Canada.", "<tag2>", "It", "is", "hoped", "that", "by", "attacking", "amyloid-beta", "plaque", "earlier", "in", "the", "disease,", "Verubecestat", "can", "still", "be", "effective.", "<tag3>"], "wordsA": ["NOXAFIL-IV", "is", "marketed", "in", "the", "United", "States,", "EU", "and", "Canada."], "wordsB": ["It", "is", "hoped", "that", "by", "attacking", "amyloid-beta", "plaque", "earlier", "in", "the", "disease,", "Verubecestat", "can", "still", "be", "effective."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_17_item1_p61_s0", "idA": "886163_16_item1_p45_s2", "sentA": "Pfizer has combined bazedoxifene with the active ingredient in Premarin to create Duavee, a combination therapy for the treatment of post-menopausal symptoms in women.", "sentB": "Carnexiv is indicated as replacement therapy for oral carbamazepine formulations, when oral administration is temporarily no feasible, in adults with certain seizure types.", "type": 1, "words": ["<tag1>", "Pfizer", "has", "combined", "bazedoxifene", "with", "the", "active", "ingredient", "in", "Premarin", "to", "create", "Duavee,", "a", "combination", "therapy", "for", "the", "treatment", "of", "post-menopausal", "symptoms", "in", "women.", "<tag2>", "Carnexiv", "is", "indicated", "as", "replacement", "therapy", "for", "oral", "carbamazepine", "formulations,", "when", "oral", "administration", "is", "temporarily", "no", "feasible,", "in", "adults", "with", "certain", "seizure", "types.", "<tag3>"], "wordsA": ["Pfizer", "has", "combined", "bazedoxifene", "with", "the", "active", "ingredient", "in", "Premarin", "to", "create", "Duavee,", "a", "combination", "therapy", "for", "the", "treatment", "of", "post-menopausal", "symptoms", "in", "women."], "wordsB": ["Carnexiv", "is", "indicated", "as", "replacement", "therapy", "for", "oral", "carbamazepine", "formulations,", "when", "oral", "administration", "is", "temporarily", "no", "feasible,", "in", "adults", "with", "certain", "seizure", "types."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_17_item1_p67_s3", "idA": "886163_16_item1_p46_s2", "sentA": "We are eligible to receive milestone payments and royalties off of these programs.", "sentB": "This list does not include all of our partnered programs.", "type": 1, "words": ["<tag1>", "We", "are", "eligible", "to", "receive", "milestone", "payments", "and", "royalties", "off", "of", "these", "programs.", "<tag2>", "This", "list", "does", "not", "include", "all", "of", "our", "partnered", "programs.", "<tag3>"], "wordsA": ["We", "are", "eligible", "to", "receive", "milestone", "payments", "and", "royalties", "off", "of", "these", "programs."], "wordsB": ["This", "list", "does", "not", "include", "all", "of", "our", "partnered", "programs."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_17_item1_p18_s0", "idA": "886163_16_item1_p47_s0", "sentA": "In December 2014, Spectrum submitted a NDA to the FDA.", "sentB": "Current OmniAb licensee exercised its option to expand access to the OmniAb platform.", "type": 1, "words": ["<tag1>", "In", "December", "2014,", "Spectrum", "submitted", "a", "NDA", "to", "the", "FDA.", "<tag2>", "Current", "OmniAb", "licensee", "exercised", "its", "option", "to", "expand", "access", "to", "the", "OmniAb", "platform.", "<tag3>"], "wordsA": ["In", "December", "2014,", "Spectrum", "submitted", "a", "NDA", "to", "the", "FDA."], "wordsB": ["Current", "OmniAb", "licensee", "exercised", "its", "option", "to", "expand", "access", "to", "the", "OmniAb", "platform."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_17_item1_p19_s0", "idA": "886163_16_item1_p48_s0", "sentA": "Evomela is intended for use in the multiple myeloma stem cell transplant setting, and has been granted Orphan Designation by the FDA.", "sentB": "Wuxi sublicensed the Chinese rights of two antibodies developed with the OmniAb platform, including to CStone, a Chinese start-up developing an immuno-oncology therapy whose investigational new drug application has been accepted by the CFDA.", "type": 1, "words": ["<tag1>", "Evomela", "is", "intended", "for", "use", "in", "the", "multiple", "myeloma", "stem", "cell", "transplant", "setting,", "and", "has", "been", "granted", "Orphan", "Designation", "by", "the", "FDA.", "<tag2>", "Wuxi", "sublicensed", "the", "Chinese", "rights", "of", "two", "antibodies", "developed", "with", "the", "OmniAb", "platform,", "including", "to", "CStone,", "a", "Chinese", "start-up", "developing", "an", "immuno-oncology", "therapy", "whose", "investigational", "new", "drug", "application", "has", "been", "accepted", "by", "the", "CFDA.", "<tag3>"], "wordsA": ["Evomela", "is", "intended", "for", "use", "in", "the", "multiple", "myeloma", "stem", "cell", "transplant", "setting,", "and", "has", "been", "granted", "Orphan", "Designation", "by", "the", "FDA."], "wordsB": ["Wuxi", "sublicensed", "the", "Chinese", "rights", "of", "two", "antibodies", "developed", "with", "the", "OmniAb", "platform,", "including", "to", "CStone,", "a", "Chinese", "start-up", "developing", "an", "immuno-oncology", "therapy", "whose", "investigational", "new", "drug", "application", "has", "been", "accepted", "by", "the", "CFDA."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_17_item1_p106_s5", "idA": "886163_16_item1_p4_s0", "sentA": "SAGE announced initiation of a Phase 3 study designed to evaluate the safety of SAGE-547 in patients with SRSE.", "sentB": "The randomized, double-blind, placebo-controlled study will evaluate the safety and efficacy of LGD-6972, as an adjunct to diet and exercise, in subjects with T2DM whose blood glucose levels are inadequately controlled with metformin.", "type": 1, "words": ["<tag1>", "SAGE", "announced", "initiation", "of", "a", "Phase", "3", "study", "designed", "to", "evaluate", "the", "safety", "of", "SAGE-547", "in", "patients", "with", "SRSE.", "<tag2>", "The", "randomized,", "double-blind,", "placebo-controlled", "study", "will", "evaluate", "the", "safety", "and", "efficacy", "of", "LGD-6972,", "as", "an", "adjunct", "to", "diet", "and", "exercise,", "in", "subjects", "with", "T2DM", "whose", "blood", "glucose", "levels", "are", "inadequately", "controlled", "with", "metformin.", "<tag3>"], "wordsA": ["SAGE", "announced", "initiation", "of", "a", "Phase", "3", "study", "designed", "to", "evaluate", "the", "safety", "of", "SAGE-547", "in", "patients", "with", "SRSE."], "wordsB": ["The", "randomized,", "double-blind,", "placebo-controlled", "study", "will", "evaluate", "the", "safety", "and", "efficacy", "of", "LGD-6972,", "as", "an", "adjunct", "to", "diet", "and", "exercise,", "in", "subjects", "with", "T2DM", "whose", "blood", "glucose", "levels", "are", "inadequately", "controlled", "with", "metformin."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_17_item1_p27_s1", "idA": "886163_16_item1_p4_s0", "sentA": "SAGE announced initiation of a Phase 3 study designed to evaluate the safety of SAGE-547 in patients with SRSE.", "sentB": "The randomized, double-blind, placebo-controlled study will evaluate the safety and efficacy of LGD-6972, as an adjunct to diet and exercise, in subjects with T2DM whose blood glucose levels are inadequately controlled with metformin.", "type": 1, "words": ["<tag1>", "SAGE", "announced", "initiation", "of", "a", "Phase", "3", "study", "designed", "to", "evaluate", "the", "safety", "of", "SAGE-547", "in", "patients", "with", "SRSE.", "<tag2>", "The", "randomized,", "double-blind,", "placebo-controlled", "study", "will", "evaluate", "the", "safety", "and", "efficacy", "of", "LGD-6972,", "as", "an", "adjunct", "to", "diet", "and", "exercise,", "in", "subjects", "with", "T2DM", "whose", "blood", "glucose", "levels", "are", "inadequately", "controlled", "with", "metformin.", "<tag3>"], "wordsA": ["SAGE", "announced", "initiation", "of", "a", "Phase", "3", "study", "designed", "to", "evaluate", "the", "safety", "of", "SAGE-547", "in", "patients", "with", "SRSE."], "wordsB": ["The", "randomized,", "double-blind,", "placebo-controlled", "study", "will", "evaluate", "the", "safety", "and", "efficacy", "of", "LGD-6972,", "as", "an", "adjunct", "to", "diet", "and", "exercise,", "in", "subjects", "with", "T2DM", "whose", "blood", "glucose", "levels", "are", "inadequately", "controlled", "with", "metformin."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_17_item1_p6_s2", "idA": "886163_16_item1_p51_s0", "sentA": "Verubecestat (Merck) Our partner, Merck is conducting two Phase 3 trials for Verubecestat (MK-8931), a BACE inhibitor for the treatment of Alzheimer s disease.", "sentB": "The external Data Monitoring Committee recommended that the ongoing Phase 3 APECS study, which is evaluating verubecestat in people with prodromal Alzheimer s disease, continue unchanged.", "type": 1, "words": ["<tag1>", "Verubecestat", "(Merck)", "Our", "partner,", "Merck", "is", "conducting", "two", "Phase", "3", "trials", "for", "Verubecestat", "(MK-8931),", "a", "BACE", "inhibitor", "for", "the", "treatment", "of", "Alzheimer", "s", "disease.", "<tag2>", "The", "external", "Data", "Monitoring", "Committee", "recommended", "that", "the", "ongoing", "Phase", "3", "APECS", "study,", "which", "is", "evaluating", "verubecestat", "in", "people", "with", "prodromal", "Alzheimer", "s", "disease,", "continue", "unchanged.", "<tag3>"], "wordsA": ["Verubecestat", "(Merck)", "Our", "partner,", "Merck", "is", "conducting", "two", "Phase", "3", "trials", "for", "Verubecestat", "(MK-8931),", "a", "BACE", "inhibitor", "for", "the", "treatment", "of", "Alzheimer", "s", "disease."], "wordsB": ["The", "external", "Data", "Monitoring", "Committee", "recommended", "that", "the", "ongoing", "Phase", "3", "APECS", "study,", "which", "is", "evaluating", "verubecestat", "in", "people", "with", "prodromal", "Alzheimer", "s", "disease,", "continue", "unchanged."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_17_item1_p5_s2", "idA": "886163_16_item1_p53_s2", "sentA": "SAGE s lead clinical program, Captisol-enabled SAGE-547 is an allosteric modulator of both synaptic and extra-synaptic GABA A receptors that is in clinical development as an adjunctive therapy, a therapy combined with current therapeutic approaches, for the treatment of SRSE.", "sentB": "Sage s PPD clinical program, now in Phase 3, will require only minor modifications, including an increase in sample size.", "type": 1, "words": ["<tag1>", "SAGE", "s", "lead", "clinical", "program,", "Captisol-enabled", "SAGE-547", "is", "an", "allosteric", "modulator", "of", "both", "synaptic", "and", "extra-synaptic", "GABA", "A", "receptors", "that", "is", "in", "clinical", "development", "as", "an", "adjunctive", "therapy,", "a", "therapy", "combined", "with", "current", "therapeutic", "approaches,", "for", "the", "treatment", "of", "SRSE.", "<tag2>", "Sage", "s", "PPD", "clinical", "program,", "now", "in", "Phase", "3,", "will", "require", "only", "minor", "modifications,", "including", "an", "increase", "in", "sample", "size.", "<tag3>"], "wordsA": ["SAGE", "s", "lead", "clinical", "program,", "Captisol-enabled", "SAGE-547", "is", "an", "allosteric", "modulator", "of", "both", "synaptic", "and", "extra-synaptic", "GABA", "A", "receptors", "that", "is", "in", "clinical", "development", "as", "an", "adjunctive", "therapy,", "a", "therapy", "combined", "with", "current", "therapeutic", "approaches,", "for", "the", "treatment", "of", "SRSE."], "wordsB": ["Sage", "s", "PPD", "clinical", "program,", "now", "in", "Phase", "3,", "will", "require", "only", "minor", "modifications,", "including", "an", "increase", "in", "sample", "size."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_17_item1_p5_s1", "idA": "886163_16_item1_p64_s0", "sentA": "Viking initiated a Phase 2 trial in hip fracture in 2015.", "sentB": "The current Sage-547 program in PPD, along with prior Phase 2 data, were confirmed as supporting, if successful, a potential NDA.", "type": 1, "words": ["<tag1>", "Viking", "initiated", "a", "Phase", "2", "trial", "in", "hip", "fracture", "in", "2015.", "<tag2>", "The", "current", "Sage-547", "program", "in", "PPD,", "along", "with", "prior", "Phase", "2", "data,", "were", "confirmed", "as", "supporting,", "if", "successful,", "a", "potential", "NDA.", "<tag3>"], "wordsA": ["Viking", "initiated", "a", "Phase", "2", "trial", "in", "hip", "fracture", "in", "2015."], "wordsB": ["The", "current", "Sage-547", "program", "in", "PPD,", "along", "with", "prior", "Phase", "2", "data,", "were", "confirmed", "as", "supporting,", "if", "successful,", "a", "potential", "NDA."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_17_item1_p6_s1", "idA": "886163_16_item1_p67_s3", "sentA": "CURx will be responsible for all development costs related to the program.", "sentB": "Results from EPOCH will be analyzed and presented at an upcoming scientific meeting.", "type": 1, "words": ["<tag1>", "CURx", "will", "be", "responsible", "for", "all", "development", "costs", "related", "to", "the", "program.", "<tag2>", "Results", "from", "EPOCH", "will", "be", "analyzed", "and", "presented", "at", "an", "upcoming", "scientific", "meeting.", "<tag3>"], "wordsA": ["CURx", "will", "be", "responsible", "for", "all", "development", "costs", "related", "to", "the", "program."], "wordsB": ["Results", "from", "EPOCH", "will", "be", "analyzed", "and", "presented", "at", "an", "upcoming", "scientific", "meeting."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_17_item1_p3_s1", "idA": "886163_16_item1_p68_s3", "sentA": "Under the terms of the agreement, we are entitled to receive potential sales milestones of up to $16 million and royalties on future net sales.", "sentB": "Ligand paid $17.5 million and in return received a portion of revenue (synthetic royalty) from CorMatrix s existing marketed products and will have the right to receive future synthetic royalties from potential future products.", "type": 1, "words": ["<tag1>", "Under", "the", "terms", "of", "the", "agreement,", "we", "are", "entitled", "to", "receive", "potential", "sales", "milestones", "of", "up", "to", "$16", "million", "and", "royalties", "on", "future", "net", "sales.", "<tag2>", "Ligand", "paid", "$17.5", "million", "and", "in", "return", "received", "a", "portion", "of", "revenue", "(synthetic", "royalty)", "from", "CorMatrix", "s", "existing", "marketed", "products", "and", "will", "have", "the", "right", "to", "receive", "future", "synthetic", "royalties", "from", "potential", "future", "products.", "<tag3>"], "wordsA": ["Under", "the", "terms", "of", "the", "agreement,", "we", "are", "entitled", "to", "receive", "potential", "sales", "milestones", "of", "up", "to", "$16", "million", "and", "royalties", "on", "future", "net", "sales."], "wordsB": ["Ligand", "paid", "$17.5", "million", "and", "in", "return", "received", "a", "portion", "of", "revenue", "(synthetic", "royalty)", "from", "CorMatrix", "s", "existing", "marketed", "products", "and", "will", "have", "the", "right", "to", "receive", "future", "synthetic", "royalties", "from", "potential", "future", "products."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_17_item1_p11_s1", "idA": "886163_16_item1_p6_s0", "sentA": "FDA approved Promacta for the treatment of children six years and older with chronic immune thrombocytopenia who have had an insufficient response to corticosteroids, immunoglobulins or splenectomy.", "sentB": "Carnexiv is the first FDA approved intravenous carbamazepine option.", "type": 1, "words": ["<tag1>", "FDA", "approved", "Promacta", "for", "the", "treatment", "of", "children", "six", "years", "and", "older", "with", "chronic", "immune", "thrombocytopenia", "who", "have", "had", "an", "insufficient", "response", "to", "corticosteroids,", "immunoglobulins", "or", "splenectomy.", "<tag2>", "Carnexiv", "is", "the", "first", "FDA", "approved", "intravenous", "carbamazepine", "option.", "<tag3>"], "wordsA": ["FDA", "approved", "Promacta", "for", "the", "treatment", "of", "children", "six", "years", "and", "older", "with", "chronic", "immune", "thrombocytopenia", "who", "have", "had", "an", "insufficient", "response", "to", "corticosteroids,", "immunoglobulins", "or", "splenectomy."], "wordsB": ["Carnexiv", "is", "the", "first", "FDA", "approved", "intravenous", "carbamazepine", "option."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_17_item1_p4_s1", "idA": "886163_16_item1_p86_s2", "sentA": "Higher tiers are only applicable for the dollar ranges specified in the table.", "sentB": "The study achieved statistical significance in the primary efficacy endpoint for the overall sparsentan treatment group, demonstrating a greater than two-fold reduction of proteinuria compared to irbesartan after the eight-week, double-blind treatment period.", "type": 1, "words": ["<tag1>", "Higher", "tiers", "are", "only", "applicable", "for", "the", "dollar", "ranges", "specified", "in", "the", "table.", "<tag2>", "The", "study", "achieved", "statistical", "significance", "in", "the", "primary", "efficacy", "endpoint", "for", "the", "overall", "sparsentan", "treatment", "group,", "demonstrating", "a", "greater", "than", "two-fold", "reduction", "of", "proteinuria", "compared", "to", "irbesartan", "after", "the", "eight-week,", "double-blind", "treatment", "period.", "<tag3>"], "wordsA": ["Higher", "tiers", "are", "only", "applicable", "for", "the", "dollar", "ranges", "specified", "in", "the", "table."], "wordsB": ["The", "study", "achieved", "statistical", "significance", "in", "the", "primary", "efficacy", "endpoint", "for", "the", "overall", "sparsentan", "treatment", "group,", "demonstrating", "a", "greater", "than", "two-fold", "reduction", "of", "proteinuria", "compared", "to", "irbesartan", "after", "the", "eight-week,", "double-blind", "treatment", "period."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_17_item1_p23_s0", "idA": "886163_16_item1_p87_s0", "sentA": "We are currently developing a small molecule glucagon receptor antagonist for the treatment of Type 2 diabetes mellitus.", "sentB": "License agreement of four programs including aplindore, a CRTH2 antagonist program, CE-acetaminophen, and an H3 receptor antagonist program with Seelos Therapeutics.", "type": 1, "words": ["<tag1>", "We", "are", "currently", "developing", "a", "small", "molecule", "glucagon", "receptor", "antagonist", "for", "the", "treatment", "of", "Type", "2", "diabetes", "mellitus.", "<tag2>", "License", "agreement", "of", "four", "programs", "including", "aplindore,", "a", "CRTH2", "antagonist", "program,", "CE-acetaminophen,", "and", "an", "H3", "receptor", "antagonist", "program", "with", "Seelos", "Therapeutics.", "<tag3>"], "wordsA": ["We", "are", "currently", "developing", "a", "small", "molecule", "glucagon", "receptor", "antagonist", "for", "the", "treatment", "of", "Type", "2", "diabetes", "mellitus."], "wordsB": ["License", "agreement", "of", "four", "programs", "including", "aplindore,", "a", "CRTH2", "antagonist", "program,", "CE-acetaminophen,", "and", "an", "H3", "receptor", "antagonist", "program", "with", "Seelos", "Therapeutics."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_17_item1_p57_s0", "idA": "886163_16_item1_p92_s3", "sentA": "Accordingly, these competitors may be better equipped to develop, manufacture and market products.", "sentB": "CorMatrix Portfolio (CorMatrix) Ligand receives a share of revenue from the currently marketed CorMatrix portfolio of vascular, cardiac and pericardial tissue repair products.", "type": 1, "words": ["<tag1>", "Accordingly,", "these", "competitors", "may", "be", "better", "equipped", "to", "develop,", "manufacture", "and", "market", "products.", "<tag2>", "CorMatrix", "Portfolio", "(CorMatrix)", "Ligand", "receives", "a", "share", "of", "revenue", "from", "the", "currently", "marketed", "CorMatrix", "portfolio", "of", "vascular,", "cardiac", "and", "pericardial", "tissue", "repair", "products.", "<tag3>"], "wordsA": ["Accordingly,", "these", "competitors", "may", "be", "better", "equipped", "to", "develop,", "manufacture", "and", "market", "products."], "wordsB": ["CorMatrix", "Portfolio", "(CorMatrix)", "Ligand", "receives", "a", "share", "of", "revenue", "from", "the", "currently", "marketed", "CorMatrix", "portfolio", "of", "vascular,", "cardiac", "and", "pericardial", "tissue", "repair", "products."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_17_item1_p37_s1", "idA": "886163_16_item1_p94_s1", "sentA": "The Federal Food, Drug and Cosmetic Act and the Public Health Service Act govern the testing, manufacture, safety, efficacy, labeling, storage, record keeping, approval, advertising and promotion of pharmaceutical products and there are often comparable regulations that apply at the state level.", "sentB": "Ligand receives a share of revenue from the currently marketed vascular, cardiac, and pericardial tissue repair products and the CanGaroo Envelope for cardiac implantable electronic devices.", "type": 1, "words": ["<tag1>", "The", "Federal", "Food,", "Drug", "and", "Cosmetic", "Act", "and", "the", "Public", "Health", "Service", "Act", "govern", "the", "testing,", "manufacture,", "safety,", "efficacy,", "labeling,", "storage,", "record", "keeping,", "approval,", "advertising", "and", "promotion", "of", "pharmaceutical", "products", "and", "there", "are", "often", "comparable", "regulations", "that", "apply", "at", "the", "state", "level.", "<tag2>", "Ligand", "receives", "a", "share", "of", "revenue", "from", "the", "currently", "marketed", "vascular,", "cardiac,", "and", "pericardial", "tissue", "repair", "products", "and", "the", "CanGaroo", "Envelope", "for", "cardiac", "implantable", "electronic", "devices.", "<tag3>"], "wordsA": ["The", "Federal", "Food,", "Drug", "and", "Cosmetic", "Act", "and", "the", "Public", "Health", "Service", "Act", "govern", "the", "testing,", "manufacture,", "safety,", "efficacy,", "labeling,", "storage,", "record", "keeping,", "approval,", "advertising", "and", "promotion", "of", "pharmaceutical", "products", "and", "there", "are", "often", "comparable", "regulations", "that", "apply", "at", "the", "state", "level."], "wordsB": ["Ligand", "receives", "a", "share", "of", "revenue", "from", "the", "currently", "marketed", "vascular,", "cardiac,", "and", "pericardial", "tissue", "repair", "products", "and", "the", "CanGaroo", "Envelope", "for", "cardiac", "implantable", "electronic", "devices."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_18_item1_p114_s0", "idA": "886163_17_item1_p113_s1", "sentA": "In addition, changes in existing regulations could have a material adverse effect on us or our partners.", "sentB": "LGD-6972 was safe and well tolerated, with no drug-related serious adverse events and no dose dependent changes in lipids, body weight or blood pressure after 12 weeks of treatment.", "type": 1, "words": ["<tag1>", "In", "addition,", "changes", "in", "existing", "regulations", "could", "have", "a", "material", "adverse", "effect", "on", "us", "or", "our", "partners.", "<tag2>", "LGD-6972", "was", "safe", "and", "well", "tolerated,", "with", "no", "drug-related", "serious", "adverse", "events", "and", "no", "dose", "dependent", "changes", "in", "lipids,", "body", "weight", "or", "blood", "pressure", "after", "12", "weeks", "of", "treatment.", "<tag3>"], "wordsA": ["In", "addition,", "changes", "in", "existing", "regulations", "could", "have", "a", "material", "adverse", "effect", "on", "us", "or", "our", "partners."], "wordsB": ["LGD-6972", "was", "safe", "and", "well", "tolerated,", "with", "no", "drug-related", "serious", "adverse", "events", "and", "no", "dose", "dependent", "changes", "in", "lipids,", "body", "weight", "or", "blood", "pressure", "after", "12", "weeks", "of", "treatment."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_18_item1_p34_s0", "idA": "886163_17_item1_p113_s1", "sentA": "In addition, changes in existing regulations could have a material adverse effect on us or our partners.", "sentB": "LGD-6972 was safe and well tolerated, with no drug-related serious adverse events and no dose-dependent changes in lipids (including total cholesterol, LDL cholesterol, HDL cholesterol and triglycerides), body weight or blood pressure after 12 weeks of treatment.", "type": 1, "words": ["<tag1>", "In", "addition,", "changes", "in", "existing", "regulations", "could", "have", "a", "material", "adverse", "effect", "on", "us", "or", "our", "partners.", "<tag2>", "LGD-6972", "was", "safe", "and", "well", "tolerated,", "with", "no", "drug-related", "serious", "adverse", "events", "and", "no", "dose-dependent", "changes", "in", "lipids", "(including", "total", "cholesterol,", "LDL", "cholesterol,", "HDL", "cholesterol", "and", "triglycerides),", "body", "weight", "or", "blood", "pressure", "after", "12", "weeks", "of", "treatment.", "<tag3>"], "wordsA": ["In", "addition,", "changes", "in", "existing", "regulations", "could", "have", "a", "material", "adverse", "effect", "on", "us", "or", "our", "partners."], "wordsB": ["LGD-6972", "was", "safe", "and", "well", "tolerated,", "with", "no", "drug-related", "serious", "adverse", "events", "and", "no", "dose-dependent", "changes", "in", "lipids", "(including", "total", "cholesterol,", "LDL", "cholesterol,", "HDL", "cholesterol", "and", "triglycerides),", "body", "weight", "or", "blood", "pressure", "after", "12", "weeks", "of", "treatment."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_18_item1_p19_s1", "idA": "886163_17_item1_p126_s3", "sentA": "Patents and pending patent applications covering LGD-6972 are owned by Ligand.", "sentB": "The IND filing resulted in a $1 million milestone payment to Ligand.", "type": 1, "words": ["<tag1>", "Patents", "and", "pending", "patent", "applications", "covering", "LGD-6972", "are", "owned", "by", "Ligand.", "<tag2>", "The", "IND", "filing", "resulted", "in", "a", "$1", "million", "milestone", "payment", "to", "Ligand.", "<tag3>"], "wordsA": ["Patents", "and", "pending", "patent", "applications", "covering", "LGD-6972", "are", "owned", "by", "Ligand."], "wordsB": ["The", "IND", "filing", "resulted", "in", "a", "$1", "million", "milestone", "payment", "to", "Ligand."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_18_item1_p38_s0", "idA": "886163_17_item1_p18_s0", "sentA": "Current OmniAb licensee exercised its option to expand access to the OmniAb platform.", "sentB": "The OmniChicken platform consists of genetically-engineered transgenic chickens which enable the generation of novel antibodies against targets that are not immunogenic in mammals like mice and rats, the core species of Ligand s existing OmniAb platform.", "type": 1, "words": ["<tag1>", "Current", "OmniAb", "licensee", "exercised", "its", "option", "to", "expand", "access", "to", "the", "OmniAb", "platform.", "<tag2>", "The", "OmniChicken", "platform", "consists", "of", "genetically-engineered", "transgenic", "chickens", "which", "enable", "the", "generation", "of", "novel", "antibodies", "against", "targets", "that", "are", "not", "immunogenic", "in", "mammals", "like", "mice", "and", "rats,", "the", "core", "species", "of", "Ligand", "s", "existing", "OmniAb", "platform.", "<tag3>"], "wordsA": ["Current", "OmniAb", "licensee", "exercised", "its", "option", "to", "expand", "access", "to", "the", "OmniAb", "platform."], "wordsB": ["The", "OmniChicken", "platform", "consists", "of", "genetically-engineered", "transgenic", "chickens", "which", "enable", "the", "generation", "of", "novel", "antibodies", "against", "targets", "that", "are", "not", "immunogenic", "in", "mammals", "like", "mice", "and", "rats,", "the", "core", "species", "of", "Ligand", "s", "existing", "OmniAb", "platform."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_18_item1_p16_s0", "idA": "886163_17_item1_p27_s0", "sentA": "Ligand announced initiation of a Phase 2 clinical trial with LGD-6972 for the treatment of T2DM.", "sentB": "CASI Pharmaceuticals announced that China s Food and Drug Administration granted priority review for CASI s import drug registration clinical trial application for EVOMELA.", "type": 1, "words": ["<tag1>", "Ligand", "announced", "initiation", "of", "a", "Phase", "2", "clinical", "trial", "with", "LGD-6972", "for", "the", "treatment", "of", "T2DM.", "<tag2>", "CASI", "Pharmaceuticals", "announced", "that", "China", "s", "Food", "and", "Drug", "Administration", "granted", "priority", "review", "for", "CASI", "s", "import", "drug", "registration", "clinical", "trial", "application", "for", "EVOMELA.", "<tag3>"], "wordsA": ["Ligand", "announced", "initiation", "of", "a", "Phase", "2", "clinical", "trial", "with", "LGD-6972", "for", "the", "treatment", "of", "T2DM."], "wordsB": ["CASI", "Pharmaceuticals", "announced", "that", "China", "s", "Food", "and", "Drug", "Administration", "granted", "priority", "review", "for", "CASI", "s", "import", "drug", "registration", "clinical", "trial", "application", "for", "EVOMELA."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_18_item1_p2_s1", "idA": "886163_17_item1_p32_s0", "sentA": "In January of 2016, Ligand acquired OMT and the OmniAb Technologies.", "sentB": "The acquisition initially added four Shots on Goal to Ligand s portfolio, and the OmniChicken technology, with the potential be utilized by multiple current OmniAb partners as they seek to develop antibodies for difficult-to-address targets.", "type": 1, "words": ["<tag1>", "In", "January", "of", "2016,", "Ligand", "acquired", "OMT", "and", "the", "OmniAb", "Technologies.", "<tag2>", "The", "acquisition", "initially", "added", "four", "Shots", "on", "Goal", "to", "Ligand", "s", "portfolio,", "and", "the", "OmniChicken", "technology,", "with", "the", "potential", "be", "utilized", "by", "multiple", "current", "OmniAb", "partners", "as", "they", "seek", "to", "develop", "antibodies", "for", "difficult-to-address", "targets.", "<tag3>"], "wordsA": ["In", "January", "of", "2016,", "Ligand", "acquired", "OMT", "and", "the", "OmniAb", "Technologies."], "wordsB": ["The", "acquisition", "initially", "added", "four", "Shots", "on", "Goal", "to", "Ligand", "s", "portfolio,", "and", "the", "OmniChicken", "technology,", "with", "the", "potential", "be", "utilized", "by", "multiple", "current", "OmniAb", "partners", "as", "they", "seek", "to", "develop", "antibodies", "for", "difficult-to-address", "targets."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_18_item1_p10_s0", "idA": "886163_17_item1_p55_s0", "sentA": "Evomela has been granted Orphan Designation by the FDA for use as a high-dose conditioning regimen for patients with multiple myeloma undergoing ASCT.", "sentB": "Takeda Pharmaceuticals announced the Phase 3 initiation of pevonedistat plus Azacitidine versus single-agent azacitidine as first-line treatment for patients with higher-risk myelodysplastic syndromes, chronic myelomonocytic leukemia, or low-blast acute myelogenous leukemia.", "type": 1, "words": ["<tag1>", "Evomela", "has", "been", "granted", "Orphan", "Designation", "by", "the", "FDA", "for", "use", "as", "a", "high-dose", "conditioning", "regimen", "for", "patients", "with", "multiple", "myeloma", "undergoing", "ASCT.", "<tag2>", "Takeda", "Pharmaceuticals", "announced", "the", "Phase", "3", "initiation", "of", "pevonedistat", "plus", "Azacitidine", "versus", "single-agent", "azacitidine", "as", "first-line", "treatment", "for", "patients", "with", "higher-risk", "myelodysplastic", "syndromes,", "chronic", "myelomonocytic", "leukemia,", "or", "low-blast", "acute", "myelogenous", "leukemia.", "<tag3>"], "wordsA": ["Evomela", "has", "been", "granted", "Orphan", "Designation", "by", "the", "FDA", "for", "use", "as", "a", "high-dose", "conditioning", "regimen", "for", "patients", "with", "multiple", "myeloma", "undergoing", "ASCT."], "wordsB": ["Takeda", "Pharmaceuticals", "announced", "the", "Phase", "3", "initiation", "of", "pevonedistat", "plus", "Azacitidine", "versus", "single-agent", "azacitidine", "as", "first-line", "treatment", "for", "patients", "with", "higher-risk", "myelodysplastic", "syndromes,", "chronic", "myelomonocytic", "leukemia,", "or", "low-blast", "acute", "myelogenous", "leukemia."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_18_item1_p31_s0", "idA": "886163_17_item1_p55_s2", "sentA": "The use of the Captisol technology to reformulate melphalan is anticipated to allow for longer administration durations and slower infusion rates, potentially enabling clinicians to safely achieve a higher dose intensity of pre-transplant chemotherapy.", "sentB": "Captisol Clinical Use Agreements with Eisai, Syros Pharmaceuticals and Vaxxas Inc.", "type": 1, "words": ["<tag1>", "The", "use", "of", "the", "Captisol", "technology", "to", "reformulate", "melphalan", "is", "anticipated", "to", "allow", "for", "longer", "administration", "durations", "and", "slower", "infusion", "rates,", "potentially", "enabling", "clinicians", "to", "safely", "achieve", "a", "higher", "dose", "intensity", "of", "pre-transplant", "chemotherapy.", "<tag2>", "Captisol", "Clinical", "Use", "Agreements", "with", "Eisai,", "Syros", "Pharmaceuticals", "and", "Vaxxas", "Inc.", "<tag3>"], "wordsA": ["The", "use", "of", "the", "Captisol", "technology", "to", "reformulate", "melphalan", "is", "anticipated", "to", "allow", "for", "longer", "administration", "durations", "and", "slower", "infusion", "rates,", "potentially", "enabling", "clinicians", "to", "safely", "achieve", "a", "higher", "dose", "intensity", "of", "pre-transplant", "chemotherapy."], "wordsB": ["Captisol", "Clinical", "Use", "Agreements", "with", "Eisai,", "Syros", "Pharmaceuticals", "and", "Vaxxas", "Inc."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_18_item1_p4_s1", "idA": "886163_17_item1_p55_s2", "sentA": "The use of the Captisol technology to reformulate melphalan is anticipated to allow for longer administration durations and slower infusion rates, potentially enabling clinicians to safely achieve a higher dose intensity of pre-transplant chemotherapy.", "sentB": "Top-line data demonstrated statistically significant, dose-dependent increases in lean body mass ranging from 4.8% to 9.1% following treatment with VK5211.", "type": 1, "words": ["<tag1>", "The", "use", "of", "the", "Captisol", "technology", "to", "reformulate", "melphalan", "is", "anticipated", "to", "allow", "for", "longer", "administration", "durations", "and", "slower", "infusion", "rates,", "potentially", "enabling", "clinicians", "to", "safely", "achieve", "a", "higher", "dose", "intensity", "of", "pre-transplant", "chemotherapy.", "<tag2>", "Top-line", "data", "demonstrated", "statistically", "significant,", "dose-dependent", "increases", "in", "lean", "body", "mass", "ranging", "from", "4.8%", "to", "9.1%", "following", "treatment", "with", "VK5211.", "<tag3>"], "wordsA": ["The", "use", "of", "the", "Captisol", "technology", "to", "reformulate", "melphalan", "is", "anticipated", "to", "allow", "for", "longer", "administration", "durations", "and", "slower", "infusion", "rates,", "potentially", "enabling", "clinicians", "to", "safely", "achieve", "a", "higher", "dose", "intensity", "of", "pre-transplant", "chemotherapy."], "wordsB": ["Top-line", "data", "demonstrated", "statistically", "significant,", "dose-dependent", "increases", "in", "lean", "body", "mass", "ranging", "from", "4.8%", "to", "9.1%", "following", "treatment", "with", "VK5211."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_18_item1_p78_s7", "idA": "886163_17_item1_p67_s6", "sentA": "Baxdela (Melinta) Our partner, Melinta , submitted an NDA for approval of a Captisol-enabled delafloxacin-IV in October 2016 for the development of Baxdela, a Captisol-enabled delafloxacin-IV.", "sentB": "The trial will include an interim analysis of proteinura as a surrogate endpoint to serve as the basis for an NDA filing for Subpart H accelerated approval of sparsentan.", "type": 1, "words": ["<tag1>", "Baxdela", "(Melinta)", "Our", "partner,", "Melinta", ",", "submitted", "an", "NDA", "for", "approval", "of", "a", "Captisol-enabled", "delafloxacin-IV", "in", "October", "2016", "for", "the", "development", "of", "Baxdela,", "a", "Captisol-enabled", "delafloxacin-IV.", "<tag2>", "The", "trial", "will", "include", "an", "interim", "analysis", "of", "proteinura", "as", "a", "surrogate", "endpoint", "to", "serve", "as", "the", "basis", "for", "an", "NDA", "filing", "for", "Subpart", "H", "accelerated", "approval", "of", "sparsentan.", "<tag3>"], "wordsA": ["Baxdela", "(Melinta)", "Our", "partner,", "Melinta", ",", "submitted", "an", "NDA", "for", "approval", "of", "a", "Captisol-enabled", "delafloxacin-IV", "in", "October", "2016", "for", "the", "development", "of", "Baxdela,", "a", "Captisol-enabled", "delafloxacin-IV."], "wordsB": ["The", "trial", "will", "include", "an", "interim", "analysis", "of", "proteinura", "as", "a", "surrogate", "endpoint", "to", "serve", "as", "the", "basis", "for", "an", "NDA", "filing", "for", "Subpart", "H", "accelerated", "approval", "of", "sparsentan."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_18_item1_p18_s0", "idA": "886163_17_item1_p6_s0", "sentA": "Merck announced that it stopped the Phase 2/3 EPOCH study evaluating verubecestat in people with mild-to-moderate Alzheimer s disease due to the conclusion that the efficacy endpoint could not be achieved.", "sentB": "CStone Pharmaceuticals announced that it received Clinical Trial Application approval from the China Food and Drug Administration to conduct clinical trials in China with CS1001, an OmniAb-derived full-length anti-PDL1 monoclonal antibody.", "type": 1, "words": ["<tag1>", "Merck", "announced", "that", "it", "stopped", "the", "Phase", "2/3", "EPOCH", "study", "evaluating", "verubecestat", "in", "people", "with", "mild-to-moderate", "Alzheimer", "s", "disease", "due", "to", "the", "conclusion", "that", "the", "efficacy", "endpoint", "could", "not", "be", "achieved.", "<tag2>", "CStone", "Pharmaceuticals", "announced", "that", "it", "received", "Clinical", "Trial", "Application", "approval", "from", "the", "China", "Food", "and", "Drug", "Administration", "to", "conduct", "clinical", "trials", "in", "China", "with", "CS1001,", "an", "OmniAb-derived", "full-length", "anti-PDL1", "monoclonal", "antibody.", "<tag3>"], "wordsA": ["Merck", "announced", "that", "it", "stopped", "the", "Phase", "2/3", "EPOCH", "study", "evaluating", "verubecestat", "in", "people", "with", "mild-to-moderate", "Alzheimer", "s", "disease", "due", "to", "the", "conclusion", "that", "the", "efficacy", "endpoint", "could", "not", "be", "achieved."], "wordsB": ["CStone", "Pharmaceuticals", "announced", "that", "it", "received", "Clinical", "Trial", "Application", "approval", "from", "the", "China", "Food", "and", "Drug", "Administration", "to", "conduct", "clinical", "trials", "in", "China", "with", "CS1001,", "an", "OmniAb-derived", "full-length", "anti-PDL1", "monoclonal", "antibody."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_18_item1_p77_s2", "idA": "886163_17_item1_p6_s1", "sentA": "Results from EPOCH will be analyzed and presented at an upcoming scientific meeting.", "sentB": "SAGE believes these data will be sufficient to support submissions of regulatory applications seeking approval of brexanolone for PPD.", "type": 1, "words": ["<tag1>", "Results", "from", "EPOCH", "will", "be", "analyzed", "and", "presented", "at", "an", "upcoming", "scientific", "meeting.", "<tag2>", "SAGE", "believes", "these", "data", "will", "be", "sufficient", "to", "support", "submissions", "of", "regulatory", "applications", "seeking", "approval", "of", "brexanolone", "for", "PPD.", "<tag3>"], "wordsA": ["Results", "from", "EPOCH", "will", "be", "analyzed", "and", "presented", "at", "an", "upcoming", "scientific", "meeting."], "wordsB": ["SAGE", "believes", "these", "data", "will", "be", "sufficient", "to", "support", "submissions", "of", "regulatory", "applications", "seeking", "approval", "of", "brexanolone", "for", "PPD."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "886163_18_item1_p26_s0", "idA": "886163_17_item1_p76_s1", "sentA": "Under the terms of the license agreement with Azure, we retained the rights to the oral formulation of lasofoxifene originally developed by Pfizer.", "sentB": "Receipt of a $2 million payment from WuXi Biologics subsequent to their licensing of exclusive rights to the anti-PD-1 antibody GLS-010 to Arcus Biosciences in North America, Europe, Japan and certain other territories.", "type": 1, "words": ["<tag1>", "Under", "the", "terms", "of", "the", "license", "agreement", "with", "Azure,", "we", "retained", "the", "rights", "to", "the", "oral", "formulation", "of", "lasofoxifene", "originally", "developed", "by", "Pfizer.", "<tag2>", "Receipt", "of", "a", "$2", "million", "payment", "from", "WuXi", "Biologics", "subsequent", "to", "their", "licensing", "of", "exclusive", "rights", "to", "the", "anti-PD-1", "antibody", "GLS-010", "to", "Arcus", "Biosciences", "in", "North", "America,", "Europe,", "Japan", "and", "certain", "other", "territories.", "<tag3>"], "wordsA": ["Under", "the", "terms", "of", "the", "license", "agreement", "with", "Azure,", "we", "retained", "the", "rights", "to", "the", "oral", "formulation", "of", "lasofoxifene", "originally", "developed", "by", "Pfizer."], "wordsB": ["Receipt", "of", "a", "$2", "million", "payment", "from", "WuXi", "Biologics", "subsequent", "to", "their", "licensing", "of", "exclusive", "rights", "to", "the", "anti-PD-1", "antibody", "GLS-010", "to", "Arcus", "Biosciences", "in", "North", "America,", "Europe,", "Japan", "and", "certain", "other", "territories."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
